WO2003068228A1 - Aryl ureas with angiogenesis inhibiting activity - Google Patents
Aryl ureas with angiogenesis inhibiting activity Download PDFInfo
- Publication number
- WO2003068228A1 WO2003068228A1 PCT/US2003/004103 US0304103W WO03068228A1 WO 2003068228 A1 WO2003068228 A1 WO 2003068228A1 US 0304103 W US0304103 W US 0304103W WO 03068228 A1 WO03068228 A1 WO 03068228A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- phenyl
- alkyl
- pyridinyl
- substituted
- Prior art date
Links
- -1 Aryl ureas Chemical class 0.000 title claims abstract description 127
- 230000033115 angiogenesis Effects 0.000 title claims abstract description 36
- 230000002401 inhibitory effect Effects 0.000 title claims description 10
- 235000013877 carbamide Nutrition 0.000 title abstract description 28
- 238000000034 method Methods 0.000 claims abstract description 87
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 34
- 201000010099 disease Diseases 0.000 claims abstract description 28
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims abstract description 24
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims abstract description 23
- 230000001404 mediated effect Effects 0.000 claims abstract description 21
- 230000008569 process Effects 0.000 claims abstract description 16
- 230000002159 abnormal effect Effects 0.000 claims abstract description 14
- 230000019491 signal transduction Effects 0.000 claims abstract description 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 80
- 150000001875 compounds Chemical class 0.000 claims description 79
- 125000000217 alkyl group Chemical group 0.000 claims description 58
- 229910052736 halogen Inorganic materials 0.000 claims description 54
- 150000002367 halogens Chemical class 0.000 claims description 53
- 125000004076 pyridyl group Chemical group 0.000 claims description 53
- 125000001424 substituent group Chemical group 0.000 claims description 46
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 39
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 37
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 37
- 239000000203 mixture Substances 0.000 claims description 35
- 229920006395 saturated elastomer Polymers 0.000 claims description 35
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 34
- 241000124008 Mammalia Species 0.000 claims description 26
- 125000001072 heteroaryl group Chemical group 0.000 claims description 25
- 229910052757 nitrogen Inorganic materials 0.000 claims description 25
- 229910052717 sulfur Inorganic materials 0.000 claims description 24
- 229910052760 oxygen Inorganic materials 0.000 claims description 23
- 125000005842 heteroatom Chemical group 0.000 claims description 22
- 206010028980 Neoplasm Diseases 0.000 claims description 21
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims description 20
- 230000015572 biosynthetic process Effects 0.000 claims description 20
- 125000001624 naphthyl group Chemical group 0.000 claims description 19
- 125000003545 alkoxy group Chemical group 0.000 claims description 18
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 16
- 125000002950 monocyclic group Chemical group 0.000 claims description 16
- 150000003839 salts Chemical group 0.000 claims description 16
- 201000011510 cancer Diseases 0.000 claims description 15
- 238000006243 chemical reaction Methods 0.000 claims description 13
- 230000000694 effects Effects 0.000 claims description 13
- 241000282412 Homo Species 0.000 claims description 12
- 208000015181 infectious disease Diseases 0.000 claims description 12
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 12
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 11
- 125000002619 bicyclic group Chemical group 0.000 claims description 11
- 125000005843 halogen group Chemical group 0.000 claims description 11
- 206010012468 Dermatitis herpetiformis Diseases 0.000 claims description 10
- 206010015218 Erythema multiforme Diseases 0.000 claims description 10
- 206010034277 Pemphigoid Diseases 0.000 claims description 10
- 206010038923 Retinopathy Diseases 0.000 claims description 10
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims description 10
- 125000003282 alkyl amino group Chemical group 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 10
- 125000001475 halogen functional group Chemical group 0.000 claims description 10
- 230000000302 ischemic effect Effects 0.000 claims description 10
- 208000002780 macular degeneration Diseases 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 206010012441 Dermatitis bullous Diseases 0.000 claims description 9
- 201000004681 Psoriasis Diseases 0.000 claims description 9
- 208000017442 Retinal disease Diseases 0.000 claims description 9
- 206010040070 Septic Shock Diseases 0.000 claims description 9
- 208000000594 bullous pemphigoid Diseases 0.000 claims description 9
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 9
- 238000009472 formulation Methods 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 208000004644 retinal vein occlusion Diseases 0.000 claims description 9
- 230000004614 tumor growth Effects 0.000 claims description 9
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 8
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 8
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 8
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 8
- 230000006378 damage Effects 0.000 claims description 8
- 125000001188 haloalkyl group Chemical group 0.000 claims description 8
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 8
- 125000002527 bicyclic carbocyclic group Chemical group 0.000 claims description 7
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 7
- 239000000651 prodrug Substances 0.000 claims description 7
- 229940002612 prodrug Drugs 0.000 claims description 7
- 206010001935 American trypanosomiasis Diseases 0.000 claims description 6
- 208000024699 Chagas disease Diseases 0.000 claims description 6
- 208000034762 Meningococcal Infections Diseases 0.000 claims description 6
- 206010040047 Sepsis Diseases 0.000 claims description 6
- 230000001154 acute effect Effects 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 6
- 229910052794 bromium Inorganic materials 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 6
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 5
- 208000027418 Wounds and injury Diseases 0.000 claims description 5
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 229910052731 fluorine Inorganic materials 0.000 claims description 5
- 208000014674 injury Diseases 0.000 claims description 5
- 210000003734 kidney Anatomy 0.000 claims description 5
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
- 208000035473 Communicable disease Diseases 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 4
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 4
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 claims description 4
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 4
- 125000002541 furyl group Chemical group 0.000 claims description 4
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 4
- 230000029663 wound healing Effects 0.000 claims description 4
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 claims description 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 3
- 206010004659 Biliary cirrhosis Diseases 0.000 claims description 3
- 208000006386 Bone Resorption Diseases 0.000 claims description 3
- 241000589969 Borreliella burgdorferi Species 0.000 claims description 3
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 3
- 206010063094 Cerebral malaria Diseases 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 241000701022 Cytomegalovirus Species 0.000 claims description 3
- 206010014824 Endotoxic shock Diseases 0.000 claims description 3
- 101710146739 Enterotoxin Proteins 0.000 claims description 3
- 241000588724 Escherichia coli Species 0.000 claims description 3
- 208000002476 Falciparum Malaria Diseases 0.000 claims description 3
- 206010019280 Heart failures Diseases 0.000 claims description 3
- 206010019375 Helicobacter infections Diseases 0.000 claims description 3
- 206010019663 Hepatic failure Diseases 0.000 claims description 3
- 206010019728 Hepatitis alcoholic Diseases 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- 206010023125 Jarisch-Herxheimer reaction Diseases 0.000 claims description 3
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 3
- 206010033645 Pancreatitis Diseases 0.000 claims description 3
- 208000008469 Peptic Ulcer Diseases 0.000 claims description 3
- 201000011336 Plasmodium falciparum malaria Diseases 0.000 claims description 3
- 208000019155 Radiation injury Diseases 0.000 claims description 3
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 3
- 201000010001 Silicosis Diseases 0.000 claims description 3
- 241000191940 Staphylococcus Species 0.000 claims description 3
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims description 3
- 241000710209 Theiler's encephalomyelitis virus Species 0.000 claims description 3
- 206010044248 Toxic shock syndrome Diseases 0.000 claims description 3
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims description 3
- 241000589884 Treponema pallidum Species 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 208000038016 acute inflammation Diseases 0.000 claims description 3
- 230000006022 acute inflammation Effects 0.000 claims description 3
- 125000002252 acyl group Chemical group 0.000 claims description 3
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 3
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 3
- 208000002353 alcoholic hepatitis Diseases 0.000 claims description 3
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims description 3
- 125000005037 alkyl phenyl group Chemical group 0.000 claims description 3
- 208000028004 allergic respiratory disease Diseases 0.000 claims description 3
- 208000010123 anthracosis Diseases 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 230000024279 bone resorption Effects 0.000 claims description 3
- 208000029028 brain injury Diseases 0.000 claims description 3
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 claims description 3
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 3
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 claims description 3
- 206010014599 encephalitis Diseases 0.000 claims description 3
- 239000000147 enterotoxin Substances 0.000 claims description 3
- 231100000655 enterotoxin Toxicity 0.000 claims description 3
- 230000003176 fibrotic effect Effects 0.000 claims description 3
- 210000002216 heart Anatomy 0.000 claims description 3
- 208000019622 heart disease Diseases 0.000 claims description 3
- 230000001771 impaired effect Effects 0.000 claims description 3
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 3
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 208000019423 liver disease Diseases 0.000 claims description 3
- 208000007903 liver failure Diseases 0.000 claims description 3
- 231100000835 liver failure Toxicity 0.000 claims description 3
- 201000004792 malaria Diseases 0.000 claims description 3
- 230000036210 malignancy Effects 0.000 claims description 3
- 230000017074 necrotic cell death Effects 0.000 claims description 3
- 208000011906 peptic ulcer disease Diseases 0.000 claims description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 230000002685 pulmonary effect Effects 0.000 claims description 3
- 201000003651 pulmonary sarcoidosis Diseases 0.000 claims description 3
- 201000003068 rheumatic fever Diseases 0.000 claims description 3
- 230000036303 septic shock Effects 0.000 claims description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 3
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims description 3
- 238000011541 total hip replacement Methods 0.000 claims description 3
- 231100000419 toxicity Toxicity 0.000 claims description 3
- 230000001988 toxicity Effects 0.000 claims description 3
- 239000003053 toxin Substances 0.000 claims description 3
- 231100000765 toxin Toxicity 0.000 claims description 3
- 201000008827 tuberculosis Diseases 0.000 claims description 3
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 claims description 2
- 125000005940 1,4-dioxanyl group Chemical group 0.000 claims description 2
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims description 2
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical compound [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 claims description 2
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 claims description 2
- 229910006074 SO2NH2 Inorganic materials 0.000 claims description 2
- YPWFISCTZQNZAU-UHFFFAOYSA-N Thiane Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 claims description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 claims description 2
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 claims description 2
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004799 bromophenyl group Chemical group 0.000 claims description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 125000000068 chlorophenyl group Chemical group 0.000 claims description 2
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 claims description 2
- 125000004598 dihydrobenzofuryl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 claims description 2
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 claims description 2
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 claims description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 2
- 230000012010 growth Effects 0.000 claims description 2
- 125000002636 imidazolinyl group Chemical group 0.000 claims description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 2
- 125000001041 indolyl group Chemical group 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 125000005969 isothiazolinyl group Chemical group 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 2
- 125000002757 morpholinyl group Chemical group 0.000 claims description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 2
- 125000002971 oxazolyl group Chemical group 0.000 claims description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 2
- 125000004193 piperazinyl group Chemical group 0.000 claims description 2
- 125000003386 piperidinyl group Chemical group 0.000 claims description 2
- 208000001685 postmenopausal osteoporosis Diseases 0.000 claims description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims description 2
- 125000004944 pyrazin-3-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims description 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 2
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 claims description 2
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 claims description 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 2
- 125000001422 pyrrolinyl group Chemical group 0.000 claims description 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 claims description 2
- 125000000565 sulfonamide group Chemical group 0.000 claims description 2
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 2
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 claims description 2
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 claims description 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- VSIYJQNFMOOGCU-UHFFFAOYSA-N 1-(cyclohexen-1-yl)cyclohexene Chemical group C1CCCC(C=2CCCCC=2)=C1 VSIYJQNFMOOGCU-UHFFFAOYSA-N 0.000 claims 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 230000004075 alteration Effects 0.000 claims 1
- 125000004188 dichlorophenyl group Chemical group 0.000 claims 1
- 125000005046 dihydronaphthyl group Chemical group 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 125000003971 isoxazolinyl group Chemical group 0.000 claims 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims 1
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 46
- 239000000243 solution Substances 0.000 description 32
- 235000019439 ethyl acetate Nutrition 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 20
- 239000007787 solid Substances 0.000 description 19
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 18
- 230000005764 inhibitory process Effects 0.000 description 18
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 18
- 239000002253 acid Substances 0.000 description 17
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 230000002829 reductive effect Effects 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- 102000001554 Hemoglobins Human genes 0.000 description 12
- 108010054147 Hemoglobins Proteins 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
- 239000004202 carbamide Substances 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 150000002148 esters Chemical class 0.000 description 10
- 238000001819 mass spectrum Methods 0.000 description 10
- 150000003672 ureas Chemical class 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 230000037396 body weight Effects 0.000 description 9
- 125000004999 nitroaryl group Chemical group 0.000 description 9
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 108010082117 matrigel Proteins 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 6
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical compound NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 6
- 239000007995 HEPES buffer Substances 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- BGVBBMZMEKXUTR-UHFFFAOYSA-N 4-chloro-n-methylpyridine-2-carboxamide Chemical compound CNC(=O)C1=CC(Cl)=CC=N1 BGVBBMZMEKXUTR-UHFFFAOYSA-N 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- 239000007859 condensation product Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 235000003599 food sweetener Nutrition 0.000 description 5
- 239000012948 isocyanate Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 5
- 108010077182 raf Kinases Proteins 0.000 description 5
- 102000009929 raf Kinases Human genes 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000003765 sweetening agent Substances 0.000 description 5
- 238000004809 thin layer chromatography Methods 0.000 description 5
- XIHHOUUTBZSYJH-UHFFFAOYSA-N 4-chloropyridine-2-carboxamide Chemical compound NC(=O)C1=CC(Cl)=CC=N1 XIHHOUUTBZSYJH-UHFFFAOYSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- 239000004305 biphenyl Substances 0.000 description 4
- 235000010290 biphenyl Nutrition 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 4
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 4
- 150000002170 ethers Chemical class 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 150000002576 ketones Chemical class 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 230000004862 vasculogenesis Effects 0.000 description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 3
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 3
- RXZZBPYPZLAEFC-UHFFFAOYSA-N 4-(4-aminophenoxy)-n-methylpyridine-2-carboxamide Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(N)=CC=2)=C1 RXZZBPYPZLAEFC-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 150000004982 aromatic amines Chemical class 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 238000007654 immersion Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 3
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 3
- 230000008707 rearrangement Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 239000012089 stop solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 238000000844 transformation Methods 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 2
- UWFQBNUDTOONHQ-UHFFFAOYSA-N 4-(4-aminophenoxy)pyridine-2-carboxamide Chemical compound C1=NC(C(=O)N)=CC(OC=2C=CC(N)=CC=2)=C1 UWFQBNUDTOONHQ-UHFFFAOYSA-N 0.000 description 2
- FYBNFLRGZHGUDY-UHFFFAOYSA-N 4-chloropyridine-2-carbonyl chloride Chemical compound ClC(=O)C1=CC(Cl)=CC=N1 FYBNFLRGZHGUDY-UHFFFAOYSA-N 0.000 description 2
- HJQLQTVZSPAUGT-UHFFFAOYSA-N 4-chloropyridine-2-carbonyl chloride;hydrochloride Chemical compound Cl.ClC(=O)C1=CC(Cl)=CC=N1 HJQLQTVZSPAUGT-UHFFFAOYSA-N 0.000 description 2
- ASPDJZINBYYZRU-UHFFFAOYSA-N 5-amino-2-chlorobenzotrifluoride Chemical compound NC1=CC=C(Cl)C(C(F)(F)F)=C1 ASPDJZINBYYZRU-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 235000006491 Acacia senegal Nutrition 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 235000003911 Arachis Nutrition 0.000 description 2
- 244000105624 Arachis hypogaea Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000036983 biotransformation Effects 0.000 description 2
- 229940045348 brown mixture Drugs 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 150000001733 carboxylic acid esters Chemical class 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 238000000451 chemical ionisation Methods 0.000 description 2
- 238000000170 chemical ionisation mass spectrum Methods 0.000 description 2
- 238000004296 chiral HPLC Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000006880 cross-coupling reaction Methods 0.000 description 2
- GTBRTGPZZALPNS-MXHVRSFHSA-N cyanoketone Chemical compound C1C=C2C(C)(C)C(=O)[C@H](C#N)C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GTBRTGPZZALPNS-MXHVRSFHSA-N 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 2
- 238000006900 dealkylation reaction Methods 0.000 description 2
- 238000006114 decarboxylation reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 150000005690 diesters Chemical class 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 2
- HCUYBXPSSCRKRF-UHFFFAOYSA-N diphosgene Chemical compound ClC(=O)OC(Cl)(Cl)Cl HCUYBXPSSCRKRF-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000010265 fast atom bombardment Methods 0.000 description 2
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 150000002194 fatty esters Chemical class 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 150000008282 halocarbons Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 150000002513 isocyanates Chemical class 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000008823 permeabilization Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
- 125000001095 phosphatidyl group Chemical group 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000007127 saponification reaction Methods 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 description 2
- 239000001593 sorbitan monooleate Substances 0.000 description 2
- 229940035049 sorbitan monooleate Drugs 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 210000001179 synovial fluid Anatomy 0.000 description 2
- 150000003505 terpenes Chemical class 0.000 description 2
- 235000007586 terpenes Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229910052718 tin Inorganic materials 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000037317 transdermal delivery Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 230000006711 vascular endothelial growth factor production Effects 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- KWMLJOLKUYYJFJ-DIHCEYMBSA-N (2r,3s,4r,5r)-2,3,4,5,6,7-hexahydroxyheptanoic acid Chemical compound OCC(O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-DIHCEYMBSA-N 0.000 description 1
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 description 1
- AFENDNXGAFYKQO-VKHMYHEASA-N (S)-2-hydroxybutyric acid Chemical compound CC[C@H](O)C(O)=O AFENDNXGAFYKQO-VKHMYHEASA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- ZXUJWPHOPHHZLR-UHFFFAOYSA-N 1,1,1-trichloro-2-fluoroethane Chemical compound FCC(Cl)(Cl)Cl ZXUJWPHOPHHZLR-UHFFFAOYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- SGUVLZREKBPKCE-UHFFFAOYSA-N 1,5-diazabicyclo[4.3.0]-non-5-ene Chemical compound C1CCN=C2CCCN21 SGUVLZREKBPKCE-UHFFFAOYSA-N 0.000 description 1
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 1
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 description 1
- NBJZEUQTGLSUOB-UHFFFAOYSA-N 1-chloro-4-isocyanato-2-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC(N=C=O)=CC=C1Cl NBJZEUQTGLSUOB-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- JVVRJMXHNUAPHW-UHFFFAOYSA-N 1h-pyrazol-5-amine Chemical group NC=1C=CNN=1 JVVRJMXHNUAPHW-UHFFFAOYSA-N 0.000 description 1
- HORQAOAYAYGIBM-UHFFFAOYSA-N 2,4-dinitrophenylhydrazine Chemical compound NNC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O HORQAOAYAYGIBM-UHFFFAOYSA-N 0.000 description 1
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 1
- TUCRZHGAIRVWTI-UHFFFAOYSA-N 2-bromothiophene Chemical compound BrC1=CC=CS1 TUCRZHGAIRVWTI-UHFFFAOYSA-N 0.000 description 1
- RKUSRLUGUVDNKP-UHFFFAOYSA-N 2-methoxy-5-(trifluoromethyl)aniline Chemical compound COC1=CC=C(C(F)(F)F)C=C1N RKUSRLUGUVDNKP-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- OSJPPGNTCRNQQC-UHFFFAOYSA-N 3-phosphoglyceric acid Chemical compound OC(=O)C(O)COP(O)(O)=O OSJPPGNTCRNQQC-UHFFFAOYSA-N 0.000 description 1
- JNWMCRIBVQCVQU-UHFFFAOYSA-N 4-[4-[[2-methoxy-5-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methylpyridine-2-carboxamide Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C(=CC=C(C=3)C(F)(F)F)OC)=CC=2)=C1 JNWMCRIBVQCVQU-UHFFFAOYSA-N 0.000 description 1
- UAEWBZYTKIMYRQ-UHFFFAOYSA-N 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]pyridine-2-carboxamide Chemical compound C1=NC(C(=O)N)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 UAEWBZYTKIMYRQ-UHFFFAOYSA-N 0.000 description 1
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 1
- RLWYFUZOXYXDCV-UHFFFAOYSA-N 6-(1,3-oxazol-2-yl)-5-phenylpyrimidine-2,4-diamine Chemical class N=1C=COC=1C1=NC(N)=NC(N)=C1C1=CC=CC=C1 RLWYFUZOXYXDCV-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- WDJHALXBUFZDSR-UHFFFAOYSA-N Acetoacetic acid Natural products CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical class [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108091016585 CD44 antigen Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- RDOFJDLLWVCMRU-UHFFFAOYSA-N Diisobutyl adipate Chemical compound CC(C)COC(=O)CCCCC(=O)OCC(C)C RDOFJDLLWVCMRU-UHFFFAOYSA-N 0.000 description 1
- 101000827763 Drosophila melanogaster Fibroblast growth factor receptor homolog 1 Proteins 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 238000006751 Mitsunobu reaction Methods 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- HXFOXFJUNFFYMO-BYPYZUCNSA-N N-alpha-acetyl-L-asparagine Chemical compound CC(=O)N[C@H](C(O)=O)CC(N)=O HXFOXFJUNFFYMO-BYPYZUCNSA-N 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241001111421 Pannus Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000002174 Styrene-butadiene Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 108090000054 Syndecan-2 Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000016663 Vascular Endothelial Growth Factor Receptor-3 Human genes 0.000 description 1
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 1
- WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 1
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 229960000250 adipic acid Drugs 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000000648 angioblast Anatomy 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000007262 aromatic hydroxylation reaction Methods 0.000 description 1
- 238000006172 aromatic nitration reaction Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000005418 aryl aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- MTAZNLWOLGHBHU-UHFFFAOYSA-N butadiene-styrene rubber Chemical compound C=CC=C.C=CC1=CC=CC=C1 MTAZNLWOLGHBHU-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 125000005026 carboxyaryl group Chemical group 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- OZECDDHOAMNMQI-UHFFFAOYSA-H cerium(3+);trisulfate Chemical compound [Ce+3].[Ce+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O OZECDDHOAMNMQI-UHFFFAOYSA-H 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 229950006137 dexfosfoserine Drugs 0.000 description 1
- WOWBFOBYOAGEEA-UHFFFAOYSA-N diafenthiuron Chemical compound CC(C)C1=C(NC(=S)NC(C)(C)C)C(C(C)C)=CC(OC=2C=CC=CC=2)=C1 WOWBFOBYOAGEEA-UHFFFAOYSA-N 0.000 description 1
- 239000012973 diazabicyclooctane Substances 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229940031769 diisobutyl adipate Drugs 0.000 description 1
- 229940031578 diisopropyl adipate Drugs 0.000 description 1
- 229940031569 diisopropyl sebacate Drugs 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- FNMTVMWFISHPEV-AATRIKPKSA-N dipropan-2-yl (e)-but-2-enedioate Chemical compound CC(C)OC(=O)\C=C\C(=O)OC(C)C FNMTVMWFISHPEV-AATRIKPKSA-N 0.000 description 1
- FNMTVMWFISHPEV-WAYWQWQTSA-N dipropan-2-yl (z)-but-2-enedioate Chemical compound CC(C)OC(=O)\C=C/C(=O)OC(C)C FNMTVMWFISHPEV-WAYWQWQTSA-N 0.000 description 1
- XFKBBSZEQRFVSL-UHFFFAOYSA-N dipropan-2-yl decanedioate Chemical compound CC(C)OC(=O)CCCCCCCCC(=O)OC(C)C XFKBBSZEQRFVSL-UHFFFAOYSA-N 0.000 description 1
- GUVUOGQBMYCBQP-UHFFFAOYSA-N dmpu Chemical compound CN1CCCN(C)C1=O GUVUOGQBMYCBQP-UHFFFAOYSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 150000002084 enol ethers Chemical class 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- OLAMWIPURJGSKE-UHFFFAOYSA-N et2o diethylether Chemical compound CCOCC.CCOCC OLAMWIPURJGSKE-UHFFFAOYSA-N 0.000 description 1
- LHWWETDBWVTKJO-UHFFFAOYSA-N et3n triethylamine Chemical compound CCN(CC)CC.CCN(CC)CC LHWWETDBWVTKJO-UHFFFAOYSA-N 0.000 description 1
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000023611 glucuronidation Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000005241 heteroarylamino group Chemical group 0.000 description 1
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- 238000007871 hydride transfer reaction Methods 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- PAGFSBPYVNFHAS-UHFFFAOYSA-N hydron;methyl 4-chloropyridine-2-carboxylate;chloride Chemical compound Cl.COC(=O)C1=CC(Cl)=CC=N1 PAGFSBPYVNFHAS-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 238000007339 nucleophilic aromatic substitution reaction Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-M phenolate Chemical compound [O-]C1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-M 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000003279 phenylacetic acid Substances 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphonic acid group Chemical group P(O)(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- DCWXELXMIBXGTH-QMMMGPOBSA-N phosphonotyrosine Chemical class OC(=O)[C@@H](N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-QMMMGPOBSA-N 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 230000001185 psoriatic effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000001957 retinal vein Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 239000011115 styrene butadiene Substances 0.000 description 1
- 229920003048 styrene butadiene rubber Polymers 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid group Chemical class S(N)(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229920003051 synthetic elastomer Polymers 0.000 description 1
- 239000005061 synthetic rubber Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 229940126703 systemic medication Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 150000007944 thiolates Chemical class 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- WMSCYGTVHFMKNS-UHFFFAOYSA-N tributyl(methyl)stannane Chemical group CCCC[Sn](C)(CCCC)CCCC WMSCYGTVHFMKNS-UHFFFAOYSA-N 0.000 description 1
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
- LYRCQNDYYRPFMF-UHFFFAOYSA-N trimethyltin Chemical compound C[Sn](C)C LYRCQNDYYRPFMF-UHFFFAOYSA-N 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000007998 vessel formation Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- This invention relates to methods of treating diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.
- Nasculogenesis involves the de novo formation of blood vessels from endothehal cell precursors or angiob lasts.
- the first vascular structures in the embryo are formed by vasculogenesis.
- Angiogenesis involves the development of capillaries from existing blood vessels, and is the principle mechanism by which organs, such as the brain and the kidney are vascularized. While vasculogenesis is restricted to embryonic development, angiogenesis can occur in the adult, for example during pregnancy, the female cycle, or wound healing.
- NEGF vascular endothehal growth factor
- NPF vascular permeability factor
- NEGF expression is induced by hypoxia (Shweiki et al. Nature 1992, 359,
- cytokines and growth factors such as interleukin-1, interleukin-6, epidermal growth factor and transforming growth factor- ⁇ and - ⁇ .
- VEGF and the NEGF family members have been reported to bind to one or more of three transmembrane receptor tyrosine kinases (Mustonen et al. J. Cell
- VEGF receptor-1 also known as flt-1 (fins-like tyrosine kinase-1)
- VEGFR-2 also known as kinase insert domain containing receptor (KDR); the murine analogue of KDR is known as fetal liver kinase-1 (flk-1)), and NEGFR-3 (also known as flt-4).
- KDR and flt-1 have been shown to have different signal transduction properties (Waltenberger et al. J. Biol. Chem. 1994, 269, 26988); Park et. al. Oncogene 1995, 10, 135).
- KDR undergoes strong ligand-dependant tyrosine phosphorylation in intact cells, whereas flt-1 displays a weak response.
- binding to KDR is a critical requirement for induction of the full spectrum of NEGF- mediated biological responses.
- VEGF plays a central role in vasculogenesis, and induces angiogenesis and permeabilization of blood vessels.
- Deregulated VEGF expression contributes to the development of a number of diseases that are characterized by abnormal angiogenesis and/or hyperpermeability processes. Regulation of the VEGF-mediated signal transduction cascade will therefore provide a useful mode for control of abnormal angiogenesis and/or hyperpermeability processes.
- Angiogenesis is regarded as an absolute prerequisite for growth of tumors beyond about 1-2 mm. Oxygen and nutrients may be supplied to cells in tumor smaller than this limit through diffusion. However, every tumor is dependent on angiogenesis for continued growth after it has reached a certain size. Tumorigenic cells within hypoxic. regions of tumors respond by stimulation of VEGF production, which triggers activation of quiescent endothehal cells to stimulate new blood vessel formation. (Shweiki et al. Proc. Nat 'I. Acad. Sci., 1995, 92, 768). In addition, VEGF production in tumor regions where there is no angiogenesis may proceed through the ras signal transduction pathway (Grugel et al. J. Biol. Chem., 1995, 270, 25915; Rak et al. Cancer Res. 1995, 55, 4575). In situ hybridization studies have demonstrated
- VEGF mR ⁇ A is strongly upregulated in a wide variety of human tumors, including lung (Mattern et al. Br. J. Cancer 1996, 73, 931), thyroid (Viglietto et al. Oncogene 1995, 11, 1569), breast (Brown et al. Human Pathol. 1995, 26, 86), gastrointestional tract (Brown et al. Cancer Res. 1993, 53, 4727; Suzuki et al. Cancer Res. 1996, 56, 3004), kidney and bladder (Brown et al. Am. J. Pathol 1993, 1431, 1255), ovary
- VEGF intraocular angiogenesis
- VEGF intraocular angiogenesis
- hyperproliferation of blood vessels leading eventually to blindness.
- retinopathies including diabetic retinopathy, ischemic retinal-vein occlusion, retinopathy of prematurity (Aiello et al. New Engl J. Med. 1994, 331, ⁇ 1480; Peer et al. Lab. Invest. 1995, 72, 638), and age-related macular degeneration (AMD; see, Lopez et al. Invest. Opththalmol. Vis. Sci. 1996, 37, 855).
- AMD age-related macular degeneration
- rheumatoid arthritis In rheumatoid arthritis (RA), the in-growth of vascular pannus may be mediated by production of angiogenic factors. Levels of immunoreactive VEGF are high in the synovial fluid of RA patients, while VEGF levels were low in the synovial fluid of patients with other forms of arthritis of with degenerative joint disease (Koch et al. J. Immunol 1994, 152, 4149).
- the angiogenesis inhibitor AGM-170 has been shown to prevent neovascularization of the joint in the rat collagen arthritis model
- Increased VEGF expression has also been shown in psoriatic skin, as well as bullous disorders associated with subepidermal blister formation, such as bullous pemphigoid, erythema multiforme, and dermatitis herpetiformis (Brown et al. J.
- KDR inhibitors will be useful in treatment of diseases characterized by abnormal angiogenesis and/or hyperpermeability processes, including the above listed diseases Summary of the Invention
- the present invention provides a method for treating diseases in humans or other mammals which are mediated by the VEGF induced signal transduction pathway, including those characterized by abnormal angiogenesis or hyperpermiability processes. These methods comprise administering a compound of formula I below or a salt, prodrug or stereoisomer thereof to a human or other mammal with a disease characterized by abnormal angiogenesis or hyperpermiability processes.
- A is selected from the group consisting of
- phenyl optionally substituted with 1-3 substituents independently selected from the group consisting of R 1 , OR 1 , C(O)R 1 , C(O)OR ⁇ C ⁇ N ⁇ R 2 , NR ! C(O)R 2 , NR ⁇ OR 2 , halogen, cyano, and nitro;
- the bicyclic heteroaryl group is optionally substituted with 1-3 substituents independently selected from the group consisting of R 1 , OR 1 , NR ! R 2 , C(O)NR 1 R 2 , NR 1 C(O)R 2 , NR ⁇ OR 2 , halogen, cyano, and nitro.
- B is selected from the group consisting of (i) phenyl, optionally substituted with 1-3 substituents independently selected from the group consisting of -L-M, C ⁇ -C 5 linear or branched alkyl, C ⁇ -C 5 linear or branched haloalkyl, C C 3 alkoxy, hydroxy, amino, C C 3 alkylamino, CrC 6 dialkylamino, halogen, cyano, and nitro;
- naphthyl optionally substituted with 1-3 substituents independently selected from the group consisting of -L-M, C ⁇ -C 5 linear or branched alkyl, C1-C5 linear or branched haloalkyl, Q-C 3 alkoxy, hydroxy, amino, C ⁇ -C 3 alkylamino, C ⁇ -C 6 dialkylamino, halogen, cyano, and nitro;
- m and 1 are integers independently selected from 0-4.
- M is selected from the group consisting of : (i) phenyl, optionally substituted with 1-3 substituents independently selected from the group consisting of R 1 , OR 1 , NR'R 2 , S ⁇ qR 1 , SO 2 NR ! R 2 , NR'SO 2 R 2 , C(O)NR 1 R 2 , NR ! C(O)R 2 , NR 1 C(O)OR 2 , halogen, cyano and nitro;
- R 1 , OR 1 , NR ⁇ 2 , S ⁇ R 1 , SO 2 R 1 R 2 , N ⁇ OzR 2 , C(O)R l , C(O)OR', C(O)NR 1 R 2 , NR 1 C(O)R 2 , NR'C(O)OR 2 , halogen, cyano and nitro, and also oxides (e.g. O, -O " or -OH).
- Each R 1 - R 5 are independently selected from the group consisting of: (a) hydrogen, (b) -C 6 alkyl, preferably, C ⁇ -C 5 linear, branched, or cyclic alkyl, wherein said alkyl is optionally substituted with halogen up to per-halo;
- d-C 3 alkyl-heteroaryl having 1-4 heteroatoms selected from the group consisting of O, N and S, wherein said heteroaryl group is a 5-6 membered monocyclic heteroaryl or a 8-10 membered bicyclic heteroaryl, and wherein said alkyl moiety is optionally substituted with halogen up to per-halo.
- Each R 1 - R 5 when not hydrogen is optionally substituted with 1-3 substituents independently selected from the group consisting of d-C 5 linear branched or cyclic alkyl, wherein said alkyl is optionally substituted with halogen up to per-halo, d-C 3 alkoxy, wherein said alkoxy is optionally substituted with halogen up to per-halo, hydroxy, amino, d-C alkylamino, C -C 6 dialkylamino, halogen, cyano, and nitro;
- Each variable q is independently selected from 0, 1, or 2.
- Suitable substituted and unsubstituted heteroaryl groups for the compounds of this invention include, but are not limited to the following monocyclic heteroaryl groups:
- Suitable aryl groups which do not contain heteroatoms include, for example, phenyl and 1- and 2-naphthyl, tetrahydronaphthyl, indanyl, indenyl, benzocyclobutanyl, benzocycloheptanyl and benzocycloheptenyl.
- Suitable linear alkyl groups and alkyl portions of groups include methyl, ethyl, propyl, butyl, pentyl, etc.
- Suitable branched alkyl groups include all branched isomers such as isopropyl, isobutyl, see-butyl, tert-butyl, etc.
- Suitable halogen groups include F, CI, Br, and/or I, from one to per- substitution (i.e. all H atoms on a group replaced by a halogen atom) being possible where an alkyl group is substituted by halogen, mixed substitution of halogen atom types also being possible on a given moiety.
- Preferred halogens are CI, Br and F.
- perhalo substituted linear and branched alkyl includes alkyl groups having one alkyl hydrogen replaced with halogen, alkyl groups wherein all hydrogens are replaced with halogen, alkyl groups wherein more than one but less than all hydrogens are replaced by halogen and alkyl groups having alkyl hydrogens replaced by halogen and other substituents.
- cycloalkyl refers to cyclic structures having 3-8 members in the ring such as cyclopropyl, cyclobutyl and cyclopentyl and cyclic structures having 3-8 members with alkyl substituents such that, for example, "C 3 cycloalkyl” includes methyl substituted cyclopropyl groups.
- saturated carbocyclic moieties defines only the cyclic structure, i.e. cyclopentyl, cyclohexyl, etc. Any alkyl substitution on these cyclic structures is specifically identified.
- Saturated monocyclic and bicyclic carbocyclic moieties include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and decahydronapthalene.
- Partially saturated monocyclic and bicyclic carbocyclic moieties include cyclopentenyl, cyclohexenyl, cyclohexadienyl and tetrahydronaphthalene.
- Saturated monocyclic and bicyclic heterocyclic moieties include tetrahydropyranyl, tetraliydrofuranyl, 1,3-dioxolane, 1,4-dioxanyl, morpholinyl, thiomorpholinyl, piperazinyl, piperidinyl, piperidinonyl, tetrahydropyrimidonyl, pentamethylene sulfide and tetramethylene sulf ⁇ de.
- Partially saturated monocyclic and bicyclic heterocyclic moieties include dihydropyranyl, dihydrofuranyl, dihydrothienyl, dihydropiperidinyl, and dihydropyrimidonyl.
- a subclass of compounds of this invention is defined by formula I, wherein A B and M are selected from phenyl, naphthyl, furyl, isoindolinyl, oxadiazolyl, oxazolyl, isooxazolyl, pyrazolyl, pyridinyl, pyrimidinyl, pyrrolyl, quinolinyl, isoquinolinyl, tetrazolyl, thiadiazolyl, thiazolyl and thienyl and are optionally substituted as defined above.
- substituents for B include methyl, trifluoromethyl, ethyl, n-propyl, n- butyl, n-pentyl, isopropyl, isobutyl, sec-butyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl, methoxy, ethoxy, propoxy, CI, Br and F, cyano, nitro, hydroxy, amino, methylamino, dimethylamino, ethylamino and diethylamino as well as the structure -L-M.
- Preferred substituents for A and M include methyl, trifluoromethyl, ethyl, n- propyl, n-butyl, n-pentyl, isopropyl, tert-butyl, sec-butyl, isobutyl, cyclopropyl, cyclobutyl, cyclopentyl, methoxy, ethoxy, propoxy, CI, Br and F, cyano, nitro, hydroxy, amino, methylamino, dimethylamino, ethylamino and diethylamino and further include: phenyl, pyridinyl, pyrimidinyl, chlorophenyl, dichlorqphenyl, bromophenyl, dibromophenyl, chloropyridinyl, bromopyridinyl, dichloropyridinyl, dibromopyridinyl methylphenyl, methylpyridinyl quinoliny
- d-C 5 acyl NH(C ⁇ -C 5 alkyl, phenyl or pyridinyl), such as aminophenyl; N(d-C 5 alky ⁇ )(d-C 5 alkyl, phenyl or pyridinyl), such as diethylamino and dimethyl amino;
- S(O) q (d-d alkyl) such as methanesulfonyl; S(O) q H; SO 2 NH 2 ;
- Each of the above substituents is optionally partially or fully halogenated, such as difluoromethyl sulfonyl.
- An embodiment of this invention includes the administration of compounds of this invention wherein in formula I, A, B and M follow one of the following of combinations:
- A phenyl
- B phenyl and M is phenyl, pyridinyl, quinolinyl, isoquinolinyl or not present,
- A phenyl
- B pyridinyl and M is phenyl, pyridinyl, quinolinyl, isoquinolinyl or not present,
- A pyridinyl
- B pyridinyl and M is phenyl, pyridinyl, quinolinyl, isoquinolinyl or not present,
- A pyridinyl
- B naphthyl and M is. phenyl, pyridinyl, quinolinyl, isoquinolinyl or not present,
- A isoquinolinyl
- B phenyl and M is phenyl, pyridinyl, quinolinyl, isoquinolinyl or not present,
- A quinolinyl
- B pyridinyl and M is phenyl, pyridinyl, quinolinyl, isoquinolinyl or not present
- A quinolinyl
- B naphthyl and M is phenyl, pyridinyl, quinolinyl, isoquinolinyl or not present.
- the structure L of formula I is preferably -O-, a single bond, -S-, -NH-, -
- optical isomers can be obtained by resolution of the racemic mixtures according to conventional processes, for example, by the formation of diastereoisomeric salts using an optically active acid or base.
- appropriate acids are tartaric, diacetyltartaric, dibenzoyltartaric, ditoluoyltartaric and camphorsulfonic acid.
- Mixtures of diastereoisomers can be separated into their individual diastereomers on the basis of their physical chemical differences by methods known to those skilled in the art, for example, by chromatography or fractional crystallization.
- the optically active bases or acids are liberated from the separated diastereomeric salts.
- Another process, for separation of optical isomers involves the use of a chiral chromatography column (e.g., chiral HPLC columns) optimally chosen to maximize the separation of the enantiomers.
- a chiral HPLC column e.g., chiral HPLC columns
- Suitable chiral HPLC columns are manufactured by Diacel, e.g., Chiracel OD and Chiracel OJ.
- Formula (I) can likewise be obtained by utilizing optically active starting materials.
- the present invention encompasses any isolated racemic or optically active form of compounds described in Formula I which possess angiogenesis inhibitory activity.
- the term . stereoisomer is understood to encompass diastereoisomers, enantiomers, geometric isomers, etc.
- substantially pure enantiomers is intended to mean that no more than 5% w/w of the corresponding opposite enantiomer is present.
- Salts are especially the pharmaceutically acceptable salts of compounds of formula (I) or such as, for example, organic or inorganic acid addition salts of compounds of formula (I).
- Suitable inorganic acids include but are not limited to halogen acids (such as hydrochloric acid and hydrobromic acid), sulfuric acid, or phosphoric acid.
- Suitable organic acids include but are not limited to carboxylic, phosphonic, sulfonic, or sulfamic acids, with examples including acetic acid, propionic acid, octanoic acid, decanoic acid, trifluoroacetic acid, dodecanoic acid, glycoiic acid, lactic acid, 2- or 3-hydroxybutyric acid, ⁇ -aminobutyric acid (GAB A), gluconic acid, glucosemonocarboxylic acid, benzoic acid, salicylic acid, phenylacetic acid and mandelic acid, fumaric acid, succinic acid, adipic acid, pimelie acid, suberic acid, azeiaic acid, malic acid, tartaric acid, citric acid, glucaric acid, galactaric acid, amino acids (such as glutamic acid, aspartic acid, N-methylglycine, acetytaminoacetic acid, N-acetylasparagine or N-aceryl
- pharmaceutically acceptable salts include acid salts of inorganic bases, such as salts containing alkaline cations (e.g., Li + Na + or K + ), alkaline earth cations (e.g., Mg +2 , Ca +2 or Ba +2 ), the ammonium cation, as well as acid salts of organic bases, including aliphatic and aromatic substituted ammonium, and quaternary ammonium cations, such as those arising from protonation or peralkylation of triethylamine, N,N-diethylamine, N,N-dicyclohexylamine, lysine, pyridine, N,N- dimethylaminopyridine (DMAP), l,4-diazabiclo[2.2.2]pctane (DABCO), 1,5- diazabicyclo[4.3.0]non-5-ene (DB ⁇ ) and l,8-diazabicyclo[5.4.0]undec-7-ene
- prodrugs are well known in the art in order to enhance the properties of the parent compound; such properties include solubility, absorption, biostability and release time (see “Pharmaceutical Dosage Form and Drug Delivery
- Major drug biotransformation reactions include ⁇ -dealkylation, O-dealkylation, aliphatic hydroxylation, aromatic hydroxylation, ⁇ -oxidation, S-oxidation, deamination, hydrolysis reactions, glucuronidation, sulfation and acetylation (see Goodman and Gilman's The Pharmacological Basis of Therapeutics (Ninth Edition), editor Molinoff et al., pub. by
- the invention also relates to methods for treating and preventing diseases, for example, angiogenesis disorders in mammals by administering a compound of this invention or a pharmaceutical composition comprising one or more compounds of this invention.
- a compound according to the invention can be administered simultaneously with another angiogenesis inhibiting agent to a patient with such a disorder, in the- same formulation or, more typically in separate formulations and, often, using different administration routes. Administration can also be sequentially, in any order.
- a compound according to the invention can be administered in tandem with another angiogenesis inhibiting agent, wherein a compound according to the invention can be administered to a patient once or more per day for up to 28 consecutive days with the concurrent or intermittent administration of another angiogenesis inhibiting agent over the same total time period.
- a compound according to the invention can be administered to a patient at an oral, intravenous, intramuscular, subcutaneous, or parenteral dosage which can range from about 0.1 to about 200 mg/kg ,of total body weight and the additional angiogenesis inhibiting agent can be administered to a patient at an intravenous, intramuscular, subcutaneous, or parenteral dosage which can range from about 0.1 mg to 200 mg/kg of patient body weight.
- An embodiment of the present invention is a method for treating diseases in humans and/or other mammals which are mediated by the VEGF induced signal transduction pathway which comprises administering a compound of this invention to a human or other mammal.
- Another embodiment of this invention is a method for treating diseases in humans and/or other mammals which are characterized by abnormal angiogenesis or hyperpermiability processes with a compound of this invention to a human or other mammal.
- Another embodiment of this invention is a method for treating diseases in humans and/or other mammals which are characterized by abnormal angiogenesis or hyperpermiability processes, which are not raf-mediated, which comprises administering a compound of this invention to a human or .other mammal.
- Another embodiment of this invention is a method for treating diseases in humans and/or other mammals which are characterized by abnormal angiogenesis or hyperpermiability processes, which are not ' raf mediated or p38-mediated, which comprises administering a compound of this invention to a human or other mammal.
- Another embodiment of this, invention is a method for treating diseases in humans and/or other mammals which are characterized by abnormal angiogenesis or hyperpermiability processes, which are raf-mediated and/or p38 mediated, which; comprises administering a compound of this invention to a human or other mammal.
- Another embodiment of this invention is a method for treating one or more of the following conditions in humans and/or other mammals: tumor growth, retinopathy, including diabetic retinopathy, ischemic retinal-vein occlusion, retinopathy of prematurity and age related macular degeneration; rheumatoid arthritis, psoriasis, or bullous disorder associated with subepidermal blister formation, including bullous pemphigoid, erythema multiforme, or dermatitis herpetiformis, which comprises administering a compound of this invention to a human or other mammal with one or more of these conditions.
- Another embodiment of this invention is a method for treating one or more of the following conditions in humans and/or other mammals: tumor growth, retinopathy, diabetic retinopathy, ischemic retinal-vein occlusion, retinopathy of prematurity, age related macular degeneration; rheumatoid arthritis, psoriasis, bullous disorder associated with subepidermal blister formation, bullous ⁇ pemphigoid, erythema multiforme, and dermatitis herpetiformis in combination with another condition selected from the group consisting of: rheumatic fever, bone resorption, postmenopausal osteoporosis, sepsis, gram negative sepsis, septic shock, endotoxic shock, toxic shock syndrome, systemic inflammatory response syndrome, inflammatory bowel disease (Crohn's disease and ulcerative colitis), Jarisch-Herxheimer reaction, asthma, adult respiratory distress syndrome, acute pulmonary fibrotic disease, pulmonary sarcoidosis,
- Another embodiment of this invention is a method for treating one or more of the following conditions in humans and/or other mammals: tumor growth, retinopathy, diabetic retinopathy, ischemic retinal- vein occlusion, retinopathy of prematurity, age related macular degeneration; rheumatoid arthritis, psoriasis, bullous disorder associated with subepidermal blister formation, bullous pemphigoid, erythema multiforme, and dermatitis herpetiformis, in combination with an infectious disease selected from the group consisting of : tuberculosis, Helicobacter pylori infection during peptic ulcer disease, .
- Chaga's disease resulting from Trypanosoma cruzi infection effects of Shiga-like toxin resulting from E. coli infection, effects " of enterotoxin A resulting from Staphylococcus infection, meningococcal infection, and infections from Borrelia burgdorferi, Treponema pallidum, cytomegalovirus, influenza virus, Theiler's encephalomyelitis virus, and the human immunodeficiency virus (FfTV).
- These methods comprise administering a compound of this invention to a human or other mammal with a combination of one of the above infectious diseases and one of the above diseases characterized by abnormal angiogenesis or hyperpermiability processes.
- This invention further relates to kits comprising separate doses of the two mentioned chemotherapeutic agents in separate containers.
- the combinations of angiogenesis inhibiting agents can also be formed in vivo, e.g., in a patient's body.
- angiogenesis inhibiting agents can be administered in the conventional formulations and regimens in which they are known for use alone.
- Conditions within a human or other mammal which can be treated by administering a compound of this invention are those characterized by abnormal angiogenesis or hyperpermiability processes.
- Conditions to be treated include tumor growth, retinopathy, including diabetic retinopathy, ischemic retinal-vein occlusion, retinopathy of prematurity and age related macular degeneration; rheumatoid arthritis, psoriasis, or a bullous disorder associated with subepidermal blister formation, including bullous pemphigoid, erythema multiforme, and dermatitis herpetiformis.
- Methods of interest include the treatment of combinations of the conditions above (tumor growth, retinopathy, diabetic retinopathy, ischemic retinal-vein j occlusion, retinopathy of prematurity, age related macular degeneration; rheumatoid arthritis, psoriasis, bullous disorder associated with subepidermal blister formation, bullous pemphigoid, erythema multiforme, and dermatitis herpetiformis) and another condition selected from the group consisting of:
- rheumatic fever fever, bone resorption, postmenopausal osteoperosis, sepsis, gram negative sepsis, septic shock, endotoxic shock, toxic shock syndrome, systemic inflammatory response syndrome, inflammatory bowel disease (Crohn's disease and ulcerative colitis), Jarisch-Herxheimer reaction,- asthma, adult respiratory distress syndrome, acute pulmonary fibrotic disease, pulmonary sarcoidosis, allergic respiratory disease, silicosis, coal worker's pneumoconiosis, alveolar injury, hepatic failure, liver disease during acute inflammation, severe alcoholic hepatitis, malaria (Plasmodium falciparum malaria and cerebral malaria), non-insulin-dependent diabetes mellitus (NTDDM), congestive heart failure, damage following heart disease, atherosclerosis, Alzheimer's disease, acute encephalitis, brain injury, multiple sclerosis (demyelation and oligi ⁇ dendrocyte loss in multiple sclerosis), advanced cancer, lymphoi
- tuberculosis Helicobacter pylori infection during peptic ulcer disease
- Staphylococcus infection meningococcal infection, and infections from Borrelia burgdorferi, Treponema pallidum, cytomegalo virus, influenza virus, Theiler's encephalomyelitis virus, and the human immunodeficiency virus (HIV).
- HIV human immunodeficiency virus
- the compounds of this invention can be made according to conventional chemical methods, and/or as disclosed below, from starting materials which are either commercially available or producible according to routine, conventional chemical methods. General methods for the preparation of the compounds are given below, and the preparation of a suitable compound is specifically illustrated in the Examples.
- Heterocyclic amines may be synthesized utilizing known methodology (Katritzky, et al. Comprehensive Heterocyclic Chemistry; Permagon Press: Oxford, UK (1984). March. Advanced Organic Chemistry, 3 rd Ed.; John Wiley: New York (1985)).
- Cyanoketone 2 in turn, is available from the reaction of acetamidate ion with an appropriate acyl derivative, such as an ester, an acid halide, or an acid anhydride.
- an appropriate acyl derivative such as an ester, an acid halide, or an acid anhydride.
- 2-aryl- and 2-heteroarylfurans may be synthesized from a Mitsunobu reaction of cyanoketone 2 with alcohol 5, followed by base catalyzed cyclization of enol ether 6 to give furylamine 7.
- aryl amines are commonly synthesized by reduction of nitroaryls using a metal catalyst, such as Ni, Pd, or Pt, and H or a hydride transfer agent, such as formate, cyclohexadiene, or a borohydride (Rylander. Hydrogenation Methods;
- Nitroaryls may also be directly reduced using a strong hydride source, such as LiAlEU (Seyden-Penne. Reductions by the Alumino- and Borohydrides in Organic Synthesis; VCH Publishers: New York (1991)), or using a zero valent metal, such as Fe, Sn or Ca, often in acidic media.
- a strong hydride source such as LiAlEU (Seyden-Penne. Reductions by the Alumino- and Borohydrides in Organic Synthesis; VCH Publishers: New York (1991)
- a zero valent metal such as Fe, Sn or Ca
- Nitroaryls are commonly formed by electrophilic aromatic nitration using HNO 3 , or an alternative NO 2 + source. Nitro aryls may be further elaborated prior to reduction. Thus, nitroaryls substituted with
- potential leaving groups may undergo substitution reactions on treatment with nucleophiles, such as thiolate (exemplified in Scheme HT) or phenoxide. Nitroaryls may also undergo Ullman-type coupling reactions (Scheme AT).
- urea formation may involve reaction of a heteroaryl isocyanate (12) with an aryl amine (11).
- the heteroaryl isocyanate may be synthesized from a heteroaryl amine by treatment with phosgene or a phosgene equivalent, such as trichloromethyl chloroformate (diphosgene), bis(trichlorom . ethyl) carbonate (triphosgene), or N.N'-carbonyldiimidazole (GDI).
- the isocyanate may also be derived from a heterocyclic carboxylic acid derivative, such as an ester, an acid halide or an anhydride by a Curtius-type rearrangement.
- reaction of acid derivative 16 with an azide source, followed by rearrangement affords the isocyanate.
- the corresponding carboxylic acid (17) may also be subjected to Curtius-type rearrangements using diphenylphosphoryl azide (DPP A) or a similar reagent.
- DPP A diphenylphosphoryl azide
- a urea may also be generated from the reaction of an aryl isocyanate (15) with a heterocyclic amine.
- ureas may be further manipulated using methods familiar to those skilled in the art.
- 2-aryl and 2-heteroarylthieriyl ureas are available from the corresponding 2-halothienyl urea through transition metal mediated cross coupling reactions (exemplified with 2-bromothiophene 25, Scheme V).
- reaction. of nitrile 20 with an ⁇ -thioacetate ester gives 5-substituted-3-amino-2- thiophenecarboxylate 21 (Ishizaki et al. JP 6025221).
- Decarboxylation of ester 21 may be achieved by protection of the amine, for example as the tert-butoxy (BOC) carbamate (22), followed by saponification and treatment with acid.
- BOC protection is used, decarboxylation may be accompanied by deprotection giving the substituted 3-thiopheneammonium salt 23.
- ammonium salt 23 may be directly generated through saponification of ester 21 followed by treatment with acid. Following urea formation as described above, bromination affords penultimate halothiophene 25.
- ureas may be further manipulated using methods familiar to those skilled in the art.
- the compounds may be administered orally, . topically, parenterally, by inhalation or spray or vaginally, sublingually, or rectally in dosage unit formulations.
- injection includes intravenous, intramuscular, subcutaneous and parenteral injections, as well as use of infusion techniques.
- Dermal administration may include topical application or transdermal administration.
- One or more compounds may be present in association with one or more non-toxic pharmaceutically acceptable carriers and if desired other active ingredients.
- compositions intended for oral use may be prepared according to any suitable method known to the art for the manufacture of pharmaceutical compositions.
- Such compositions may contain one or more- agents selected from the group consisting of diluents, sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide palatable preparations.
- Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
- excipients may be, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, microcrystalline cellulose, carboxymethyl cellulose, hydroxypropylmethylcellulose or alginic acid; and binding agents, for example magnesium stearate, stearic acid or talc . and lubricants/surfactants such as sodium lauryl sulfate.
- the tablets may be uncoated or they may be coated by known techniques to delay disintegration and adsorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
- a time delay material such as glyceryl monostearate or -glyceryl distearate may be employed. These compounds may also be prepared in solid, rapidly released form.
- Formulations for oral use may also -be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an . oil medium, for example peanut oil, liquid paraffin or olive oil.
- an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
- water or an . oil medium for example peanut oil, liquid paraffin or olive oil.
- Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions.
- excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be .
- a naturally occurring phosphatide for example, lecithin, or condensation products or an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethylene oxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate.
- a naturally occurring phosphatide for example, lecithin
- condensation products or an alkylene oxide with fatty acids for example polyoxyethylene stearate
- condensation products of ethylene oxide with long chain aliphatic alcohols for example heptadecaethylene oxycetanol
- condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol such as polyoxyethylene
- the aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl jp-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.
- preservatives for example ethyl, or n-propyl jp-hydroxybenzoate
- coloring agents for example ethyl, or n-propyl jp-hydroxybenzoate
- flavoring agents such as sucrose or saccharin.
- sweetening agents such as sucrose or saccharin.
- Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives.
- a dispersing or wetting agent e.g., talc, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol,
- the compounds may also be in the form of non-aqueous liquid formulations, e.g., oily suspensions which may be formulated by suspending the active ingredients in a vegetable oil, for example arachis oil, olive oil, sesame oil or peanut oil, or in a mineral oil such as liquid paraffin.
- the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and. flavoring agents may be added to provide palatable oral preparations. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
- compositions of the invention may also be in the form of oil- in-water emulsions.
- the oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these.
- Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate.
- the emulsions may also contain sweetening and flavoring agents.
- Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.
- sweetening agents for example glycerol, propylene glycol, sorbitol or sucrose.
- Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.
- the compounds may also be administered in the form of suppositories for rectal or vaginal administration of the drug.
- compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal or yaginal temperature and will therefore melt in the rectum or vagina to release the drug.
- suitable non-irritating excipient include cocoa butter and polyethylene glycols.
- Compounds of the invention may also be administrated transdermally using methods known to those skilled in the art (see, for example: Chien; “Transdermal Controlled Systemic Medications”; Marcel Dekker, Inc.; 1987. Lipp et al. WO94/04157 3Mar94).
- Formula I in a suitable volatile solvent optionally containing penetration enhancing agents can be combined with additional additives known to those skilled in the art, such as matrix materials and bacteriocides. After sterilization, the resulting mixture can be formulated following known procedures into dosage forms, hi addition, on treatment with emulsifying agents and water, a solution or suspension of a compound of Formula I may be formulated into a lotion or salve.
- Suitable solvents for processing transdermal delivery systems are known to those skilled in the art, and include lower alcohols such as ethanol or isopropyl alcohol, lower ketones such as acetone, lower carboxylic acid esters such as ethyl acetate, polar ethers such as tetrahydrofuran, lower hydrocarbons such as hexane, cyclohexane or benzene, or halogenated hydrocarbons such as dichloromethane, chloroform, trichlorotriffuoroethane, or trichlorofluoroethane.
- Suitable solvents may also include mixtures of one or more materials selected from lower alcohols, lower ketones, lower carboxylic acid esters, polar ethers, lower hydrocarbons, halogenated hydrocarbons.
- Suitable penetration enhancing materials for transdermal. delivery system include,- for example, monohydroxy or polyhydroxy alcohols such as ethanol, propylene glycol Or benzyl alcohol, saturated or unsaturated C 8 -C ⁇ 8 fatty alcohols such, as lauryl alcohol or cetyl alcohol, saturated or - unsaturated C 8 -C ⁇ 8 fatty acids such as stearic acid, saturated or unsaturated fatty esters with up to 24 carbons such as methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl isobutyl tertbutyl or monoglycerin esters of acetic acid, capronic acid, lauric acid, myristinic acid, stearic acid, or palmitic acid, or.diesters of saturated or unsaturated dicarboxylic acids with a total of up to 24 carbons such as diisopropyl adipate, diisobutyl adip
- Additional penetration enhancing materials include phosphatidyl derivatives such as lecithin or cephalin, terpenes, amides, ketones, ureas and their derivatives, and ethers such as dimethyl isosorbid and diethyleneglycol monoethyl ether.
- Suitable penetration enhancing formulations may also include mixtures of one or more .
- materials selected from -monohydroxy or polyhydroxy alcohols, saturated or unsaturated C 8 -C 18 fatty alcohols, saturated or unsaturated C 8 -C 18 fatty acids, saturated or unsaturated fatty esters with up to 24 carbons, diesters of saturated or unsaturated discarboxylic acids with a total of up to 24 carbons, phosphatidyl derivatives, terpenes, amides, ketones, ureas and their derivatives, and ethers.
- Suitable binding materials for transdermal delivery systems are known to those skilled in the art and include polyacrylates, silicones, polyurethanes, block polymers, styrenebutadiene coploymers, and natural and synthetic rubbers. Cellulose ethers, derivatized polyethylenes, and silicates may also be used as matrix components. Additional additives, such as viscous resins or oils may be added to increase the viscosity of the matrix.
- the daily oral dosage regimen will preferably be from 0.01 to 200 mg/Kg of total body weight.
- the daily dosage for administration by injection will preferably be from 0.01 to 200 mg/Kg of total body weight.
- the daily vaginal dosage regimen will preferably be from 0.01 to 200 mg/Kg of total body weight.
- the daily rectal dosage regime will preferably be from 0.01 to 200 mg/Kg of total body weight.
- the daily topical dosage regime will preferably be from 0.1 to 200 mg administered
- the transdermal concentration will preferably be that required to maintain a daily dose of from 0.01 to 200 mg/Kg.
- the daily inhalation dosage regime will preferably be from 0.01 to 10 mg/Kg of total body weight.
- the specific dose level for any given patient will depend upon a variety of factors, including, the activity of the specific compound employed, the age of the patient, the body weight of the patient, the general health of the patient, the gender of the patient, the diet of the patient, time of administration, route of administration, rate of excretion, drug combinations, and the severity of the condition undergoing therapy.
- the specific dose level for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, and rate of excretion, drug combination and the severity of the condition undergoing therapy.
- Neoplasm by Inhibition of raf Kinase using N-Heteroaryl-N'-(hetero)arylureas" PCT
- the compounds of this invention are producible from known compounds (or from starting materials which, in turn, are producible from known compounds), e.g., through the general preparative methods shown below.
- the activity of a given compound to inhibit angiogenesis activity can be routinely assayed, e.g., according to procedures disclosed below.
- Thin-layer chromatography was performed on Whatman ® pre-coated glass-backed silica gel 60A F-254 250 ⁇ m plates. Visualization of plates was effected by one or more of the following techniques: (a) ultraviolet illumination, (b) exposure to iodine vapor, (c) immersion of the plate in a 10% solution of phosphomolybdic acid in ethanol followed by heating, (d) immersion of the plate in a cerium sulfate solution followed by heating, and/or (e) immersion of the plate in an acidic ethanol solution of 2,4-dinitrophenylhydrazine followed by heating. Column chromatography (flash chromatography) was performed using 230-400 mesh EM Science ® silica gel.
- Carbon ( 13 C) NMR spectra were measured with a General Electric GN-Omega 300 (75 MHz) spectrometer with solvent (CDC1 3 ⁇ 77.0; MeOD-d 3 ; ⁇ 49.0; DMSO-d 6 ⁇ 39.5) as standard.
- Low resolution mass spectra (MS) and high resolution mass spectra (HRMS) were either obtained as electron impact (El) mass spectra or as fast atom bombardment (FAB) mass spectra.
- Electron impact mass spectra (EI-MS) were obtained with a Hewlett Packard 5989A mass spectrometer equipped with a Vacumetrics Desqrption Chemical Ionization Probe for sample introduction. The ion source was maintained at 250 °C.
- Electron impact ionization was performed with electron energy of 70 eV and a trap current of 300 ⁇ A.
- Liquid-cesium secondary ion mass spectra (FAB-MS), an updated version of fast atom bombardment were obtained using a Kratos Concept 1-H spectrometer.
- Chemical ionization mass spectra (CI-MS) were obtained using a Hewlett Packard MS-Engine (5989A) with methane as the reagent gas (lxlO "4 torr to 2.5xl0 "4 torr).
- the direct insertion desorption chemical ionization (DCI) probe (Vaccumetrics, Inc.) was ramped from 0-1.5 amps in 10 sec and held at 10 amps until all traces of the sample disappeared ( ⁇ l-2 min). Spectra were scanned from 50-800 amu at 2 sec per scan.
- HPLC - electrospray mass spectra (HPLC ES-MS) were obtained using a Hewlett-Packard 1100 HPLC equipped with a quaternary pump, a variable wavelength detector, a C-18 column, and a Finnigan LCQ ion trap mass spectrometer with electrospray ionization. Spectra were scanned from 120-800 amu using a variable ion time according to the number of ions in the source.
- GC-MS Gas chromatography - ion selective mass spectra
- Step 3 Preparation of N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ⁇ 4-[2-carbamoyl-(4- pyridyloxy)]phenyl ⁇ urea
- Step 1 4-Chloro-N-methyl-2-pyridinecarboxamide is first synthesized from 4- chloropyridine-2-carbonyl chloride by adding 4-chloropyridine-2-carbonyl chloride HCl salt (7.0 g, 32.95 mmol) in portions to a mixture of a 2.0 M methylamine solution in THF (100 mL) and MeOH (20 mL) at 0 °C. The resulting mixture is stored at 3 °C for 4 h, then concentrated under reduced pressure.
- Step 2 A solution of 4-aminophenol (9.60 g, 88.0 mmol) in anh. DMF (150 mL) is treated with potassium tert-butoxide (10.29 g, 91.7 mmol), and the reddish-brown mixture is stirred at room temp, for 2 h. The contents are treated with 4-chloro-N- methyl-2-pyridinecarboxamide (15.0 g, 87.9 mmol) from Step 1 and K 2 CO 3 (6.50 g,
- Step 3 A solution of 4-chloro-3-(trifluoromethyl)phenyl isocyanate (14.60 g, 65.90 mmol) in CH 2 C1 2 (35 mL) is added .dropwise to a suspension of 4-(2-(N- methylcarbamoyl)-4-pyridyloxy)aniline from Step 2; (16.0 g, 65.77 mmol) in CH 2 C1 (35 mL) at 0 °C. The resulting mixture is stirred at room temp, for 22 h.
- Step 1 4-Chloro-N-methyl-2-pyridmecarboxamide ' is first synthesized from 4- chloropyridine-2-carbonyl chloride by adding 4-chloropyridine-2-carbonyl chloride HCl salt (7.0 g, 32.95 mmol) in portions to a mixture of a 2.0 M methylamine solution in THF (100 mL) and MeOH (20 mL) at 0 °C. The resulting mixture is stored at 3 °C for 4 h, then concentrated under reduced pressure. The resulting nearly dry solids are. suspended in EtOAc (100 mL) and filtered. The filtrate is washed with a saturated NaCl solution (2 x 100 mL), dried (Na 2 SO ) and concentrated under reduced pressure to provide 4-chloro-N-methyl-2-pyridinecarboxamide as a yellow, crystalline solid.
- 4-chloro-N-methyl-2-pyridmecarboxamide ' is first synthesized from 4- chloropyridine-2-carbonyl
- Step 2 A solution of 4-aminophenol (9.60 g, 88.0 mmol) in anh. DMF (150 mL) is treated with potassium tert-butoxide (10.29 g, 91.7 mmol), and the reddish-brown mixture is stirred at room temp, for 2 h. The contents are treated with 4-chloro-N- methyl-2-pyridinecarboxamide (1-5.0 g, 87.9 mmol) from Step 1 and K 2 CO 3 (6.50 g, 47.0 mmol) and then heated at 80 °C for 8 h. The mixture is cooled to room temp. ' and separated between EtOAc (500 mL) and a saturated ⁇ aCl solution (500 mL).
- Step 3 To a solution of 2-methoxy-5-(trifluoromethyl)aniline (0.15 g) in anh CH C1 2 (15 mL) at 0 °C is added GDI (0.13 g). The resulting solution is allowed to warm to room temp, over 1 h, is stirred at room temp, for 16 h, then is treated with 4-(2-(N- methylcarbamoyl)-4-pyridyloxy)aniline (0.18 g) from Step 2. The resulting yellow solution is stirred at room temp, for 72 h, then is treated with H O (125 mL). The resulting aqueous mixture is extracted with EtOAc (2 x 150 mL).
- the cytosolic kinase domain of KDR kinase was expressed as a 6His fusion protein in Sf9 insect cells.
- the KDR kinase domain fusion protein was purified over a Ni++ chelating column.
- HEPES buffer 20 mM poly(Glu4;Tyrl) (Sigma Chemical Co., St. Louis, MO) in 100 ⁇ k HEPES buffer (20 mM HEPES, pH 7.5, 150 mM Na CI, 0.02% Thimerosal) at 4° overnight.
- test compounds were serially diluted in 100% DMSO form 4 mM to 0.12 ⁇ M in half-log dilutions. These dilutions were further diluted twenty fold in H 2 O to obtain compound solutions in 5% DMSO.
- assay buffer (20 mM HEPES, pH 7.5, 100 mM KC1, 10 mM MgCl 2 , 3 mM MnCl 2 , 0.05% glycerol, 0.005% Triton X-100, 1 mM -mercaptoethanol, with or without 3.3 ⁇ M ATP
- 5 ⁇ l of the diluted compounds were added to a final assay volume of 100 ⁇ l.
- Final concentrations were between 10 ⁇ M, and 0.3 mM in 0.25% DMSO.
- the assay was initiated by the addition of lO ⁇ l (30 ' ng) of KDR kinase domain.
- the assay was incubated with test compound or vehicle alone with gentle agitation at room temperature for 60 minutes.
- the wells were washed and phosphotyrosines (PY) were probed with ah anti-phosphotyrosine (PY), mAb clone 4G10 (Upstate Biotechnology, Lake Placid, NY).
- PY/anti-PY complexes were detected with an anti-mouse IgG/HRP conjugate Iamersham International pic, Buckinghamshire, England).
- Phosphotyrosine was quantitated by incubating with 100 ⁇ l 3, 3', 5, 5' tetramethylbenzidine solution (Kirkegaard and Perry, TMB Microwell 1 Component peroxidase substrate). Color development was arrested by the addition of 100 ⁇ l 1% HCl-based stop solution (Kirkegaard and Perry, TMB 1 Component Stop Solution).
- % Inhibition (ODfvehicle control) - OD (with compound) X 100 OD (vehicle control) - OD (no ATP added)
- IC 5 o values were determined with a least squares analysis program using compound concentration versus percent inhibition.
- NTH3T3 cells expressing the full length KDR receptor are grown in DMEM (Life Technologies, Inc., Grand Island, NY) supplemented with 10% newborn calf serum, low glucose, 25 mM/L sodium pyruvate, pyridoxine hydrochlori.de and 0.2 mg/ml of G418 (Life Technologies Inc., Grand Island, NY).
- the cells are maintained in collagen I-coated T75 flasks (Becton Dickinson Labware, Bedford, MA) in a humidified 5% CO2 atmosphere at 37°C.
- the buffer is removed and the cells are lysed by addtion of 150 ⁇ l of extraction buffer (50 mM Tris, pH 7.8, supplemented with 10% glycerol, 50 mM BGP, 2 mM EDTA, 10 mM NaF, 0.5 mM NaVO4, and 0.3% TX-100) at 4°C for 30 minutes.
- extraction buffer 50 mM Tris, pH 7.8, supplemented with 10% glycerol, 50 mM BGP, 2 mM EDTA, 10 mM NaF, 0.5 mM NaVO4, and 0.3% TX-100
- each cell lysate 100 micro liters of each cell lysate are added to the wells of an ELISA plate precoated with 300 ng of antibody C20 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA). Following a 60-minute incubation, the plate is washed and bound KDR is probed for phosphotyrosine using an anti- phospho tyrosine mAb clone 4G10 (Upstate Biotechnology, Lake Placid, NY). The plate is washed and wells are incubated with anti-mouse IgG/HRP conjugate
- Optical densities are determined spectrophotometrically at 450 mm in a
- IC 5 os are determined on some of the exemplary materials with at least squares analysis program using compound concentration versus percent inhibition.
- Matrigel® (Collaborative Biomedical Products, Bedord, MA) is a basement membrane extract from a murine tumor composed primarily of laminin, collagen IV and heparan sulfate proteoglycan.
- Liquid Matrigel at 4°C is mixed with SK-MEL2 human tumor cells that are transfected with a plasmid containing the murine VEGF gene with a selectable marker. Tumor cells are grown in vitro under selection and cells are mixed with cold liquid Matrigel at a ratio of 2 X 10 6 per 0.5 ml. One half milliliter is implanted subcutaneously near the abdominal midline using a 25 gauge needle. Test compounds are dosed as solutions in Ethanol/Ceremaphor EL/saline (12.5%:12.5%:75%) at 30, 100, and 300 mg/kg po once daily starting on the day of implantation. Mice are euthanized 12 days post-implantation and the Matrigel pellets are harvested for analysis of hemoglobin content.
- the Matrigel pellets are placed in 4 volumes (w/v) of 4°C Lysis Buffer (20mM Tris pH 7.5, lmM EGTA, ImM EDTA, 1% Triton X-100 [EM Science, Gibbstown, N.J.], and complete EDTA-free protease inhibitor cocktail [Mannheim, Germany]), and homogenized at 4°C. homogenates are incubated on ice for 30 minutes with shaking and centrifuged at 14K x g for 30 minutes at 4°C.
- 4°C Lysis Buffer 20mM Tris pH 7.5, lmM EGTA, ImM EDTA, 1% Triton X-100 [EM Science, Gibbstown, N.J.], and complete EDTA-free protease inhibitor cocktail [Mannheim, Germany]
- Mouse hemoglobin (Sigma Chemical Co., St. Louis, MO) is suspended in autoclaved water (BioWhittaker, Lie, Walkersville, MD.) at 5 mg/ml. A standard curve is generated from 500 micrograms/ml to 30 micrograms/ml in Lysis Buffer (see above). Standard curve and lysate samples are added at 5 microliters/well in duplicate to a polystyrene 96-well plate.
- TMB substrate is reconstituted in 50 mis room temperature acetic acid solution. One hundred microliters of substrate is added to each well, followed by 100 microliters/well of Hydrogen Peroxide Solution at room temperature. The plate is incubated at room temperature for 10 minutes.
- Optical densities are determined spectrophotometrically at 600 nm in a 96-well plate reader, SpectraMax 250 Microplate Spectrophotometer System (Molecular
- % Inhibition (Average Total Hemoglobin Drug-Treated Tumor Lysates) X 100 (Average Total Hemoglobin Non-Treated Tumore Lysates).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SI200332285T SI1478358T1 (en) | 2002-02-11 | 2003-02-11 | Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis |
CA2475703A CA2475703C (en) | 2002-02-11 | 2003-02-11 | Aryl ureas with angiogenesis inhibiting activity |
EP03707846.6A EP1478358B1 (en) | 2002-02-11 | 2003-02-11 | Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis |
MXPA04007832A MXPA04007832A (en) | 2002-02-11 | 2003-02-11 | Aryl ureas with angiogenesis inhibiting activity. |
AU2003209116A AU2003209116A1 (en) | 2002-02-11 | 2003-02-11 | Aryl ureas with angiogenesis inhibiting activity |
DK03707846.6T DK1478358T3 (en) | 2002-02-11 | 2003-02-11 | Sorafenibtosylate for the treatment of diseases characterized by abnormal angiogenesis |
ES03707846T ES2425739T3 (en) | 2002-02-11 | 2003-02-11 | Sorafenib-tosylate for the treatment of diseases characterized by abnormal angiogenesis |
JP2003567410A JP4636486B2 (en) | 2002-02-11 | 2003-02-11 | Arylurea with angiogenesis inhibitory activity |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35495002P | 2002-02-11 | 2002-02-11 | |
US60/354,950 | 2002-02-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003068228A1 true WO2003068228A1 (en) | 2003-08-21 |
Family
ID=27734443
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/004103 WO2003068228A1 (en) | 2002-02-11 | 2003-02-11 | Aryl ureas with angiogenesis inhibiting activity |
Country Status (11)
Country | Link |
---|---|
US (4) | US7838541B2 (en) |
EP (2) | EP2324825A1 (en) |
JP (2) | JP4636486B2 (en) |
AU (1) | AU2003209116A1 (en) |
CA (1) | CA2475703C (en) |
DK (1) | DK1478358T3 (en) |
ES (1) | ES2425739T3 (en) |
MX (1) | MXPA04007832A (en) |
PT (1) | PT1478358E (en) |
SI (1) | SI1478358T1 (en) |
WO (1) | WO2003068228A1 (en) |
Cited By (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004078748A2 (en) | 2003-02-28 | 2004-09-16 | Bayer Pharmaceuticals Corporation | Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders |
WO2005000284A2 (en) * | 2003-05-20 | 2005-01-06 | Bayer Pharmaceuticals Corporation | Diaryl ureas for diseases mediated by pdgfr |
WO2005051366A2 (en) * | 2003-11-28 | 2005-06-09 | Novartis Ag | Diaryl urea derivatives in the treatment of protein kinase dependent diseases |
WO2006026500A1 (en) * | 2004-08-27 | 2006-03-09 | Bayer Pharmaceuticals Corporation | New pharmaceutical compositions comprising 4-(4-(3-(4-chloro-3-trifluoromethyl-phenyl)-ureido)-3-fluoro-phenoxy)-pyridine-2-carboxylic acid for the treatment of hyper-proliferative disorders |
WO2006026501A1 (en) * | 2004-08-27 | 2006-03-09 | Bayer Pharmaceuticals Corporation | New pharmaceutical compositions for the treatment of cancer |
WO2006034797A1 (en) * | 2004-09-29 | 2006-04-06 | Bayer Healthcare Ag | Thermodynamically stable form of bay 43-9006 tosylate |
WO2006042599A1 (en) * | 2004-10-13 | 2006-04-27 | Merck Patent Gmbh | Phenylurea derivatives used as inhibitors of tyrosinkinase for treating tumors |
WO2006091801A2 (en) * | 2005-02-23 | 2006-08-31 | Alcon, Inc. | Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective rtk inhibitors |
WO2006125539A2 (en) * | 2005-05-27 | 2006-11-30 | Bayer Healthcare Ag | Combination therapy comprising diaryl ureas for treating diseases |
WO2007054215A1 (en) * | 2005-11-10 | 2007-05-18 | Bayer Healthcare Ag | Diaryl ureas for treating pulmonary hypertension |
WO2007068381A1 (en) * | 2005-12-15 | 2007-06-21 | Bayer Healthcare Ag | Diaryl ureas for treating inflammatory skin, eye and/or ear diseases |
JP2007519653A (en) * | 2004-01-30 | 2007-07-19 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | Bisaryl urea derivatives |
US7297709B2 (en) | 2003-05-22 | 2007-11-20 | Abbott Laboratories | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
JP2008514657A (en) * | 2004-09-29 | 2008-05-08 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | 4- {4-[({[4-Chloro-3- (trifluoromethyl) phenyl] amino} carbonyl) amino] phenoxy} -N-methylpyridine-2-carboxamide |
JP2008531741A (en) * | 2005-03-07 | 2008-08-14 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | Pharmaceutical composition comprising omega-carboxyaryl substituted diphenylurea for the treatment of cancer |
EP1959960A2 (en) * | 2005-12-15 | 2008-08-27 | Cytokinetics, Inc. | Certain chemical entities, compositions and methods |
JP2009514910A (en) * | 2005-11-10 | 2009-04-09 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | Diarylureas for treating pulmonary hypertension |
WO2009054004A2 (en) * | 2007-10-22 | 2009-04-30 | Natco Pharma Limited | Process for the preparation of sorafenib |
WO2009156070A1 (en) * | 2008-06-25 | 2009-12-30 | Bayer Schering Pharma Aktiengesellschaft | Diaryl urea for treating heart failure |
WO2010015672A1 (en) * | 2008-08-08 | 2010-02-11 | S.I.F.I. Societa' Industria Farmaceutica Italiana S.P.A. | Ophthalmic pharmaceutical compositions comprising sorafenib for the treatment of neoangiogenic pathologies of the eye |
US7678811B2 (en) | 2002-02-11 | 2010-03-16 | Bayer Healthcare Llc | Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors |
WO2010083649A1 (en) * | 2009-01-22 | 2010-07-29 | 沈阳药科大学 | Bisarylurea derivatives and their use |
US7838541B2 (en) | 2002-02-11 | 2010-11-23 | Bayer Healthcare, Llc | Aryl ureas with angiogenesis inhibiting activity |
US7897623B2 (en) | 1999-01-13 | 2011-03-01 | Bayer Healthcare Llc | ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors |
EP2338488A1 (en) | 2006-05-26 | 2011-06-29 | Bayer HealthCare, LLC | Drug combinations with substituted diaryl ureas for the treatment of cancer |
US7989455B2 (en) | 2005-12-19 | 2011-08-02 | Cytokinetics, Inc. | Compounds, compositions and methods |
US8026247B2 (en) | 2004-09-15 | 2011-09-27 | Novartis Ag | Bicyclic amides as kinase inhibitors |
US8101617B2 (en) | 2004-06-17 | 2012-01-24 | Amgen, Inc. | Disubstituted ureas and uses thereof in treating heart failure |
US8110587B2 (en) | 2002-02-11 | 2012-02-07 | Bayer Healthcare Llc | Aryl ureas as kinase inhibitors |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US8207166B2 (en) | 2004-04-30 | 2012-06-26 | Bayer Healthcare Llc | Substituted pyrazolyl urea derivatives useful in the treatment of cancer |
CN102643252A (en) * | 2012-04-17 | 2012-08-22 | 沈阳药科大学 | Piperazinoacethydrazide-containing diarylurea derivatives and application thereof |
US8293748B2 (en) | 2008-10-02 | 2012-10-23 | Respivert Ltd. | p38 MAP kinase inhibitors |
US8293771B2 (en) | 2008-10-02 | 2012-10-23 | Respivert Ltd. | p38 MAP kinase inhibitors |
US8299073B2 (en) | 2008-12-11 | 2012-10-30 | Respivert Ltd. | P38 MAP kinase inhibitors |
CN101550136B (en) * | 2009-05-06 | 2013-06-19 | 沈阳药科大学 | Diarylurea derivatives and application thereof used for preparing anti-neoplastic medicament |
US8552002B2 (en) | 2004-06-24 | 2013-10-08 | Novartis Ag | Compounds and compositions as protein kinase inhibitors |
WO2013161919A1 (en) | 2012-04-26 | 2013-10-31 | 小野薬品工業株式会社 | Trk-INHIBITING COMPOUND |
WO2013175506A2 (en) | 2012-05-21 | 2013-11-28 | Hetero Research Foundation | Process for sorafenib tosylate polymorph iii |
US8609656B2 (en) | 2004-02-23 | 2013-12-17 | Chugai Seiyaku Kabushiki Kaisha | Heteroarylphenylurea derivative |
US8637553B2 (en) | 2003-07-23 | 2014-01-28 | Bayer Healthcare Llc | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
US8642773B2 (en) | 2009-04-03 | 2014-02-04 | Respivert Ltd. | P38MAP kinase inhibitor |
WO2014076484A1 (en) | 2012-11-16 | 2014-05-22 | Respivert Limited | Kinase inhibitors |
WO2014129431A1 (en) | 2013-02-19 | 2014-08-28 | 小野薬品工業株式会社 | Trk-INHIBITING COMPOUND |
CN104045598A (en) * | 2014-05-29 | 2014-09-17 | 烟台大学 | Thiourea compounds containing arylamine structure, and preparation method and application thereof |
US8927563B2 (en) | 2013-04-02 | 2015-01-06 | Respivert Limited | Kinase inhibitor |
US9108950B2 (en) | 2011-10-03 | 2015-08-18 | Respivert, Ltd. | 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as p38 MAP kinase inhibitors |
US9249125B2 (en) | 2012-08-29 | 2016-02-02 | Respivert Limited | Pyrazole derivatives as p38 MAP inhibitors |
EP2922820A4 (en) * | 2012-05-23 | 2016-06-01 | Shilpa Medicare Ltd | Process for preparing crystalline sorafenib tosylate |
US9447076B2 (en) | 2014-02-14 | 2016-09-20 | Respivert Ltd. | Inhibitor of p38 map kinase |
US9475796B2 (en) | 2011-10-03 | 2016-10-25 | Respivert Limited | 1-pyrazolyl-3-((4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as p38 MAP kinase inhibitors |
US9499486B2 (en) | 2014-10-01 | 2016-11-22 | Respivert Limited | Kinase inhibitor |
WO2017036405A1 (en) * | 2015-09-02 | 2017-03-09 | 陈昆锋 | Compound having protein tyrosine phosphatase shp-1 agonist activity |
CN106573913A (en) * | 2014-08-18 | 2017-04-19 | 小野药品工业株式会社 | Acid-addition salt of trk-inhibiting compound |
US9701670B2 (en) | 2012-08-17 | 2017-07-11 | Respivert Limited | Pyrazolyl-ureas as kinase inhibitors |
US9771353B2 (en) | 2013-04-02 | 2017-09-26 | Topivert Pharma Limited | Kinase inhibitors based upon N-alkyl pyrazoles |
US9783556B2 (en) | 2012-08-29 | 2017-10-10 | Respivert Limited | Kinase inhibitors |
EP3228630A1 (en) | 2016-04-07 | 2017-10-11 | IMBA-Institut für Molekulare Biotechnologie GmbH | Combination of an apelin antagonist and an angiogenesis inhibitor for the treatment of cancer |
US9790209B2 (en) | 2012-08-29 | 2017-10-17 | Respivert Limited | Kinase inhibitors |
US9796742B2 (en) | 2012-08-29 | 2017-10-24 | Respivert Limited | Kinase inhibitors |
US9815842B2 (en) | 2014-05-28 | 2017-11-14 | Novartis Ag | Pyrazolo pyrimidine derivatives and their use as MALT1 inhibitors |
US9850233B2 (en) | 2013-03-14 | 2017-12-26 | Respivert Limited | Kinase inhibitors |
US9890185B2 (en) | 2013-12-20 | 2018-02-13 | Respivert Limited | Urea derivatives useful as kinase inhibitors |
CN107814773A (en) * | 2017-11-13 | 2018-03-20 | 西安交通大学 | diaryl urea compound containing quinazolinone and its preparation method and application |
US9957232B2 (en) | 2006-10-11 | 2018-05-01 | Bayer Healthcare Llc | 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrate |
US10072034B2 (en) | 2016-04-06 | 2018-09-11 | Respivert Limited | Kinase inhibitors |
US10653684B2 (en) | 2002-02-11 | 2020-05-19 | Bayer Healthcare Llc | Aryl ureas with angiogenisis inhibiting activity |
EP3715473A1 (en) | 2019-03-26 | 2020-09-30 | Universidade de Santiago de Compostela | Prognostic markers, therapeutic target and treatment for acromegaly |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2453147A1 (en) * | 2001-07-11 | 2003-01-23 | Boehringer Ingelheim Pharmaceuticals, Inc. | Methods of treating cytokine mediated diseases |
DK2305255T3 (en) * | 2001-12-03 | 2012-12-10 | Bayer Healthcare Llc | Aryulin compounds in combination with other cytostatic or cytotoxic agents for the treatment of human cancers |
MY140561A (en) | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
UA80171C2 (en) * | 2002-12-19 | 2007-08-27 | Pfizer Prod Inc | Pyrrolopyrimidine derivatives |
US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
US7550499B2 (en) * | 2004-05-12 | 2009-06-23 | Bristol-Myers Squibb Company | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
AU2005245389A1 (en) * | 2004-05-12 | 2005-12-01 | Bristol-Myers Squibb Company | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
CA2592118C (en) | 2004-12-23 | 2015-11-17 | Deciphera Pharmaceuticals, Llc | Urea derivatives as enzyme modulators |
KR101292598B1 (en) * | 2005-01-14 | 2013-08-05 | 질레드 코네티컷 인코포레이티드 | 1,3-diaryl substituted ureas as modulators of kinase activity |
EP1954696B1 (en) * | 2005-01-19 | 2011-02-23 | Bristol-Myers Squibb Company | 2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3-amine derivatives and related compounds as p2y1 receptor inhibitors for the treatment of thromboembolic disorders |
DE602006017694D1 (en) * | 2005-06-27 | 2010-12-02 | Bristol Myers Squibb Co | C-LINKED CYCLIC ANTAGONISTS OF THE P2Y1 RECEPTOR SUITABLE FOR THE TREATMENT OF THROMBOTIC SUFFERING |
KR20080027890A (en) * | 2005-06-27 | 2008-03-28 | 브리스톨-마이어스 스큅 컴퍼니 | N-linked heterocyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions |
WO2007002634A1 (en) * | 2005-06-27 | 2007-01-04 | Bristol-Myers Squibb Company | Carbocycle and heterocycle antagonists of p2y1 receptor useful in the treatment of thrombotic conditions |
EP1896417B1 (en) | 2005-06-27 | 2011-03-23 | Bristol-Myers Squibb Company | Linear urea mimics antagonists of p2y1 receptor useful in the treatment of thrombotic conditions |
GT200600411A (en) * | 2005-09-13 | 2007-05-21 | Novartis Ag | COMBINATIONS THAT INCLUDE AN INHIBITOR OF THE RECEIVER OF THE VASCULAR ENDOTELIAL GROWTH FACTOR |
TW200804349A (en) * | 2005-12-23 | 2008-01-16 | Kalypsys Inc | Novel substituted pyrimidinyloxy ureas as inhibitors of protein kinases |
WO2007087575A2 (en) * | 2006-01-24 | 2007-08-02 | University Of Chicago | Compositions and methods for treating pulmonary hypertension |
US8188113B2 (en) | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
US7960569B2 (en) * | 2006-10-17 | 2011-06-14 | Bristol-Myers Squibb Company | Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
US8680124B2 (en) | 2007-01-19 | 2014-03-25 | Bayer Healthcare Llc | Treatment of cancers with acquired resistance to kit inhibitors |
US20110189167A1 (en) * | 2007-04-20 | 2011-08-04 | Flynn Daniel L | Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases |
BRPI0807717A2 (en) * | 2007-04-20 | 2014-05-20 | Deciphera Pharmaceuticals Llc | KINASE INHIBITORS USEFUL FOR TREATMENT OF MYELOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES. |
AU2009244504A1 (en) * | 2008-05-05 | 2009-11-12 | Amgen Inc. | Urea compounds as gamma secretase modulators |
US20110243957A1 (en) * | 2008-09-24 | 2011-10-06 | University Of South Florida | Materials and methods for preventing or treating neurodegenerative conditions associated with abeta peptide accumulation |
JP5444365B2 (en) * | 2008-10-29 | 2014-03-19 | デシフェラ ファーマシューティカルズ,エルエルシー | Cyclopropanamide and similar substances with anticancer and antiproliferative activity |
US20110112121A1 (en) * | 2009-07-06 | 2011-05-12 | Joerg Berghausen | Pharmaceutical Compositions and Solid Forms |
AR081060A1 (en) | 2010-04-15 | 2012-06-06 | Bayer Schering Pharma Ag | PROCEDURE TO PREPARE 4- {4 - [({[4-CHLORINE-3- (TRIFLUOROMETIL) PHENYL] AMINO} CARBONYL) AMINO] -3-FLUOROPHENOXY} -N-METHYLPIRIDIN-2-CARBOXAMIDE |
US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
CN105764502A (en) | 2013-07-26 | 2016-07-13 | 现代化制药公司 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof |
WO2015051149A1 (en) * | 2013-10-04 | 2015-04-09 | The Trustees Of Columbia University In The City Of New York | Sorafenib analogs and uses thereof |
EP3139927A4 (en) * | 2014-05-06 | 2017-12-13 | The Regents of The University of California | Wound healing using braf inhibitors |
US20200237736A1 (en) | 2017-06-23 | 2020-07-30 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for preventing or treating cancer resistance to egfr inhibition |
EP3746059A1 (en) | 2018-01-31 | 2020-12-09 | Deciphera Pharmaceuticals, LLC | Combination therapy for the treatment of gastrointestinal stromal tumors |
US11179322B2 (en) | 2018-07-10 | 2021-11-23 | Novocure Gmbh | Methods and compositions for treating tumors with TTFields and sorafenib |
EP3873477A4 (en) | 2018-11-01 | 2022-09-07 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
CA3149796A1 (en) | 2019-08-02 | 2021-02-11 | Onehealthcompany, Inc. | Anti-cancer agents for the treatment of canine cancers |
TW202122082A (en) | 2019-08-12 | 2021-06-16 | 美商迪賽孚爾製藥有限公司 | Methods of treating gastrointestinal stromal tumors |
KR20220045189A (en) | 2019-08-12 | 2022-04-12 | 데시페라 파마슈티칼스, 엘엘씨. | How to treat gastrointestinal stromal tumors |
KR20220123058A (en) | 2019-12-30 | 2022-09-05 | 데시페라 파마슈티칼스, 엘엘씨. | 1-(4-Bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl ) -3-Phenylurea composition |
EP4327827A3 (en) | 2019-12-30 | 2024-05-29 | Deciphera Pharmaceuticals, LLC | Amorphous kinase inhibitor formulations and methods of use thereof |
CN112159351B (en) * | 2020-09-21 | 2021-12-07 | 广州南鑫药业有限公司 | Preparation method of multi-target antitumor drug |
US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
WO2024152194A1 (en) * | 2023-01-17 | 2024-07-25 | 盛裕新药股份有限公司 | Use of 1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[3-(4-cyanophenoxy)phenyl]urea in the preparation of pharmaceutical compositions used for preventing and/or treating eye diseases |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0625221A (en) | 1992-07-10 | 1994-02-01 | Tokuyama Soda Co Ltd | Production of 3-amino-2-thiophenecarboxylic acid derivative |
WO1994004157A1 (en) | 1992-08-21 | 1994-03-03 | Schering Aktiengesellschaft | Transdermal application agent containing 3-keto-desogestrel |
WO1999032455A1 (en) | 1997-12-22 | 1999-07-01 | Bayer Corporation | Inhibition of raf kinase using aryl and heteroaryl substituted heterocyclic ureas |
WO1999032106A1 (en) | 1997-12-22 | 1999-07-01 | Bayer Corporation | Inhibition of raf kinase using substituted heterocyclic ureas |
WO1999032110A1 (en) | 1997-12-22 | 1999-07-01 | Bayer Corporation | INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS |
WO1999032463A1 (en) | 1997-12-22 | 1999-07-01 | Bayer Corporation | INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS |
WO1999032436A1 (en) | 1997-12-22 | 1999-07-01 | Bayer Corporation | Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas |
WO1999032111A1 (en) | 1997-12-22 | 1999-07-01 | Bayer Corporation | INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS |
WO2000041698A1 (en) | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS |
WO2000042012A1 (en) | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS |
US8339998B2 (en) | 2009-12-28 | 2012-12-25 | Fih (Hong Kong) Limited | Meeting information distribution system and method |
Family Cites Families (489)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US502504A (en) | 1893-08-01 | Hermann thoms | ||
DE487014C (en) | 1927-10-23 | 1929-12-09 | I G Farbenindustrie Akt Ges | Process for the preparation of urea derivatives |
US1792156A (en) * | 1928-01-17 | 1931-02-10 | Gen Aniline Works Inc | 5-halogen-2-amino-1-alkyloxy and 1-aralkyloxy-benzenes and intermediate products thereof and process of preparing them |
DE511468C (en) | 1928-01-18 | 1930-10-30 | I G Farbenindustrie Akt Ges | Process for the preparation of 5-chloro-2-amino-1-methoxybenzene |
DE523437C (en) | 1928-12-25 | 1931-05-05 | I G Farbenindustrie Akt Ges | Process for the preparation of 5-chloro- and 5-bromo-2-amino-1-alkyloxy- and 1-aralkyloxybenzenes |
US1792158A (en) | 1930-04-24 | 1931-02-10 | Robert H Gleckner | Belt |
US2093265A (en) | 1931-03-31 | 1937-09-14 | Ici Ltd | Process for the manufacture of diaryl ureas |
US2046375A (en) | 1931-06-04 | 1936-07-07 | Ici Ltd | p-halogen-omicron-alkoxy-aniline derivatives and process of preparing the same |
US2048375A (en) | 1935-07-06 | 1936-07-21 | Edison Splitdorf Corp | Magneto-electric generator |
US2288422A (en) | 1938-11-11 | 1942-06-30 | Gen Aniline & Film Corp | Mixed ureas |
US2973386A (en) * | 1943-01-05 | 1961-02-28 | Harry A Weldon | Purification of sym dichloro-bis (2, 4, 6-trichlorophenyl)urea |
DE920245C (en) | 1950-04-29 | 1954-11-18 | Variapat Ag | Process for the preparation of aromatic, colorless, water-soluble unsymmetrical ureas or thioureas containing trifluoromethyl and sulfo acid groups |
US2683082A (en) | 1950-12-09 | 1954-07-06 | Ethyl Corp | Nu-aryl-nu'-(p-hydroxyphenyl) ureas as antioxidants for petroleum hydrocarbon fuels |
US2722544A (en) | 1950-12-26 | 1955-11-01 | Variapat Ag | Trifluoromethyl halogenated diphenylcarbamide sulfonic acids and their preparation |
US2781330A (en) * | 1953-02-09 | 1957-02-12 | Monsanto Chemicals | Rubber containing urea compound as an anti-exposure cracking agent |
BE527017A (en) | 1953-03-06 | |||
US2745874A (en) | 1953-06-18 | 1956-05-15 | Geigy Ag J R | Insecticidal derivatives of diphenyl urea |
GB771333A (en) | 1953-12-22 | 1957-03-27 | Geigy Ag J R | Improvements relating to halogen substituted diphenyl urea and thiourea compounds and their use |
NL193403A (en) * | 1953-12-22 | 1924-02-17 | ||
GB828231A (en) | 1955-10-20 | 1960-02-17 | Geigy Ag J R | Improvements relating to insecticidal compounds and their use |
US2877268A (en) * | 1956-12-24 | 1959-03-10 | Monsanto Chemicals | Substituted ureas |
US2960488A (en) | 1958-04-25 | 1960-11-15 | Eastman Kodak Co | Poly-alpha-olefins containing substituted ureas |
NL254871A (en) * | 1959-08-14 | |||
NL277504A (en) | 1961-04-21 | |||
US3177110A (en) * | 1961-07-24 | 1965-04-06 | Aschaffenburger Zellstoffwerke | Process for pretreating wood for the production of cellulose |
CH479557A (en) | 1961-09-11 | 1969-10-15 | Wander Ag Dr A | Process for the preparation of new polybasic compounds |
US3200035A (en) | 1962-06-01 | 1965-08-10 | Ciba Ltd | Treatment of synthetic products, especially synthetic fibers |
US3284433A (en) | 1963-07-17 | 1966-11-08 | Merck & Co Inc | 4-phenoxy-carbanilides |
FR1457172A (en) | 1964-12-12 | 1966-10-28 | Ferrania Spa | Process for the production of color photographic images and corresponding photographic material |
FR90420E (en) | 1965-06-09 | 1968-02-21 | ||
US3424761A (en) * | 1966-03-07 | 1969-01-28 | Robins Co Inc A H | 3-ureidopyrrolidines |
US3424760A (en) * | 1966-03-07 | 1969-01-28 | Robins Co Inc A H | 3-ureidopyrrolidines |
US3424762A (en) * | 1966-03-07 | 1969-01-28 | Robins Co Inc A H | Certain 3-ureidopyrrolidines |
US3547940A (en) | 1967-10-31 | 1970-12-15 | Du Pont | Substituted ureido isoxazoles |
US3743498A (en) | 1967-10-31 | 1973-07-03 | Du Pont | Method of selectively controlling undesirable vegetation |
SE370866B (en) | 1968-03-21 | 1974-11-04 | Ciba Geigy Ag | |
DE1768244A1 (en) * | 1968-04-19 | 1971-10-14 | Bayer Ag | N- (2,2,4,4-tetrafluoro-1,3-benz-dioxanyl) ureas and process for their preparation |
US3754887A (en) | 1969-05-05 | 1973-08-28 | Du Pont | Ureidopyrazoles defoliants |
US3646059A (en) * | 1969-05-05 | 1972-02-29 | Du Pont | Plant growth regulatory ureidopyrazoles |
US3668222A (en) | 1969-05-14 | 1972-06-06 | Sandoz Ltd | 11-desacetoxy-wortmannin |
BE754782A (en) | 1969-08-14 | 1971-02-12 | May & Baker Ltd | THIOPHENE DERIVATIVES WITH HERBICIDAL ACTION |
US3823161A (en) | 1970-05-07 | 1974-07-09 | Exxon Research Engineering Co | Aminothiophene derivatives |
US3860645A (en) * | 1973-05-23 | 1975-01-14 | Givaudan Corp | Bacteriostatic substituted carbanilides |
JPS5031039A (en) | 1973-07-27 | 1975-03-27 | ||
US4116671A (en) | 1973-07-27 | 1978-09-26 | Shionogi & Co., Ltd. | 3-Isoxazolylcarbamate derivatives |
US4212981A (en) | 1973-07-27 | 1980-07-15 | Shionogi & Co., Ltd. | Process for preparing 3-isoxazolylurea derivatives |
US4062861A (en) | 1973-07-27 | 1977-12-13 | Shionogi & Co., Ltd. | 3-Isoxazolylurea derivatives |
US4001256A (en) * | 1973-12-26 | 1977-01-04 | The Upjohn Company | Pyridylalkyl phenyl ureas and their n-oxides |
US3931201A (en) | 1974-01-22 | 1976-01-06 | The Dow Chemical Company | Substituted pyridinyloxy(thio)phenyl -acetamides, -ureas and urea derivatives |
US4009847A (en) * | 1974-04-17 | 1977-03-01 | E. I. Du Pont De Nemours And Company | 1-Tertiary-alkyl-3-(substituted thienyl)ureas and 1-tertiary-alkyl-3-(substituted thietyl)ureas as antihypertensive agents |
US3990879A (en) | 1974-12-26 | 1976-11-09 | Eli Lilly And Company | Method of controlling aquatic weeds |
US4111683A (en) | 1975-06-27 | 1978-09-05 | Chevron Research Company | N-alkyl or alkoxy-N'-substituted hydrocarbyl urea |
DE2637947C2 (en) | 1976-08-24 | 1985-09-19 | Bayer Ag, 5090 Leverkusen | Tetrafluoro-1,3-benzodioxanyl-benzoylureas, process for their preparation and their use as insecticides |
JPS5840946B2 (en) | 1976-10-29 | 1983-09-08 | 石原産業株式会社 | N-benzoyl-N'-pyridyloxyphenylurea compounds, methods for producing them, and insecticides containing them |
US4173637A (en) | 1976-10-29 | 1979-11-06 | Ishihara Sangyo Kaisha Ltd. | N-Benzoyl-N'-pyridyloxy phenyl urea and insecticidal compositions thereof |
US4071524A (en) * | 1976-11-08 | 1978-01-31 | Riker Laboratories, Inc. | Derivatives of urea |
US4183854A (en) * | 1976-11-10 | 1980-01-15 | John Wyeth & Brother Limited | Thiazole compound |
US4042372A (en) | 1976-11-19 | 1977-08-16 | Eli Lilly And Company | Substituted thiadiazolotriazinediones and method of preparation |
DE2817449A1 (en) | 1978-04-21 | 1979-10-31 | Bayer Ag | MEANS OF REGULATING PLANT GROWTH |
GB1590870A (en) | 1978-05-31 | 1981-06-10 | Shionogi & Co | N-(5-t-butyl-3-isoxazolyl) alkanamide derivatives having herbicidal activity |
JPS5562066A (en) | 1978-11-03 | 1980-05-10 | Toshihiko Okamoto | N-(2-substituted-4-pyridyl)-urea and thio urea, their preparation and plant growth regulator |
DE2848330A1 (en) | 1978-11-03 | 1980-05-14 | Schering Ag | METHOD FOR PRODUCING 1,2,3-THIADIAZOL-5-YL UREA |
FI800559A (en) | 1979-03-14 | 1980-09-15 | Hoffmann La Roche | URINAEMNEDERIVAT |
JPS55124763A (en) | 1979-03-19 | 1980-09-26 | Ishihara Sangyo Kaisha Ltd | 5-trifluoromethyl-2-pyridone derivative |
DE2928485A1 (en) | 1979-07-14 | 1981-01-29 | Bayer Ag | USE OF UREA DERIVATIVES AS A MEDICINAL PRODUCT IN THE TREATMENT OF FATTY METABOLISM DISORDERS |
US4468380A (en) | 1979-12-26 | 1984-08-28 | Eli Lilly And Company | Anticoccidial combinations comprising polyether antibiotics and carbanilides |
WO1981002156A1 (en) | 1980-01-25 | 1981-08-06 | Reanal Finomvegyszergyar | Process for the preparation of n-aryl-n'-(mono-or disubstiuted)-urea derivatives |
EP0057797B1 (en) | 1981-02-03 | 1986-06-25 | Imperial Chemical Industries Plc | Process for the extraction of metal values and novel metal extractants |
US4526997A (en) | 1981-05-06 | 1985-07-02 | Doherty George O P O | Anticoccidial combinations comprising polyether antibiotics and carbanilides |
US4511571A (en) * | 1981-10-20 | 1985-04-16 | Ciba Geigy Corporation | N-(2-Pyridyloxyphenyl)-N'-benzoyl ureas, pesticidal compositions containing same and pesticidal methods of use |
US4473579A (en) | 1982-01-26 | 1984-09-25 | American Cyanamid Company | Antiatherosclerotic tetrasubstituted ureas and thioureas |
US4623662A (en) | 1985-05-23 | 1986-11-18 | American Cyanamid Company | Antiatherosclerotic ureas and thioureas |
DE3211851A1 (en) * | 1982-03-31 | 1983-10-06 | Basf Ag | DIHYDROTHIOPHENE-CARBONESTER, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE FOR CONTROLLING UNWANTED PLANT GROWTH |
JPS58203957A (en) * | 1982-05-25 | 1983-11-28 | Ube Ind Ltd | Preparation of urea derivative |
AU1862083A (en) | 1982-09-02 | 1984-03-08 | Duphar International Research B.V. | Tumor growth inhibitors |
CA1254212A (en) * | 1982-11-12 | 1989-05-16 | Shiro Hirai | Amine derivatives, salts thereof, process for preparing the same and an anti-ulcer agent containing the same |
DE3305866A1 (en) | 1983-02-19 | 1984-08-23 | Basf Ag, 6700 Ludwigshafen | THIOPHEN-CARBONESTER, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE FOR CONTROLLING UNWANTED PLANT GROWTH |
US4499097A (en) * | 1983-03-10 | 1985-02-12 | American Cyanamid Company | 2-(Pyridyl)imidazolyl ketones |
GB8325496D0 (en) | 1983-09-23 | 1983-10-26 | Hider R C | Pharmaceutical compositions |
US4540566A (en) | 1984-04-02 | 1985-09-10 | Forest Laboratories, Inc. | Prolonged release drug dosage forms based on modified low viscosity grade hydroxypropylmethylcellulose |
US4727077A (en) | 1985-02-20 | 1988-02-23 | Ishihara Sangyo Kaisha Ltd. | Benzoyl urea compounds, process for their production, and antitumorous compositions containing them |
DE3529247A1 (en) | 1985-05-17 | 1986-11-20 | Bayer Ag, 5090 Leverkusen | USE OF THIENYL UREAS AND ISOHARNS AS AN PERFORMANCE DRIVER IN ANIMALS, NEW THIENYL URINS AND ISOHARNS AND THEIR PRODUCTION |
DE3540377A1 (en) | 1985-11-14 | 1987-05-21 | Bayer Ag | THIENOOXAZINONE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A PERFORMANCE PROVIDER |
DE3541631A1 (en) * | 1985-11-26 | 1987-05-27 | Bayer Ag | SELECTIVE-FUNGICIDAL USE OF THIENYL URINE DERIVATIVES |
AU594098B2 (en) | 1985-12-11 | 1990-03-01 | Ishihara Sangyo Kaisha Ltd. | N-benzoyl urea compounds, antitumorous compositions containing them, and process for their preparation |
EP0230400A3 (en) | 1986-01-21 | 1990-02-14 | Ciba-Geigy Ag | N-3-(5-trifluoromethyl-pyridyl-2-oxy)phenyl-n'-benzoylureas for combating helminths in livestock |
JPS62185013A (en) | 1986-02-08 | 1987-08-13 | Green Cross Corp:The | Easily absorbable pharmaceutical composition |
DE3612830A1 (en) | 1986-04-16 | 1987-10-22 | Basf Ag | THIADIAZOLYL URINE CONTAINING AGENT FOR DEBELING PLANTS |
EP0255297B1 (en) * | 1986-07-31 | 1993-04-21 | Beecham Group Plc | Azabicyclic compounds, process for their preparation, and their pharmaceutical use |
NZ221964A (en) * | 1986-10-03 | 1990-03-27 | Ishihara Sangyo Kaisha | Benzoylurea compounds and insecticidal compositions |
EP0264904A3 (en) | 1986-10-23 | 1988-08-17 | Ishihara Sangyo Kaisha, Ltd. | Pharmaceutical compositions containing benzoyl urea derivatives |
DE3636190A1 (en) * | 1986-10-24 | 1988-04-28 | Bayer Ag | METHOD FOR PRODUCING N, N-DIARYL UREAS |
DD253997A1 (en) | 1986-11-26 | 1988-02-10 | Karl Marx Uni Buero Fuer Neuer | PROCESS FOR PREPARING SUBSTITUTED 2-ARYLUREIDOPHENOLES |
JPH06100808B2 (en) | 1987-05-28 | 1994-12-12 | 富士写真フイルム株式会社 | Processing method of silver halide color photographic light-sensitive material |
EP0314615B1 (en) * | 1987-10-16 | 1995-04-26 | Ciba-Geigy Ag | Pesticides |
DE3810382A1 (en) | 1988-03-26 | 1989-10-12 | Bayer Ag | 5-AMINO-1-PHENYLPYRAZOLE, METHOD AND 5-HALOGEN-1-PHENYLPYRAZOLE AS INTERMEDIATE PRODUCTS FOR THE PRODUCTION THEREOF AND THEIR USE AS HERBICIDES |
WO1990002112A1 (en) | 1988-08-23 | 1990-03-08 | The Nutrasweet Company | Substituted aryl ureas as high potency sweeteners |
DE68917233T2 (en) | 1988-09-08 | 1995-02-09 | Dainippon Ink & Chemicals | Liquid crystal device. |
JPH0278699A (en) | 1988-09-12 | 1990-03-19 | Green Cross Corp:The | Benzoylurea compound-albumin complex |
FR2639636B1 (en) | 1988-11-30 | 1994-03-04 | Novapharme | NOVEL HETEROCYCLIC COMPOUNDS WITH ANTICONVULSIVE ACTIVITY, PREPARATION METHOD AND THERAPEUTIC COMPOSITIONS CONTAINING THEM |
FR2662692B1 (en) | 1990-05-30 | 1995-04-28 | Novapharme | HETEROCYCLIC DERIVATIVES WITH ANTICONVULSIVE ACTIVITY, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION. |
JPH02237922A (en) | 1989-01-24 | 1990-09-20 | Green Cross Corp:The | Antiviral agent |
JPH02196719A (en) | 1989-01-24 | 1990-08-03 | Green Cross Corp:The | Powdery drug composition |
EP0379915A1 (en) | 1989-01-26 | 1990-08-01 | Bayer Ag | Substituted phenoxybenzonitrile derivatives, processes for their preparation and their use as herbicides and plant growth regulators |
JP3002204B2 (en) * | 1989-03-13 | 2000-01-24 | 株式会社東芝 | Time-series signal recognition device |
US4973675A (en) | 1989-04-13 | 1990-11-27 | University Of Tennessee Research Center | Hybrid nitrosoureidoanthracyclines having antitumor activity |
JPH0395153A (en) | 1989-06-15 | 1991-04-19 | Mitsubishi Kasei Corp | Diphenyl urea derivative |
US5665543A (en) | 1989-07-18 | 1997-09-09 | Oncogene Science, Inc. | Method of discovering chemicals capable of functioning as gene expression modulators |
IL95860A0 (en) | 1989-10-13 | 1991-07-18 | Ciba Geigy Ag | Thienylthioureas,-isothioureas and-carbodiimides |
US5177110A (en) | 1989-10-27 | 1993-01-05 | Ciba-Geigy Corporation | Injectable parasiticidal composition |
EP0425443A1 (en) | 1989-10-27 | 1991-05-02 | Ciba-Geigy Ag | Injectable antiparasitic agent |
NZ238624A (en) * | 1990-06-19 | 1994-08-26 | Meiji Seika Co | Pyridine derivatives, compositions, preparations and use thereof |
DE4022720A1 (en) * | 1990-07-17 | 1992-01-23 | Flohe Gmbh & Co | UNDERWAY OF A DC ARC FURNACE |
GB9017892D0 (en) | 1990-08-15 | 1990-09-26 | May & Baker Ltd | New compositions of matter |
PT98990A (en) | 1990-09-19 | 1992-08-31 | American Home Prod | PROCESS FOR THE PREPARATION OF CARBOXYLIC ACID ESTERS OF RAPAMICIN |
HU214333B (en) | 1991-01-21 | 1998-03-02 | Shionogi Seiyaku Kabushiki Kaisha | Process for producing benzylidene-carbamoyl-2-pyrrolidone, -4-thiazolidinone, -4-oxazolidinone, -3-isothiazolidinone and -3-isoxazolidinone analogues and pharmaceutical compositions containing them |
JP2671693B2 (en) | 1991-03-04 | 1997-10-29 | 松下電器産業株式会社 | Biosensor and manufacturing method thereof |
US5120842A (en) | 1991-04-01 | 1992-06-09 | American Home Products Corporation | Silyl ethers of rapamycin |
US5270458A (en) | 1991-04-02 | 1993-12-14 | The Trustees Of Princeton University | Nucleic acids encoding fragments of hematopoietic stem cell receptor flk-2 |
US5185438A (en) * | 1991-04-02 | 1993-02-09 | The Trustees Of Princeton University | Nucleic acids encoding hencatoporetic stem cell receptor flk-2 |
US5100883A (en) * | 1991-04-08 | 1992-03-31 | American Home Products Corporation | Fluorinated esters of rapamycin |
US5118678A (en) | 1991-04-17 | 1992-06-02 | American Home Products Corporation | Carbamates of rapamycin |
FI921595A (en) | 1991-04-17 | 1992-10-18 | American Home Prod | RAPAMYCINKARBAMATER |
US5721237A (en) * | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
US5118677A (en) | 1991-05-20 | 1992-06-02 | American Home Products Corporation | Amide esters of rapamycin |
US5185358A (en) * | 1991-06-24 | 1993-02-09 | Warner-Lambert Co. | 3-heteroatom containing urea and thiourea ACAT inhibitors |
US5162360A (en) | 1991-06-24 | 1992-11-10 | Warner-Lambert Company | 2-heteroatom containing urea and thiourea ACAT inhibitors |
AU2552492A (en) * | 1991-08-23 | 1993-03-16 | United States of America as represented by The Secretary Department of Health and Human Services, The | Raf protein kinase therapeutics |
US5151413A (en) | 1991-11-06 | 1992-09-29 | American Home Products Corporation | Rapamycin acetals as immunosuppressant and antifungal agents |
EP0630373A1 (en) * | 1992-03-12 | 1994-12-28 | Smithkline Beecham Plc | Indole derivatives as 5ht1c antagonists |
US6001860A (en) | 1992-05-28 | 1999-12-14 | Pfizer Inc. | N-aryl and N-heteroarylurea derivatives as inhibitors of acyl coenzyme A: Cholesterol acyl transferase (ACAT) |
ZA935111B (en) | 1992-07-17 | 1994-02-04 | Smithkline Beecham Corp | Rapamycin derivatives |
US5312820A (en) | 1992-07-17 | 1994-05-17 | Merck & Co., Inc. | Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines |
ZA935112B (en) | 1992-07-17 | 1994-02-08 | Smithkline Beecham Corp | Rapamycin derivatives |
EP0655066A1 (en) | 1992-08-12 | 1995-05-31 | PHARMACIA & UPJOHN COMPANY | Protein kinase inhibitors and related compounds combined with taxol |
US5256790A (en) | 1992-08-13 | 1993-10-26 | American Home Products Corporation | 27-hydroxyrapamycin and derivatives thereof |
JP2717481B2 (en) | 1992-08-25 | 1998-02-18 | 富士写真フイルム株式会社 | Silver halide color photographic materials |
CN2146707Y (en) | 1992-09-08 | 1993-11-17 | 华东冶金学院 | Leak detector for use in soft water cooling system of blast furnace |
US5258389A (en) | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
US6177401B1 (en) * | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
CN2148707Y (en) | 1992-12-15 | 1993-12-08 | 高英郎 | Improved apparatus of joint for wiper with screw mounting |
WO1994014801A1 (en) | 1992-12-29 | 1994-07-07 | Smithkline Beecham Plc | Heterocyclic urea derivatives as 5ht2c and 5ht2b antagonists |
US5512473A (en) | 1993-01-29 | 1996-04-30 | Brent; Roger | Max-interacting proteins and related molecules and methods |
GB9302275D0 (en) | 1993-02-05 | 1993-03-24 | Smithkline Beecham Plc | Novel compounds |
TW272942B (en) | 1993-02-10 | 1996-03-21 | Takeda Pharm Industry Co Ltd | |
DK41193D0 (en) | 1993-04-07 | 1993-04-07 | Neurosearch As | ion channel openers |
WO1994023755A1 (en) | 1993-04-09 | 1994-10-27 | Board Of Regents Of The University Of Nebraska | Novel methods and compositions for the treatment of ras-activated cancer with heterotypic anti-raf antisense oligonucleotides |
GB9308802D0 (en) | 1993-04-28 | 1993-06-09 | Smithkline Beecham Plc | Treatment |
DE4322806A1 (en) | 1993-07-08 | 1995-01-12 | Janich Gmbh & Co | Device for sealing between two parts of the system |
IL110296A (en) | 1993-07-16 | 1999-12-31 | Smithkline Beecham Corp | Imidazole compounds process for their preparation and pharmaceutical compositions containing them |
US6514745B1 (en) * | 1993-07-19 | 2003-02-04 | The Regents Of The University Of California | Oncoprotein protein kinase |
US5378725A (en) * | 1993-07-19 | 1995-01-03 | The Arizona Board Of Regents | Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof |
NZ264063A (en) * | 1993-08-13 | 1995-11-27 | Nihon Nohyaku Co Ltd | N-(2-phenylpyrid-3-yl)- and n-(4-phenylpyrimidin-5-yl)-n'-phenylurea derivatives and pharmaceutical compositions |
US5441947A (en) | 1993-08-25 | 1995-08-15 | Eli Lilly And Company | Methods of inhibiting vascular restenosis |
US5468773A (en) | 1993-08-25 | 1995-11-21 | Eli Lilly And Company | Methods for inhibiting bone loss and cartilage degradation using wortmannin and its analogs |
US6361773B1 (en) * | 1993-09-17 | 2002-03-26 | Smithkline Beecham Corporation | Antibodies produced against cytokine suppressive anti-inflammatory drug binding proteins |
US5783664A (en) | 1993-09-17 | 1998-07-21 | Smithkline Beecham Corporation | Cytokine suppressive anit-inflammatory drug binding proteins |
DK0724588T3 (en) | 1993-09-17 | 2000-05-15 | Smithkline Beecham Corp | Drug binding protein |
US5869043A (en) * | 1993-09-17 | 1999-02-09 | Smithkline Beecham Corporation | Drug binding protein |
US5547966A (en) | 1993-10-07 | 1996-08-20 | Bristol-Myers Squibb Company | Aryl urea and related compounds |
CA2133815A1 (en) * | 1993-10-12 | 1995-04-13 | Jeffrey Alan Dodge | Inhibition of phosphatidylinositol 3-kinase with viridin, demethoxyviridin, viridiol, demethoxyviridiol, virone, wortmannolone, and analogs thereof |
US5596001A (en) * | 1993-10-25 | 1997-01-21 | Pfizer Inc. | 4-aryl-3-(heteroarylureido)quinoline derivatves |
DE69433501T2 (en) | 1993-11-08 | 2004-11-04 | Smithkline Beecham Corp. | OXAZOLES FOR TREATING CYTOKINE MEDIATED DISEASES |
JPH07141053A (en) | 1993-11-17 | 1995-06-02 | Nec Niigata Ltd | Clock generating circuit |
WO1995014023A1 (en) | 1993-11-19 | 1995-05-26 | Abbott Laboratories | Semisynthetic analogs of rapamycin (macrolides) being immunomodulators |
BR9408323A (en) | 1993-12-17 | 1997-08-19 | Sandoz Ag | Rapamycin derivatives |
US5700823A (en) | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
CH686211A5 (en) | 1994-01-27 | 1996-02-15 | Ciba Geigy Ag | Moth and Koferschutzmittel. |
US6524832B1 (en) | 1994-02-04 | 2003-02-25 | Arch Development Corporation | DNA damaging agents in combination with tyrosine kinase inhibitors |
US6811779B2 (en) | 1994-02-10 | 2004-11-02 | Imclone Systems Incorporated | Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy |
CA2146495C (en) * | 1994-04-08 | 2006-06-27 | Len C. Decandia | Method for making an elastic adhesive bandage |
DE4412334A1 (en) | 1994-04-11 | 1995-10-19 | Hoechst Ag | Substituted N-heteroaroylguanidines, process for their preparation, their use as a medicament or diagnostic agent, and medicament containing them |
US5559137A (en) | 1994-05-16 | 1996-09-24 | Smithkline Beecham Corp. | Compounds |
US5656612A (en) | 1994-05-31 | 1997-08-12 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
US5744362A (en) | 1994-05-31 | 1998-04-28 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
WO1995033458A1 (en) | 1994-06-02 | 1995-12-14 | Smithkline Beecham Corporation | Anti-inflammatory compounds |
US5470882A (en) | 1994-06-02 | 1995-11-28 | Smithkline Beecham Corp. | Anti-inflammatory compounds |
US5447957A (en) | 1994-06-02 | 1995-09-05 | Smithkline Beecham Corp. | Anti-inflammatory compounds |
US5786362A (en) | 1994-06-16 | 1998-07-28 | University Of Miami | Method of treating Hormone independent cancer |
EP0690344A1 (en) | 1994-06-29 | 1996-01-03 | Konica Corporation | Silver halide color photographic light-sensitive material |
US5480906A (en) * | 1994-07-01 | 1996-01-02 | Eli Lilly And Company | Stereochemical Wortmannin derivatives |
FR2722319B1 (en) | 1994-07-08 | 1996-08-14 | Thomson Csf | COLOR DISPLAY DEVICE |
US5597719A (en) * | 1994-07-14 | 1997-01-28 | Onyx Pharmaceuticals, Inc. | Interaction of RAF-1 and 14-3-3 proteins |
EP0784612A1 (en) | 1994-10-04 | 1997-07-23 | Fujisawa Pharmaceutical Co., Ltd. | Urea derivatives and their use as acat-inhibitors |
PT708085E (en) | 1994-10-19 | 2002-11-29 | Novartis Ag | PROTEASE ASPARTATE SUBSTRATE ISOSTERATE ETERIS ANTERIORS |
JP3591938B2 (en) | 1994-10-27 | 2004-11-24 | キヤノン株式会社 | Ink jet recording medium and image forming method using the same |
CA2161376C (en) | 1994-10-27 | 2005-01-11 | Toshiaki Minami | Reversible multi-color thermal recording medium |
PT788564E (en) | 1994-10-28 | 2001-11-30 | Novozymes As | PROCESS FOR THE CHEMICAL PRESENTATION OF INSOLUBLE POLYMERS |
TW313568B (en) | 1994-12-20 | 1997-08-21 | Hoffmann La Roche | |
US5780483A (en) | 1995-02-17 | 1998-07-14 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
EP0809492A4 (en) * | 1995-02-17 | 2007-01-24 | Smithkline Beecham Corp | Il-8 receptor antagonists |
US5814646A (en) | 1995-03-02 | 1998-09-29 | Eli Lilly And Company | Inhibitors of amyloid beta-protein production |
US5624937A (en) * | 1995-03-02 | 1997-04-29 | Eli Lilly And Company | Chemical compounds as inhibitors of amyloid beta protein production |
DE19512639A1 (en) | 1995-04-05 | 1996-10-10 | Merck Patent Gmbh | Benzonitriles and fluorides |
FR2733324B1 (en) | 1995-04-19 | 1997-05-30 | Schlumberger Ind Sa | AUTOMATIC PARALLEL TEST METHOD AND EQUIPMENT FOR ELECTRONIC COMPONENTS |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US5658903A (en) | 1995-06-07 | 1997-08-19 | Smithkline Beecham Corporation | Imidazole compounds, compositions and use |
US5773459A (en) | 1995-06-07 | 1998-06-30 | Sugen, Inc. | Urea- and thiourea-type compounds |
US5710173A (en) | 1995-06-07 | 1998-01-20 | Sugen, Inc. | Thienyl compounds for inhibition of cell proliferative disorders |
US5985890A (en) | 1995-06-09 | 1999-11-16 | Novartis Ag | Rapamycin derivatives |
GB9514265D0 (en) | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
US5849761A (en) | 1995-09-12 | 1998-12-15 | Regents Of The University Of California | Peripherally active anti-hyperalgesic opiates |
MX9604165A (en) * | 1995-09-18 | 1997-10-31 | Sankyo Co | Amide and urea derivatives. |
SE510846C2 (en) | 1995-11-06 | 1999-06-28 | Moelnlycke Health Care Ab | Inner packaging for in an outer package sterile-packed abdominal cloths |
JP4009681B2 (en) | 1995-11-07 | 2007-11-21 | キリンファーマ株式会社 | Quinoline derivatives and quinazoline derivatives that inhibit platelet-derived growth factor receptor autophosphorylation and pharmaceutical compositions containing them |
AU1173997A (en) * | 1995-12-28 | 1997-07-28 | Kureha Kagaku Kogyo Kabushiki Kaisha | Process for producing pyridinecarboxamides or thiocarboxamides |
US5807876A (en) | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
US6005008A (en) | 1996-02-16 | 1999-12-21 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
US6011029A (en) | 1996-02-26 | 2000-01-04 | Bristol-Myers Squibb Company | Inhibitors of farnesyl protein transferase |
US6103692A (en) | 1996-03-12 | 2000-08-15 | The General Hospital Corporation | Inhibiting protein interactions |
US6211373B1 (en) | 1996-03-20 | 2001-04-03 | Smithkline Beecham Corporation | Phenyl urea antagonists of the IL-8 receptor |
US6262113B1 (en) | 1996-03-20 | 2001-07-17 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
ATE189814T1 (en) | 1996-04-15 | 2000-03-15 | Takeda Chemical Industries Ltd | HYDROXYPYRIDINE DERIVATIVES, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE |
HUP0004421A3 (en) | 1996-04-23 | 2002-10-28 | Vertex Pharmaceuticals Inc Cam | Urea derivatives and pharmaceutical compositions containing them, use thereof for the treatment of deseases mediated by impdh enzyme |
US6232299B1 (en) | 1996-05-01 | 2001-05-15 | Eli Lilly And Company | Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy |
JPH09301858A (en) | 1996-05-13 | 1997-11-25 | Senju Pharmaceut Co Ltd | Aqueous medicine containing stabilized cholorohexidine gluconate |
DE69716424T2 (en) | 1996-05-24 | 2003-02-20 | Neurosearch A/S, Ballerup | PHENYL DERIVATIVES CONTAINING ACID GROUPS, THEIR PRODUCTION AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS |
US5910417A (en) | 1996-05-31 | 1999-06-08 | National Jewish Center For Immunology And Respiratory Medicine | Regulation of cytokine production in a hematopoietic cell |
HUP9903922A3 (en) | 1996-06-27 | 2001-12-28 | Smithkline Beecham Corp | Il-8 receptor antagonists |
KR20000022274A (en) | 1996-06-27 | 2000-04-25 | 스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스 | Il-8 receptor antagonist |
EP0932405A4 (en) | 1996-06-27 | 2001-10-17 | Smithkline Beckman Corp | Il-8 receptor antagonists |
JP2000513359A (en) | 1996-06-27 | 2000-10-10 | スミスクライン・ビーチャム・コーポレイション | IL-8 receptor antagonist |
US6150415A (en) | 1996-08-13 | 2000-11-21 | The Regents Of The University Of California | Epoxide hydrolase complexes and methods therewith |
US5808080A (en) | 1996-09-05 | 1998-09-15 | Eli Lilly And Company | Selective β3 adrenergic agonists |
WO1998017207A1 (en) | 1996-10-21 | 1998-04-30 | Synthes Ag Chur | Surgical prosthetic device |
US5965573A (en) | 1996-10-23 | 1999-10-12 | Zymogenetics, Inc. | Compositions and methods for treating bone deficit conditions |
WO1998017267A1 (en) | 1996-10-23 | 1998-04-30 | Zymogenetics, Inc. | Compositions and methods for treating bone deficit conditions |
DE69739734D1 (en) | 1996-11-15 | 2010-02-25 | Cytokine Pharmasciences Inc | GUANYL HYDRAZONE USEFUL FOR THE TREATMENT OF T-CELL ASSOCIATED DISEASES |
GB9623833D0 (en) | 1996-11-16 | 1997-01-08 | Zeneca Ltd | Chemical compound |
AU4966497A (en) | 1996-11-18 | 1998-06-10 | Yamanouchi Pharmaceutical Co., Ltd. | Novel acylamino-substituted acylanilide derivatives or pharmaceutical composition comprising the same |
FR2755967B1 (en) * | 1996-11-21 | 1999-01-29 | Pf Medicament | PYRIDIN-2-YL-METHYLAMINE DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR APPLICATION AS MEDICAMENTS |
US5929250A (en) * | 1997-01-23 | 1999-07-27 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
KR20000070368A (en) | 1997-01-23 | 2000-11-25 | 스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스 | IL-8 Receptor Antagonists |
JP2001512445A (en) | 1997-02-12 | 2001-08-21 | スミスクライン・ビーチャム・コーポレイション | IL-8 receptor antagonist |
CN1254335A (en) | 1997-04-04 | 2000-05-24 | 辉瑞产品公司 | Nicotinamide derivatives |
US20020111495A1 (en) | 1997-04-04 | 2002-08-15 | Pfizer Inc. | Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes |
EP0973735B1 (en) | 1997-04-10 | 2003-01-29 | PHARMACIA & UPJOHN COMPANY | Polyaromatic antiviral compositions |
WO1998049150A1 (en) | 1997-04-25 | 1998-11-05 | Takeda Chemical Industries, Ltd. | Triazine derivatives, their production and agrochemical composition |
US6210710B1 (en) * | 1997-04-28 | 2001-04-03 | Hercules Incorporated | Sustained release polymer blend for pharmaceutical applications |
AR012634A1 (en) * | 1997-05-02 | 2000-11-08 | Sugen Inc | QUINAZOLINE BASED COMPOUND, FAMACEUTICAL COMPOSITION THAT UNDERSTANDS IT, METHOD TO SYNTHESIZE IT, ITS USE, METHODS OF MODULATION OF THE DESERINE / TREONIN PROTEIN-KINASE FUNCTION AND IN VITRO METHOD TO IDENTIFY COMPOUNDS THAT MODULATE |
US6316479B1 (en) | 1997-05-19 | 2001-11-13 | Sugen, Inc. | Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders |
EP1019394A1 (en) | 1997-05-22 | 2000-07-19 | G.D. Searle & Co. | PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS |
JP2002502379A (en) | 1997-05-22 | 2002-01-22 | ジー.ディー.サール アンド カンパニー | 3 (5) -heteroaryl-substituted pyrazoles as p38 kinase inhibitors |
US6514977B1 (en) | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
ES2153337T3 (en) | 1997-05-23 | 2008-11-01 | Bayer Pharmaceuticals Corporation | QUINASA RAF INHIBITORS. |
ES2151467T3 (en) | 1997-05-23 | 2005-03-01 | Bayer Corporation | ARILURES FOR THE TREATMENT OF INFLAMMATORY OR IMMUNOMODULATING DISEASES. |
US6187799B1 (en) | 1997-05-23 | 2001-02-13 | Onyx Pharmaceuticals | Inhibition of raf kinase activity using aryl ureas |
US6344476B1 (en) | 1997-05-23 | 2002-02-05 | Bayer Corporation | Inhibition of p38 kinase activity by aryl ureas |
US6150395A (en) | 1997-05-30 | 2000-11-21 | The Regents Of The University Of California | Indole-3-carbinol (I3C) derivatives and methods |
US5985592A (en) * | 1997-06-05 | 1999-11-16 | Dalhousie University | Uses for pentoxifylline or functional derivatives/metabolites thereof |
US6294350B1 (en) | 1997-06-05 | 2001-09-25 | Dalhousie University | Methods for treating fibroproliferative diseases |
EP1023066A4 (en) | 1997-06-13 | 2001-05-23 | Smithkline Beecham Corp | Novel pyrazole and pyrazoline substituted compounds |
US6093742A (en) | 1997-06-27 | 2000-07-25 | Vertex Pharmaceuticals, Inc. | Inhibitors of p38 |
EP1020444A4 (en) | 1997-06-27 | 2001-04-11 | Kureha Chemical Ind Co Ltd | 6-phenoxypicolinic acid, alkylidenehydrazide derivatives, process for producing the same, and herbicide |
US6525065B1 (en) * | 1997-06-30 | 2003-02-25 | Targacept, Inc. | Pharmaceutical compositions and methods for effecting dopamine release |
AUPP003197A0 (en) | 1997-09-03 | 1997-11-20 | Fujisawa Pharmaceutical Co., Ltd. | New heterocyclic compounds |
UA71555C2 (en) * | 1997-10-06 | 2004-12-15 | Zentaris Gmbh | Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives |
WO1999020617A1 (en) | 1997-10-21 | 1999-04-29 | Active Biotech Ab | Antiinflammatory thiadiazolyl ureas which act as lfa-1 and mac-1 inhibitors |
AU748041B2 (en) | 1997-10-31 | 2002-05-30 | Aventis Pharma Limited | Substituted anilides |
JP2001521934A (en) | 1997-11-03 | 2001-11-13 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | Aromatic heterocyclic compounds as anti-inflammatory drugs |
US6022884A (en) * | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
US6018065A (en) | 1997-11-10 | 2000-01-25 | Advanced Technology Materials, Inc. | Method of fabricating iridium-based materials and structures on substrates, iridium source reagents therefor |
CA2309319A1 (en) | 1997-11-10 | 1999-05-20 | Bristol-Myers Squibb Company | Benzothiazole protein tyrosine kinase inhibitors |
GB9723789D0 (en) | 1997-11-12 | 1998-01-07 | Zeneca Ltd | Chemical compounds |
WO1999026657A1 (en) | 1997-11-25 | 1999-06-03 | Musc Foundation For Research Development | Inhibitors of nitric oxide synthase |
AU1407899A (en) | 1997-12-01 | 1999-06-16 | E.I. Du Pont De Nemours And Company | Fungicidal cyclic amides |
US6635421B1 (en) | 1997-12-09 | 2003-10-21 | Children's Medical Center Corporation | Neuropilins and use thereof in methods for diagnosis and prognosis of cancer |
SK282727B6 (en) | 1997-12-19 | 2002-11-06 | Slovakofarma, A. S. | 1,3-Disubstituted ureas - ACAT inhibitors and method of preparing |
US6174901B1 (en) * | 1998-12-18 | 2001-01-16 | Amgen Inc. | Substituted pyridine and pyridazine compounds and methods of use |
US7517880B2 (en) | 1997-12-22 | 2009-04-14 | Bayer Pharmaceuticals Corporation | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
US7329670B1 (en) * | 1997-12-22 | 2008-02-12 | Bayer Pharmaceuticals Corporation | Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas |
US20080300281A1 (en) | 1997-12-22 | 2008-12-04 | Jacques Dumas | Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas |
US20070244120A1 (en) | 2000-08-18 | 2007-10-18 | Jacques Dumas | Inhibition of raf kinase using substituted heterocyclic ureas |
AU1712899A (en) | 1997-12-23 | 1999-07-12 | Bristol-Myers Squibb Company | 7-deoxy-6-nitrogen substituted paclitaxels |
WO1999033458A1 (en) | 1997-12-25 | 1999-07-08 | Daiichi Pharmaceutical Co., Ltd. | Medicinal composition for percutaneous administration |
GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
WO1999037604A2 (en) | 1998-01-21 | 1999-07-29 | Zymogenetics, Inc. | Dialkyl ureas as calcitonin mimetics |
FR2774824B1 (en) | 1998-02-09 | 2000-04-28 | Moving Magnet Tech | IMPROVED LINEAR ACTUATOR |
US6878526B1 (en) * | 1998-02-18 | 2005-04-12 | Theryte Limited | Treating cancer |
MY132496A (en) | 1998-05-11 | 2007-10-31 | Vertex Pharma | Inhibitors of p38 |
US6413773B1 (en) * | 1998-06-01 | 2002-07-02 | The Regents Of The University Of California | Phosphatidylinositol 3-kinase inhibitors as stimulators of endocrine differentiation |
UA60365C2 (en) | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Isothiazole derivatives, a method for preparing thereof, a pharmaceutical composition and a method for treatment of hyperproliferative disease of mammal |
US6667340B1 (en) | 1998-06-26 | 2003-12-23 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Inhibitors of phosphatidyl myo-inositol cycle |
US6352977B1 (en) * | 1998-07-13 | 2002-03-05 | Aventis Pharma Limited | Substituted β-alanines |
US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
JP2002526482A (en) | 1998-09-18 | 2002-08-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | inhibitors of p38 |
US6383734B1 (en) | 1998-09-30 | 2002-05-07 | Advanced Research And Technology Institute, Inc. | Method to determine inhibition of PAK3 activation of Raf-1 |
US6130053A (en) | 1999-08-03 | 2000-10-10 | Cell Pathways, Inc. | Method for selecting compounds for inhibition of neoplastic lesions |
GB9823873D0 (en) | 1998-10-30 | 1998-12-30 | Pharmacia & Upjohn Spa | 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents |
HUP0104302A3 (en) | 1998-11-06 | 2002-11-28 | Abbott Gmbh & Co Kg | Inhibition of the formation of vascular hyperpermeability |
IL143328A0 (en) | 1998-11-25 | 2002-04-21 | Genetica Inc | Methods and reagents for increasing proliferative capacity and preventing replicative senescence |
US6114517A (en) | 1998-12-10 | 2000-09-05 | Isis Pharmaceuticals Inc. | Methods of modulating tumor necrosis factor α-induced expression of cell adhesion molecules |
WO2000035455A1 (en) | 1998-12-15 | 2000-06-22 | Telik, Inc. | Heteroaryl-aryl ureas as igf-1 receptor antagonists |
UY25842A1 (en) | 1998-12-16 | 2001-04-30 | Smithkline Beecham Corp | IL-8 RECEPTOR ANTAGONISTS |
US6331541B1 (en) * | 1998-12-18 | 2001-12-18 | Soo S. Ko | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
CA2348923A1 (en) | 1998-12-18 | 2000-06-22 | Dean A. Wacker | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
US6147107A (en) | 1998-12-20 | 2000-11-14 | Virginia Commonwealth University | Specific inhibition of the P42/44 mitogen activated protein (map) kinase cascade sensitizes tumor cells |
US20080269265A1 (en) | 1998-12-22 | 2008-10-30 | Scott Miller | Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas |
GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
WO2000039116A1 (en) | 1998-12-25 | 2000-07-06 | Teikoku Hormone Mfg. Co., Ltd. | Aminopyrazole derivatives |
US20020065296A1 (en) | 1999-01-13 | 2002-05-30 | Bayer Corporation | Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US7928239B2 (en) | 1999-01-13 | 2011-04-19 | Bayer Healthcare Llc | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas |
US7351834B1 (en) | 1999-01-13 | 2008-04-01 | Bayer Pharmaceuticals Corporation | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
TWI284642B (en) | 1999-01-18 | 2007-08-01 | Hoffmann La Roche | Novel heterocyclic sulfonamides |
UA73492C2 (en) | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
TR200102090T2 (en) | 1999-01-22 | 2002-01-21 | Kirin Beer Kabushiki Kaisha | Quinoline derivatives and quinazoline derivatives. |
DE60013250T2 (en) | 1999-02-12 | 2005-09-08 | Smithkline Beecham P.L.C., Brentford | Phenylurea and phenylthiourea derivatives as orexin receptor antagonists |
JP2002537397A (en) | 1999-02-22 | 2002-11-05 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | Polycyclic heterocyclic derivatives as anti-inflammatory agents |
JP2002539206A (en) | 1999-03-12 | 2002-11-19 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | Aromatic heterocyclic compounds as anti-inflammatory agents |
CN1511830A (en) | 1999-03-12 | 2004-07-14 | ���ָ��.Ӣ��ķҩ�﹫˾ | Compound used as antiphlogistic |
SK13332001A3 (en) | 1999-03-19 | 2002-02-05 | Vertex Pharmaceuticals Incorporated | Inhibitors of impdh enzyme |
EP2266960B1 (en) | 1999-03-26 | 2014-01-22 | Euro-Celtique S.A. | Aryl-substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles as anticonvulsants |
US6140124A (en) | 1999-04-06 | 2000-10-31 | Isis Pharmaceuticals Inc. | Antisense modulation of P38 mitogen activated protein kinase expression |
US6316462B1 (en) | 1999-04-09 | 2001-11-13 | Schering Corporation | Methods of inducing cancer cell death and tumor regression |
ES2218156T3 (en) | 1999-05-05 | 2004-11-16 | Aventis Pharma Limited | UREAS AND ITS USE AS MODULATORS OF CELL ADHESION. |
KR20020000223A (en) | 1999-05-14 | 2002-01-05 | 존 비. 랜디스 | Treatment of Refractory Human Tumors with Epidermal Growth Factor Receptor Antagonists |
HN2000000051A (en) | 1999-05-19 | 2001-02-02 | Pfizer Prod Inc | USEFUL HETEROCICLIC DERIVATIVES AS ANTI-TARGET AGENTS |
TWI234557B (en) | 1999-05-26 | 2005-06-21 | Telik Inc | Novel naphthalene ureas as glucose uptake enhancers |
DE19927835A1 (en) | 1999-06-18 | 2000-12-21 | Clariant Gmbh | Use of improved cyan pigments in electrophotographic toners and developers, powder coatings and ink jet inks |
ATE312823T1 (en) | 1999-07-09 | 2005-12-15 | Boehringer Ingelheim Pharma | METHOD FOR PRODUCING HETEROARYL-SUBSTITUTED UREA COMPOUNDS |
DE60024631T2 (en) | 1999-07-26 | 2006-06-14 | Banyu Pharma Co Ltd | Biaryl UREA DERIVATIVES |
ATE321751T1 (en) | 1999-07-28 | 2006-04-15 | Kirin Brewery | UREA DERIVATIVES AS CCR-3 RECEPTOR INHIBITORS |
US6387900B1 (en) | 1999-08-12 | 2002-05-14 | Pharmacia & Upjohn S.P.A. | 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents |
US6372933B1 (en) | 1999-08-26 | 2002-04-16 | Smithkline Beecham Corporation | Process for preparing certain phenyl urea compounds |
MXPA02003742A (en) | 1999-10-15 | 2003-10-14 | Kampen Group Inc Van | Treatment of dermal tumors, warts, and viral infections using heat killed p. acnes. |
US6420378B1 (en) | 1999-10-15 | 2002-07-16 | Supergen, Inc. | Inhibition of abnormal cell proliferation with camptothecin and combinations including the same |
US6794393B1 (en) | 1999-10-19 | 2004-09-21 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
DE60036726T2 (en) | 1999-11-16 | 2008-02-07 | Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield | UREA DERIVATIVES AS ANTI-INFLAMMATORY AGENTS |
EP1242382B1 (en) | 1999-12-29 | 2007-02-07 | Wyeth | Tricyclic protein kinase inhibitors |
US6525046B1 (en) * | 2000-01-18 | 2003-02-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as antiinflammatory agents |
US7740841B1 (en) | 2000-01-28 | 2010-06-22 | Sunnybrook Health Science Center | Therapeutic method for reducing angiogenesis |
MXPA02007632A (en) | 2000-02-07 | 2004-08-23 | Abbott Gmbh & Co Kg | 2 benzothiazolyl urea derivatives and their use as protein kinase inhibitors. |
US6608052B2 (en) | 2000-02-16 | 2003-08-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as anti-inflammatory agents |
US6658473B1 (en) | 2000-02-25 | 2003-12-02 | Sun Microsystems, Inc. | Method and apparatus for distributing load in a computer environment |
ES2377119T3 (en) | 2000-03-02 | 2012-03-22 | Vegenics Pty Ltd | Procedures for treating cancers that express vascular endothelial growth factor D |
AU2001235804A1 (en) | 2000-03-06 | 2001-09-17 | Astrazeneca Ab | Therapy |
GB0005357D0 (en) | 2000-03-06 | 2000-04-26 | Smithkline Beecham Plc | Compounds |
WO2001072751A1 (en) * | 2000-03-29 | 2001-10-04 | Knoll Gesellschaft Mit Beschraenkter Haftung | Pyrrolopyrimidines as tyrosine kinase inhibitors |
US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
US6403588B1 (en) | 2000-04-27 | 2002-06-11 | Yamanouchi Pharmaceutical Co., Ltd. | Imidazopyridine derivatives |
FR2811670B1 (en) | 2000-07-13 | 2004-05-14 | Rhodia Chimie Sa | STABILIZATION OF POLYMERIC, ORGANOSILICIC OR SILICONE COMPOSITIONS |
US6390102B1 (en) | 2000-07-14 | 2002-05-21 | General Electric Company | Silicone compositions for personal care products and method for making |
EP1311277A4 (en) | 2000-07-18 | 2004-08-25 | Joslin Diabetes Center Inc | Methods of modulating fibrosis |
MXPA02012909A (en) | 2000-07-24 | 2004-05-05 | Boehringer Ingelheim Pharma | Improved oral dosage formulations of 1-(5-tert-butyl -2-p-tolyl-2h-pyrazol -3-yl)-3 -[4-(2-morpholin-4 -yl-ethoxy) -naphthalen -1-yl] -urea. |
GT200100147A (en) | 2000-07-31 | 2002-06-25 | IMIDAZOL DERIVATIVES | |
US20020165349A1 (en) | 2000-08-04 | 2002-11-07 | Kirsch Wolff M. | Iron regulating protein -2 (IRP-2) as a diagnostic for neurodegenerative disease |
WO2002014281A1 (en) | 2000-08-11 | 2002-02-21 | Vertex Pharmaceuticals Incorporated | Pyridine derivatives as inhibitors of p38 |
US20020173507A1 (en) | 2000-08-15 | 2002-11-21 | Vincent Santora | Urea compounds and methods of uses |
KR20040074096A (en) | 2000-08-17 | 2004-08-21 | 샤단호칭키타사토겐큐쇼 | Novel pseudoerythromycin derivatives |
IL154016A0 (en) | 2000-08-31 | 2003-07-31 | Pfizer Prod Inc | Pyrazole derivatives and their use as protein kinase inhibitors |
US20020055117A1 (en) | 2000-09-20 | 2002-05-09 | James Fett | Methods for detecting prostate cancer |
AUPR034000A0 (en) | 2000-09-25 | 2000-10-19 | Fujisawa Pharmaceutical Co., Ltd. | Aminoalcohol derivatives |
NZ525324A (en) | 2000-10-20 | 2005-03-24 | Eisai Co Ltd | Nitrogenous aromatic ring compounds |
JP3768800B2 (en) | 2000-10-31 | 2006-04-19 | キヤノン株式会社 | Image forming apparatus |
JP2004513935A (en) | 2000-11-17 | 2004-05-13 | ノボ ノルディスク アクティーゼルスカブ | Glucagon antagonist / inverse agonist |
AU2002217870A1 (en) | 2000-11-27 | 2002-06-03 | Eric A. Brill | System, method, and program for sorting objects |
GEP20053652B (en) | 2000-11-28 | 2005-11-10 | Pfizer Prod Inc | Salts of A Isothiazole-4-Carboxamide and their Use as Anti-Hyperproliferation Agents |
JP2004517080A (en) | 2000-11-29 | 2004-06-10 | グラクソ グループ リミテッド | Benzimidazole derivatives useful as inhibitors of TIE-2 and / or VEGFR-2 |
EP1488797B1 (en) * | 2000-12-08 | 2008-04-23 | Kyowa Hakko Kogyo Co., Ltd. | Oral preprations having itching-relieving or antipruritic activity |
EP1363925B8 (en) | 2000-12-21 | 2007-04-25 | Glaxo Group Limited | Macrolide antibiotics |
KR100362390B1 (en) | 2000-12-29 | 2002-11-23 | 삼성전자 주식회사 | Developing device-toner cartridge assembly for image forming apparatus |
US7235576B1 (en) | 2001-01-12 | 2007-06-26 | Bayer Pharmaceuticals Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
CA2435829A1 (en) | 2001-01-25 | 2002-08-01 | Guilford Pharmaceuticals Inc. | Trisubstituted carbocyclic cyclophilin binding compounds and their use |
FR2820136A1 (en) | 2001-01-26 | 2002-08-02 | Aventis Pharma Sa | NOVEL UREA DERIVATIVES, PROCESS FOR THEIR PREPARATION, USE THEREOF AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF |
WO2002059081A2 (en) | 2001-01-26 | 2002-08-01 | Kirin Beer Kabushiki Kaisha | Urea derivatives as inhibitors of ccr-3 receptor |
US6670364B2 (en) | 2001-01-31 | 2003-12-30 | Telik, Inc. | Antagonists of MCP-1 function and methods of use thereof |
WO2002066019A2 (en) | 2001-02-19 | 2002-08-29 | Novartis Ag | Cancer treatment |
UA76977C2 (en) | 2001-03-02 | 2006-10-16 | Icos Corp | Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers |
US6525091B2 (en) * | 2001-03-07 | 2003-02-25 | Telik, Inc. | Substituted diarylureas as stimulators for Fas-mediated apoptosis |
EP1366021B1 (en) | 2001-03-07 | 2007-07-11 | Telik, Inc. | Substituted diarylureas as stimulators for fas-mediated apoptosis |
ES2280517T3 (en) | 2001-03-23 | 2007-09-16 | Bayer Pharmaceuticals Corporation | RHO-CINASA INHIBITOR. |
CA2440831C (en) | 2001-04-02 | 2013-05-28 | Genentech, Inc. | Combination therapy using cd40 and cd20 ligands |
JP2005504727A (en) | 2001-04-13 | 2005-02-17 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | Urea compounds useful as anti-inflammatory drugs |
JP2005507367A (en) | 2001-04-13 | 2005-03-17 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 1,4-disubstituted benzofused compounds |
US7371763B2 (en) | 2001-04-20 | 2008-05-13 | Bayer Pharmaceuticals Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
DE60218445T2 (en) | 2001-04-20 | 2007-11-29 | Bayer Pharmaceuticals Corp., West Haven | INHIBITION OF RAF KINASE BY CHINOLIN, ISOCHINOLINE OR PYRIDINE UREA |
US20030207914A1 (en) | 2001-04-20 | 2003-11-06 | Bayer Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
WO2002088090A2 (en) | 2001-04-27 | 2002-11-07 | Vertex Pharmaceuticals Incorporated | Pyrazole derived kinase inhibitors |
EP1392661A1 (en) | 2001-05-16 | 2004-03-03 | Boehringer Ingelheim Pharmaceuticals Inc. | Diarylurea derivatives useful as anti-inflammatory agents |
WO2003004523A1 (en) | 2001-07-02 | 2003-01-16 | Bayer Aktiengesellschaft | Regulation of human citron rho/rac-interacting kinase |
CA2453147A1 (en) | 2001-07-11 | 2003-01-23 | Boehringer Ingelheim Pharmaceuticals, Inc. | Methods of treating cytokine mediated diseases |
DK2305255T3 (en) | 2001-12-03 | 2012-12-10 | Bayer Healthcare Llc | Aryulin compounds in combination with other cytostatic or cytotoxic agents for the treatment of human cancers |
EP1578346A4 (en) | 2001-12-04 | 2007-11-28 | Onyx Pharma Inc | Raf-mek-erk pathway inhibitors to treat cancer |
JP4643909B2 (en) | 2001-12-21 | 2011-03-02 | ザ ウェルカム トラスト リミテッド | gene |
AU2002356323A1 (en) | 2001-12-24 | 2003-07-30 | Catalyst Biomedica Limited | Cancer-specific mutants of b-raf genes and uses thereof |
US20040096855A1 (en) | 2001-12-24 | 2004-05-20 | Michael Stratton | Genes |
US20030207872A1 (en) | 2002-01-11 | 2003-11-06 | Bayer Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US20080108672A1 (en) | 2002-01-11 | 2008-05-08 | Bernd Riedl | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors |
WO2003059373A2 (en) | 2002-01-16 | 2003-07-24 | Ramot At Tel Aviv University Ltd. | Compositions and their use for enhancing and inhibiting fertilization |
US6998391B2 (en) | 2002-02-07 | 2006-02-14 | Supergen.Inc. | Method for treating diseases associated with abnormal kinase activity |
US20030216396A1 (en) | 2002-02-11 | 2003-11-20 | Bayer Corporation | Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors |
WO2003068223A1 (en) | 2002-02-11 | 2003-08-21 | Bayer Corporation | Aryl ureas with raf kinase and angiogenesis inhibiting activity |
WO2003068228A1 (en) | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Aryl ureas with angiogenesis inhibiting activity |
PT1580188E (en) | 2002-02-11 | 2012-01-25 | Bayer Healthcare Llc | Aryl ureas as kinase inhibitors |
AU2003226211B2 (en) | 2002-03-29 | 2008-05-29 | Novartis Vaccines And Diagnostics, Inc. | Substituted benzazoles and use thereof as RAF kinase inhibitors |
US8299108B2 (en) | 2002-03-29 | 2012-10-30 | Novartis Ag | Substituted benzazoles and methods of their use as inhibitors of raf kinase |
DE10221524A1 (en) | 2002-05-14 | 2003-12-04 | Kmb Produktions Ag Felben | Method and device for producing consumer goods |
AU2003233576A1 (en) | 2002-05-17 | 2003-12-02 | Sugen, Inc. | Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals |
PE20040522A1 (en) | 2002-05-29 | 2004-09-28 | Novartis Ag | DIARYLUREA DERIVATIVES DEPENDENT ON PROTEIN KINASE |
US20060063782A1 (en) | 2002-07-03 | 2006-03-23 | Murray Christopher W | 3-Hetero arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors |
AU2003250197B2 (en) | 2002-08-27 | 2009-11-12 | Merck Patent Gmbh | Glycinamide derivatives as raf-kinase inhibitors |
CA2495284A1 (en) | 2002-09-05 | 2004-03-18 | Neurosearch A/S | Diarylurea derivatives and their use as chloride channel blockers |
CA2503445C (en) | 2002-10-24 | 2012-07-31 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Methylene urea derivatives as raf-kinase inhibitors |
AU2003291356A1 (en) | 2002-11-06 | 2004-06-03 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for treating cancer using proteasome inhibitors |
AU2003283399B2 (en) | 2002-11-15 | 2007-04-19 | Novartis Ag | Drug delivery system |
SE0203654D0 (en) | 2002-12-09 | 2002-12-09 | Astrazeneca Ab | New compounds |
US20030232400A1 (en) | 2002-12-20 | 2003-12-18 | Susan Radka | Methods of screening subjects for expression of soluble receptors of vascular endothelial growth factor (VEGF) for use in managing treatment and determining prognostic outcome |
US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
WO2004078128A2 (en) | 2003-02-28 | 2004-09-16 | Bayer Pharmaceuticals Corporation | Substituted pyridine derivatives useful in the treatment of cancer and other disorders |
WO2004078746A2 (en) | 2003-02-28 | 2004-09-16 | Bayer Pharmaceuticals Corporation | 2-oxo-1,3,5-perhydrotriazapine derivatives useful in the treatment of hyper-proliferative, angiogenesis, and inflammatrory disorders |
CA2516931C (en) | 2003-02-28 | 2014-09-09 | Bayer Pharmaceuticals Corporation | Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders |
US7531553B2 (en) | 2003-03-21 | 2009-05-12 | Amgen Inc. | Heterocyclic compounds and methods of use |
PL377124A1 (en) | 2003-03-24 | 2006-01-23 | Merck Patent Gmbh | Oxamide derivatives useful as raf-kinase inhibitors |
WO2004084889A1 (en) | 2003-03-28 | 2004-10-07 | Pfizer Inc. | Use of protein kinase c inhibitor for suppressing sustained slow postsynaptic excitation (sspe) of enteric neurons |
US6896863B2 (en) | 2003-04-01 | 2005-05-24 | E. I. Du Pont De Nemours And Company | Sodium cyanide process |
EP1636585B2 (en) | 2003-05-20 | 2012-06-13 | Bayer HealthCare LLC | Diaryl ureas with kinase inhibiting activity |
BRPI0410913A (en) | 2003-06-05 | 2006-06-27 | Warner Lambert Co | cycloalkyl and heterocycloalkyl substituted benzothiophenes as therapeutic agents |
US20040259926A1 (en) | 2003-06-05 | 2004-12-23 | Bruendl Michelle M. | 3-Aryloxy and 3-heteroaryloxy substituted benzo[b]thiophenes as therapeutic agents |
WO2005002673A1 (en) | 2003-07-03 | 2005-01-13 | Astex Therapeutics Limited | Raf kinase inhibitors |
CA2531485C (en) | 2003-07-07 | 2013-03-26 | Merck Patent Gmbh | Malonamide derivatives |
PT1646634E (en) | 2003-07-08 | 2009-02-16 | Novartis Ag | Use of rapamycin and rapamycin derivatives for the treatment of bone loss |
WO2005016252A2 (en) | 2003-07-11 | 2005-02-24 | Ariad Gene Therapeutics, Inc. | Phosphorus-containing macrocycles |
WO2005004863A1 (en) | 2003-07-11 | 2005-01-20 | Merck Patent Gmbh | Benzimidazole carboxamides as raf kinase inhibitors |
US7691886B2 (en) | 2003-07-11 | 2010-04-06 | Merck Patent Gmbh | Benzimidazole derivatives as raf kinase inhibitors |
US20060234931A1 (en) | 2003-07-17 | 2006-10-19 | Biggs William H Iii | Treatment of diseases with kinase inhibitors |
MY142799A (en) | 2003-07-23 | 2010-12-31 | Bayer Healthcare Llc | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
AR045134A1 (en) | 2003-07-29 | 2005-10-19 | Smithkline Beecham Plc | COMPOSITE OF 1H - IMIDAZO [4,5-C] PIRIDIN-ILO, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, PROCESS TO PREPARE IT, ITS USE TO PREPARE SUCH PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL COMBINATION, USE OF PHARMACEUTICAL COMBINATION FOR THE PREPARATION OF A MEDIA PROCEDURE, TO PREPARE DIC |
DE10334663A1 (en) | 2003-07-30 | 2005-03-10 | Merck Patent Gmbh | urea derivatives |
JP2007502983A (en) * | 2003-08-15 | 2007-02-15 | ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | Multifactor assay for cancer detection |
KR20060097000A (en) | 2003-09-23 | 2006-09-13 | 노파르티스 아게 | Combination of a vegf receptor inhibitor with a chemotherapeutic agent |
DE10344223A1 (en) | 2003-09-24 | 2005-04-21 | Merck Patent Gmbh | New 2-anilino-1,3-benzoxazole derivatives, are inhibitors of kinases, especially tyrosine- or Raf-kinases, useful e.g. for treating solid tumors, angiogenesis, diabetic retinopathy, inflammation or psoriasis |
WO2005040100A1 (en) * | 2003-10-15 | 2005-05-06 | Bayer Healthcare Ag | Tetrahydro-naphthalene and urea derivatives |
CA2542653A1 (en) | 2003-10-16 | 2005-04-28 | Chiron Corporation | Substituted benzazoles and use thereof as inhibitors of raf kinase |
AU2004281154A1 (en) | 2003-10-16 | 2005-04-28 | Novartis Vaccines And Diagnostics, Inc. | 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of Raf kinase for treatment of cancer |
DE10349587A1 (en) | 2003-10-24 | 2005-05-25 | Merck Patent Gmbh | Benzimidazolylderivate |
DE10352979A1 (en) | 2003-11-13 | 2005-06-09 | Merck Patent Gmbh | Pyridopyrimidinone |
US20050165074A1 (en) | 2003-11-13 | 2005-07-28 | Ambit Biosciences Corporation | Amide derivatives as C-KIT modulators |
DE10354060A1 (en) | 2003-11-19 | 2005-06-02 | Merck Patent Gmbh | pyrrole |
BRPI0417302A (en) | 2003-12-05 | 2007-03-06 | Compound Therapeutics Inc | type 2 vascular endothelial growth factor receptor inhibitors |
CN1889958A (en) | 2003-12-09 | 2007-01-03 | 美国政府健康及人类服务部 | Methods for suppressing an immune response or a treating a proliferative disorder |
EP1692110A1 (en) | 2003-12-10 | 2006-08-23 | MERCK PATENT GmbH | Diacylhydrazine derivatives |
US20070134670A1 (en) | 2003-12-12 | 2007-06-14 | Bayer Pharmaceuticals Corporation | Methods for prediction and prognosis of cancer, and monitoring cancer therapy |
KR20060132882A (en) | 2004-01-30 | 2006-12-22 | 메르크 파텐트 게엠베하 | Bisarylurea derivatives |
CA2560269A1 (en) | 2004-03-19 | 2005-09-29 | The Penn State Research Foundation | Combinatorial methods and compositions for treatment of melanoma |
EP2295426A1 (en) | 2004-04-30 | 2011-03-16 | Bayer HealthCare, LLC | Substituted pyrazolyl urea derivatives useful in the treatment of cancer |
MY191349A (en) | 2004-08-27 | 2022-06-17 | Bayer Pharmaceuticals Corp | New pharmaceutical compositions for the treatment of hyper-proliferative disorders |
WO2006026501A1 (en) | 2004-08-27 | 2006-03-09 | Bayer Pharmaceuticals Corporation | New pharmaceutical compositions for the treatment of cancer |
JP5334414B2 (en) | 2004-09-06 | 2013-11-06 | バイエル インテレクチュアル プロパティー ゲゼルシャフト ミット ベシュレンクテル ハフツング | Novel pyrazolopyrimidine |
BRPI0515946A (en) | 2004-09-29 | 2008-08-12 | Bayer Healthcare Ag | tosylate salt, its preparation and use, as well as pharmaceutical composition comprising the same |
DK1797037T3 (en) | 2004-09-29 | 2015-03-30 | Bayer Healthcare Llc | PROCESS FOR THE PREPARATION OF 4- {4 - [({[4-chloro-3- (trifluoromethyl) phenyl] AMINO} CARBONYL) AMINO] PHENYOXY} N-methylpyridine-2-carboxamide |
ES2465469T3 (en) | 2005-01-14 | 2014-06-05 | Gilead Connecticut, Inc. | Diaryl ureas 1,3-substituted as kinase activity modulators |
ATE482693T1 (en) | 2005-03-07 | 2010-10-15 | Bayer Schering Pharma Ag | PHARMACEUTICAL COMPOSITION CONTAINING AN OMEGA CARBOXYARYL SUBSTITUTED DIPHENYL UREA FOR THE TREATMENT OF CANCER |
DE102005015253A1 (en) | 2005-04-04 | 2006-10-05 | Merck Patent Gmbh | New pyrazole derivatives are tyrosine kinase inhibitors useful to treat e.g. solid tumors, diabetic retinopathy, age-related macular degeneration or inflammatory disease, osteoarthritis and rickets |
JP2008545670A (en) | 2005-05-27 | 2008-12-18 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | Combination therapy involving diarylureas for the treatment of disease |
JP2008542214A (en) | 2005-05-27 | 2008-11-27 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | Combination therapy comprising a diaryl urea compound and PI3, AKT kinase or MTOR inhibitor (rapamycin) for treating disease |
WO2007015947A2 (en) | 2005-07-29 | 2007-02-08 | Bayer Healthcare Llc | Methods and kits for the prediction of therapeutic success, recurrence free and overall survival in cancer therapies |
EP1913391B1 (en) * | 2005-08-11 | 2010-12-29 | Siemens Healthcare Diagnostics Inc. | QUANTITATIVE ASSAYS FOR PDGFR-beta IN BODY FLUIDS |
US20070066060A1 (en) | 2005-09-19 | 2007-03-22 | Taiwan Semiconductor Manufacturing Co., Ltd. | Semiconductor devices and fabrication methods thereof |
PL1928872T3 (en) | 2005-09-21 | 2012-08-31 | 4Sc Ag | Novel sulphonylpyrroles as inhibitors of hdac |
EP1928826B1 (en) | 2005-09-21 | 2013-04-24 | 4Sc Ag | Sulphonylpyrrole hydrochloride salts as histone deacetylases inhibitors |
BRPI0617488A2 (en) | 2005-10-21 | 2011-07-26 | Bayer Healthcare Llc | Method for monitoring the condition of a disease associated with a vegf-165 pathway activated by ultra-expression or vegf-165 protein mutation in one patient, Therapy selection method for a human patient with a dignified disease and method to detect disease associated with an ultra-expression-activated vegf-165 pathway or vegf-165 protein mutation in a patient |
US8329408B2 (en) | 2005-10-31 | 2012-12-11 | Bayer Healthcare Llc | Methods for prognosis and monitoring cancer therapy |
WO2007053574A2 (en) * | 2005-10-31 | 2007-05-10 | Bayer Pharmaceuticals Corporation | Combinations comprising sorafenib and interferon for the treatment of cancer |
JP2009513706A (en) | 2005-10-31 | 2009-04-02 | バイエル ヘルスケア リミティド ライアビリティ カンパニー | Treatment of cancer with sorafenib |
RU2008121751A (en) | 2005-11-02 | 2009-12-20 | БАЙЕР ХЕЛСКЕР ЛЛСи (US) | METHODS FOR FORECASTING AND PREDICTION OF CANCER AND MONITORING THERAPY OF CANCER DISEASES |
RU2008121754A (en) | 2005-11-02 | 2009-12-20 | БАЙЕР ХЕЛСКЕР ЛЛСи (US) | METHODS FOR FORECASTING AND PREDICTION OF CANCER AND MONITORING THERAPY OF CANCER DISEASES |
CA2628849A1 (en) | 2005-11-10 | 2007-05-18 | Bayer Healthcare Ag | Diaryl urea for treating pulmonary hypertension |
BRPI0618524A2 (en) | 2005-11-10 | 2011-09-06 | Bayer Schering Pharma Ag | use of diaryl ureas for the treatment of pulmonary hypertension, as well as the combination and composition comprising said diaryl ureas and the use of the combination |
WO2007059155A1 (en) | 2005-11-14 | 2007-05-24 | Bayer Pharmaceuticals Corporation | Treatment of cancers having resistance to chemotherapeutic agents |
CA2629863A1 (en) | 2005-11-14 | 2007-05-24 | Scott Wilhelm | Use of sorafenib for the treatment of cancers with acquired resistance to kit inhibitors |
JP2009515553A (en) | 2005-11-14 | 2009-04-16 | バイエル ヘルスケア エルエルシー | Cancer prognosis and prognosis, and cancer treatment monitoring |
US20110195110A1 (en) | 2005-12-01 | 2011-08-11 | Roger Smith | Urea compounds useful in the treatment of cancer |
US20090227637A1 (en) | 2005-12-15 | 2009-09-10 | Olaf Weber | Diaryl ureas for treating virus infections |
WO2007087575A2 (en) | 2006-01-24 | 2007-08-02 | University Of Chicago | Compositions and methods for treating pulmonary hypertension |
KR20080103977A (en) | 2006-02-22 | 2008-11-28 | 4에스체 악티엔게젤샤프트 | Indolopyridines as eg5 kinesin modulators |
US8530493B2 (en) | 2006-02-22 | 2013-09-10 | 4Sc Ag | Indolopyridines as Eg5 kinesin modulators |
US7908091B2 (en) | 2006-03-17 | 2011-03-15 | Prometheus Laboratories Inc. | Methods of predicting and monitoring tyrosine kinase inhibitor therapy |
CA2648106A1 (en) | 2006-03-31 | 2007-11-01 | Bayer Healthcare Llc | Methods for prediction and prognosis of cancer, and monitoring cancer therapy |
EP2338488A1 (en) | 2006-05-26 | 2011-06-29 | Bayer HealthCare, LLC | Drug combinations with substituted diaryl ureas for the treatment of cancer |
CA2667720A1 (en) | 2006-11-09 | 2008-05-15 | Abbott Gmbh & Co. Kg. | Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor |
EP2134677B1 (en) | 2006-12-20 | 2011-10-12 | Bayer HealthCare LLC | 4-{4-[({3-tert-butyl-1-[3-(hydroxymethyl)phenyl]-1h-pyrazol-5-yl}carbamoyl)-amino]-3-chlorophenoxy}-n-methylpyridine-2-carboxamide as an inhibitor of the vegfr kinase for the treatment of cancer |
AU2007336873A1 (en) | 2006-12-20 | 2008-07-03 | Bayer Healthcare Llc | 4-{4-[({3-tert-Butyl-1-[3-(hydroxymethyl) phenyl]-1H-pyrazol-5-yl } carbamoyl)-amino] -3-fluorophenoxy} -N-methylpyridine-2-carboxamide as well as prodrugs and salts thereof for the treatment of cancer |
US8680124B2 (en) | 2007-01-19 | 2014-03-25 | Bayer Healthcare Llc | Treatment of cancers with acquired resistance to kit inhibitors |
WO2009034308A2 (en) | 2007-09-10 | 2009-03-19 | Cipla Limited | Process for the preparation of a raf kinase inhibitor and intermediates for use in the process |
WO2009054004A2 (en) | 2007-10-22 | 2009-04-30 | Natco Pharma Limited | Process for the preparation of sorafenib |
CA2741660A1 (en) | 2008-11-07 | 2010-05-14 | Novabay Pharmaceuticals, Inc. | Antimicrobial oxazolidinone, hydantoin and imidazolidinone compositions |
JP5821626B2 (en) | 2011-12-27 | 2015-11-24 | 富士ゼロックス株式会社 | Image forming apparatus and program |
-
2003
- 2003-02-11 WO PCT/US2003/004103 patent/WO2003068228A1/en active Application Filing
- 2003-02-11 CA CA2475703A patent/CA2475703C/en not_active Expired - Lifetime
- 2003-02-11 DK DK03707846.6T patent/DK1478358T3/en active
- 2003-02-11 JP JP2003567410A patent/JP4636486B2/en not_active Expired - Fee Related
- 2003-02-11 AU AU2003209116A patent/AU2003209116A1/en not_active Abandoned
- 2003-02-11 EP EP10180600A patent/EP2324825A1/en not_active Ceased
- 2003-02-11 SI SI200332285T patent/SI1478358T1/en unknown
- 2003-02-11 US US10/361,858 patent/US7838541B2/en not_active Expired - Fee Related
- 2003-02-11 PT PT37078466T patent/PT1478358E/en unknown
- 2003-02-11 ES ES03707846T patent/ES2425739T3/en not_active Expired - Lifetime
- 2003-02-11 EP EP03707846.6A patent/EP1478358B1/en not_active Revoked
- 2003-02-11 MX MXPA04007832A patent/MXPA04007832A/en active IP Right Grant
-
2007
- 2007-07-13 JP JP2007183948A patent/JP4685068B2/en not_active Expired - Fee Related
- 2007-10-31 US US11/932,626 patent/US20080227828A1/en not_active Abandoned
-
2010
- 2010-09-23 US US12/888,887 patent/US8242147B2/en not_active Expired - Fee Related
-
2012
- 2012-07-18 US US13/551,884 patent/US8618141B2/en not_active Expired - Lifetime
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0625221A (en) | 1992-07-10 | 1994-02-01 | Tokuyama Soda Co Ltd | Production of 3-amino-2-thiophenecarboxylic acid derivative |
WO1994004157A1 (en) | 1992-08-21 | 1994-03-03 | Schering Aktiengesellschaft | Transdermal application agent containing 3-keto-desogestrel |
WO1999032455A1 (en) | 1997-12-22 | 1999-07-01 | Bayer Corporation | Inhibition of raf kinase using aryl and heteroaryl substituted heterocyclic ureas |
WO1999032106A1 (en) | 1997-12-22 | 1999-07-01 | Bayer Corporation | Inhibition of raf kinase using substituted heterocyclic ureas |
WO1999032110A1 (en) | 1997-12-22 | 1999-07-01 | Bayer Corporation | INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS |
WO1999032463A1 (en) | 1997-12-22 | 1999-07-01 | Bayer Corporation | INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS |
WO1999032436A1 (en) | 1997-12-22 | 1999-07-01 | Bayer Corporation | Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas |
WO1999032111A1 (en) | 1997-12-22 | 1999-07-01 | Bayer Corporation | INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS |
WO2000041698A1 (en) | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS |
WO2000042012A1 (en) | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS |
US8339998B2 (en) | 2009-12-28 | 2012-12-25 | Fih (Hong Kong) Limited | Meeting information distribution system and method |
Non-Patent Citations (25)
Title |
---|
AIELLO ET AL., NEW ENGL. J. MED., vol. 331, 1994, pages 1480 |
BERKMAN ET AL., J. CLIN. INVEST., vol. 91, 1993, pages 153 |
BROWN ET AL., J. INVEST. DERMATOL., vol. 104, 1995, pages 744 |
CARTER C A ET AL: "ANTI-TUMOR EFFICACY OF THE ORALLY ACTIVE RAF KINASE INHIBITOR BAY 43-9006 IN HUMAN TUMOR XENOGRAFT MODELS", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, NEW YORK, NY, US, vol. 42, no. 923, March 2001 (2001-03-01), pages 923, XP001145482, ISSN: 0197-016X * |
CHIEN: "Transdermal Controlled Systemic Medications", 1987, MARCEL DEKKER, INC. |
DUMAS J: "Protein kinase inhibitors from the urea class", CURRENT OPINION IN DRUG DISCOVERY AND DEVELOPMENT 2002 UNITED KINGDOM, vol. 5, no. 5, 2002, pages 718 - 727, XP009011493, ISSN: 1367-6733 * |
EISENHAUER ET AL.: "Impact of new non-cytotoxics in the treatment of ovarian cancer", INT. J. GYNECOL. CANCER, vol. 11, no. s1, 2001, pages 68 - 72, XP001062441 * |
HOTTE S J ET AL: "BAY 43-9006: EARLY CLINICAL DATA IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES", CURRENT PHARMACEUTICAL DESIGN, BENTHAM SCIENCE PUBLISHERS, SCHIPHOL, NL, vol. 8, no. 25, 2002, pages 2249 - 2253, XP001145745, ISSN: 1381-6128 * |
KATRITZKY ET AL.: "Comprehensive Heterocyclic Chemistry", 1984, PERMAGON PRESS |
KIM ET AL., NATURE, vol. 362, 1993, pages 841 |
KOCH ET AL., J. IMMUNOL., vol. 152, 1994, pages 4149 |
KUBO KAZUO ET AL: "Synthesis and structure-activity relationship of Quinazoline-Urea derivatives as novel orally active VEGF receptor tyrosine kinase selective inhibitors.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, vol. 43, March 2002 (2002-03-01), 93rd Annual Meeting of the American Association for Cancer Research;San Francisco, California, USA; April 06-10, 2002, March, 2002, pages 182, XP001152608, ISSN: 0197-016X * |
LAROCK: "Comprehensive Organic Transformations", 1989, VCH PUBLISHERS |
LOPEZ ET AL., INVEST. OPTHTHALMOL. VIS. SCI., vol. 37, 1996, pages 855 |
MARCH: "Advanced Organic Chemistry", 1985, JOHN WILEY |
PARK ET AL., ONCOGENE, vol. 10, 1995, pages 135 |
PEACOCK ET AL., J. EXPER. MED., vol. 175, 1992, pages 1135 |
PEER ET AL., LAB. INVEST., vol. 72, 1995, pages 638 |
PHILLIPS ET AL., INT. J. ONCOL., vol. 2, 1993, pages 913 |
PLATE ET AL., NATURE, vol. 359, 1992, pages 845 |
ROCKWELL ET AL., MOL. CELL. DIFFER., vol. 3, 1995, pages 315 |
RYLANDER: "Hydrogenation Methods", 1985, ACADEMIC PRESS |
SEYDEN-PENNE: "Reductions by the Alumino-and Borohydrides in Organic Synthesis", 1991, VCH PUBLISHERS |
STRUMBERG D ET AL: "PHASE I AND PHARMACOKINETIC STUDY OF THE RAF KINASE INHIBITOR BAY 43-9006 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC CANCER", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, NEW YORK, NY, US, vol. 42, March 2001 (2001-03-01), pages 543, XP001145481, ISSN: 0197-016X * |
WALTENBERGER ET AL., J. BIOL. CHEM., vol. 269, 1994, pages 26988 |
Cited By (167)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8841330B2 (en) | 1999-01-13 | 2014-09-23 | Bayer Healthcare Llc | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US7897623B2 (en) | 1999-01-13 | 2011-03-01 | Bayer Healthcare Llc | ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors |
US8110587B2 (en) | 2002-02-11 | 2012-02-07 | Bayer Healthcare Llc | Aryl ureas as kinase inhibitors |
US7678811B2 (en) | 2002-02-11 | 2010-03-16 | Bayer Healthcare Llc | Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors |
US7838541B2 (en) | 2002-02-11 | 2010-11-23 | Bayer Healthcare, Llc | Aryl ureas with angiogenesis inhibiting activity |
US9181188B2 (en) | 2002-02-11 | 2015-11-10 | Bayer Healthcare Llc | Aryl ureas as kinase inhibitors |
US8071616B2 (en) | 2002-02-11 | 2011-12-06 | Bayer Healthcare Llc | Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors |
US10653684B2 (en) | 2002-02-11 | 2020-05-19 | Bayer Healthcare Llc | Aryl ureas with angiogenisis inhibiting activity |
US8242147B2 (en) | 2002-02-11 | 2012-08-14 | Bayer Healthcare Llc | Aryl ureas with angiogenisis inhibiting activity |
US8618141B2 (en) | 2002-02-11 | 2013-12-31 | Bayer Healthcare Llc | Aryl ureas with angiogenesis inhibiting activity |
WO2004078748A2 (en) | 2003-02-28 | 2004-09-16 | Bayer Pharmaceuticals Corporation | Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders |
WO2004078748A3 (en) * | 2003-02-28 | 2004-11-11 | Bayer Pharmaceuticals Corp | Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders |
WO2005000284A3 (en) * | 2003-05-20 | 2005-03-10 | Bayer Pharmaceuticals Corp | Diaryl ureas for diseases mediated by pdgfr |
WO2005000284A2 (en) * | 2003-05-20 | 2005-01-06 | Bayer Pharmaceuticals Corporation | Diaryl ureas for diseases mediated by pdgfr |
WO2004113274A3 (en) * | 2003-05-20 | 2005-03-03 | Bayer Pharmaceuticals Corp | Diaryl ureas with kinase inhibiting activity |
US8796250B2 (en) | 2003-05-20 | 2014-08-05 | Bayer Healthcare Llc | Diaryl ureas for diseases mediated by PDGFR |
US8642776B2 (en) | 2003-05-22 | 2014-02-04 | Abbvie Inc. | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
US7598283B2 (en) | 2003-05-22 | 2009-10-06 | Abbott Laboratories, Inc. | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
US8940778B2 (en) | 2003-05-22 | 2015-01-27 | Abbvie Inc. | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
US7297709B2 (en) | 2003-05-22 | 2007-11-20 | Abbott Laboratories | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
US8299243B2 (en) | 2003-05-22 | 2012-10-30 | Abbvie Inc. | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
US8063091B2 (en) | 2003-05-22 | 2011-11-22 | Abbott Laboratories | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
US8637553B2 (en) | 2003-07-23 | 2014-01-28 | Bayer Healthcare Llc | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
WO2005051366A2 (en) * | 2003-11-28 | 2005-06-09 | Novartis Ag | Diaryl urea derivatives in the treatment of protein kinase dependent diseases |
WO2005051366A3 (en) * | 2003-11-28 | 2007-12-21 | Novartis Ag | Diaryl urea derivatives in the treatment of protein kinase dependent diseases |
JP2007519653A (en) * | 2004-01-30 | 2007-07-19 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | Bisaryl urea derivatives |
US8609656B2 (en) | 2004-02-23 | 2013-12-17 | Chugai Seiyaku Kabushiki Kaisha | Heteroarylphenylurea derivative |
US8207166B2 (en) | 2004-04-30 | 2012-06-26 | Bayer Healthcare Llc | Substituted pyrazolyl urea derivatives useful in the treatment of cancer |
US8871769B2 (en) | 2004-06-17 | 2014-10-28 | Cytokinetics, Inc. | Ureas and their use in the treatment of heart failure |
US10035770B2 (en) | 2004-06-17 | 2018-07-31 | Cytokinetics, Incorporated | Compounds, compositions and methods |
US8110595B2 (en) | 2004-06-17 | 2012-02-07 | Cytokinetics, Inc. | Ureas and their use in the treatment of heart failure |
US9643925B2 (en) | 2004-06-17 | 2017-05-09 | Cytokinetics, Incorporated | Compounds, compositions and methods |
US8101617B2 (en) | 2004-06-17 | 2012-01-24 | Amgen, Inc. | Disubstituted ureas and uses thereof in treating heart failure |
US10975034B2 (en) | 2004-06-17 | 2021-04-13 | Cytokinetics, Inc. | Compounds, compositions and methods |
US8513257B2 (en) | 2004-06-17 | 2013-08-20 | Cytokinetics, Incorporated | Ureas and their use in the treatment of heart failure |
US10385023B2 (en) | 2004-06-17 | 2019-08-20 | Cytokinetics, Inc. | Compounds, compositions and methods |
US9150564B2 (en) | 2004-06-17 | 2015-10-06 | Cytokinetics, Inc. | Compounds, compositions and methods |
US8552002B2 (en) | 2004-06-24 | 2013-10-08 | Novartis Ag | Compounds and compositions as protein kinase inhibitors |
CN102885813A (en) * | 2004-08-27 | 2013-01-23 | 拜尔保健公司 | Pharmaceutical compositions for the treatment of hyper-proliferative disorders |
EA010832B1 (en) * | 2004-08-27 | 2008-12-30 | Байер Фамэсьютиклс Копэрейшн | Composition (embodiments) and a method for treating hyper-proliferative processes, a method for treating cancer (embodiments) and a method for preparing solid dispersion |
WO2006026500A1 (en) * | 2004-08-27 | 2006-03-09 | Bayer Pharmaceuticals Corporation | New pharmaceutical compositions comprising 4-(4-(3-(4-chloro-3-trifluoromethyl-phenyl)-ureido)-3-fluoro-phenoxy)-pyridine-2-carboxylic acid for the treatment of hyper-proliferative disorders |
WO2006026501A1 (en) * | 2004-08-27 | 2006-03-09 | Bayer Pharmaceuticals Corporation | New pharmaceutical compositions for the treatment of cancer |
JP2008511686A (en) * | 2004-08-27 | 2008-04-17 | バイエル、ファーマシューテイカルズ、コーポレイション | Novel pharmaceutical composition for the treatment of cancer |
NO343937B1 (en) * | 2004-08-27 | 2019-07-15 | Bayer Healthcare Llc | Composition comprising a solid dispersion of at least 4 {4- [3- (4-chloro-3-trifluoromethylphenyl) -ureido] -3-fluorophenoxy} -pyridine-2-carboxylic acid methylamide in substantially amorphous form, its solvates, hydrates, pharmaceutically acceptable salts or a combination thereof and a pharmaceutically acceptable matrix comprising a pharmaceutically acceptable polymer or a sugar and / or a sugar alcohol and / or cyclodextrin, a process for preparing the solid dispersion, and a pharmaceutical composition thereof for use in the treatment of hyperproliferative disorders such as cancer |
CN101048140B (en) * | 2004-08-27 | 2013-06-19 | 拜尔保健公司 | Novel pharmaceutical compositions for the treatment of cancer |
EP2589384A1 (en) * | 2004-08-27 | 2013-05-08 | Bayer Healthcare LLC | New Pharmaceutical Compositions for the Treatment of Hyper-Proliferative Disorders |
JP2008511685A (en) * | 2004-08-27 | 2008-04-17 | バイエル、ファーマシューテイカルズ、コーポレイション | Novel pharmaceutical composition for the treatment of hyperproliferative diseases comprising 4- (4- (3- (4-chloro-3-trifluoromethylphenyl) ureido) -3-fluorophenoxy) pyridine-2-carboxylic acid object |
US8026247B2 (en) | 2004-09-15 | 2011-09-27 | Novartis Ag | Bicyclic amides as kinase inhibitors |
TWI382016B (en) * | 2004-09-29 | 2013-01-11 | Bayer Schering Pharma Ag | Thermodynamically stable form of a tosylate salt |
AU2005289100B2 (en) * | 2004-09-29 | 2011-11-03 | Bayer Healthcare Llc | Thermodynamically stable form of bay 43-9006 tosylate |
KR101381454B1 (en) * | 2004-09-29 | 2014-04-04 | 바이엘 인텔렉쳐 프로퍼티 게엠베하 | Thermodynamically stable form of bay 43-9006 tosylate |
WO2006034797A1 (en) * | 2004-09-29 | 2006-04-06 | Bayer Healthcare Ag | Thermodynamically stable form of bay 43-9006 tosylate |
US8124782B2 (en) * | 2004-09-29 | 2012-02-28 | Bayer Pharma Aktiengesellschaft | Process for the preparation of 4-{4-[({[4 chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-N-methylpyridine-2-carboxamide |
NO344272B1 (en) * | 2004-09-29 | 2019-10-21 | Bayer Healthcare Llc | Thermodynamically stable form of BAY 43-9006 tosylate |
JP2013067625A (en) * | 2004-09-29 | 2013-04-18 | Bayer Pharma AG | Method for manufacturing 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-n-methylpyridine-2-carboxamide |
KR101239489B1 (en) * | 2004-09-29 | 2013-03-06 | 바이엘 파마 악티엔게젤샤프트 | Thermodynamically stable form of bay 43-9006 tosylate |
US8877933B2 (en) | 2004-09-29 | 2014-11-04 | Bayer Intellectual Property Gmbh | Thermodynamically stable form of a tosylate salt |
JP2008514658A (en) * | 2004-09-29 | 2008-05-08 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | Thermodynamically stable form of BAY 43-9006 tosylate |
JP2008514657A (en) * | 2004-09-29 | 2008-05-08 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | 4- {4-[({[4-Chloro-3- (trifluoromethyl) phenyl] amino} carbonyl) amino] phenoxy} -N-methylpyridine-2-carboxamide |
WO2006042599A1 (en) * | 2004-10-13 | 2006-04-27 | Merck Patent Gmbh | Phenylurea derivatives used as inhibitors of tyrosinkinase for treating tumors |
US7696224B2 (en) | 2004-10-13 | 2010-04-13 | Merck Patent Gmbh | Phenylurea derivatives as inhibitors of tyrosine kinases for the treatment of tumour diseases |
WO2006091801A3 (en) * | 2005-02-23 | 2007-03-15 | Alcon Inc | Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective rtk inhibitors |
WO2006091801A2 (en) * | 2005-02-23 | 2006-08-31 | Alcon, Inc. | Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective rtk inhibitors |
NO343834B1 (en) * | 2005-03-07 | 2019-06-17 | Bayer Healthcare Llc | A pharmaceutical composition comprising an omega-carboxylaryl-substituted diphenylurea for the treatment of cancer |
JP2008531741A (en) * | 2005-03-07 | 2008-08-14 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | Pharmaceutical composition comprising omega-carboxyaryl substituted diphenylurea for the treatment of cancer |
US9737488B2 (en) | 2005-03-07 | 2017-08-22 | Bayer Healthcare Llc | Pharmaceutical composition for the treatment of cancer |
CN101132779B (en) * | 2005-03-07 | 2016-03-16 | 拜尔健康护理有限责任公司 | Be used for the treatment of the pharmaceutical composition comprising the diphenyl urea that omega-carboxyaryl replaces of cancer |
WO2006125539A2 (en) * | 2005-05-27 | 2006-11-30 | Bayer Healthcare Ag | Combination therapy comprising diaryl ureas for treating diseases |
WO2006125539A3 (en) * | 2005-05-27 | 2007-03-08 | Bayer Healthcare Ag | Combination therapy comprising diaryl ureas for treating diseases |
WO2007054215A1 (en) * | 2005-11-10 | 2007-05-18 | Bayer Healthcare Ag | Diaryl ureas for treating pulmonary hypertension |
JP2009514910A (en) * | 2005-11-10 | 2009-04-09 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | Diarylureas for treating pulmonary hypertension |
JP2009514909A (en) * | 2005-11-10 | 2009-04-09 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | Diarylureas for treating pulmonary hypertension |
US8871768B2 (en) | 2005-12-15 | 2014-10-28 | Cytokinetics, Inc. | Certain chemical entities, compositions and methods |
US8445495B2 (en) | 2005-12-15 | 2013-05-21 | Cytokinetics, Inc. | Certain Chemical entities, compositions and methods |
WO2007068381A1 (en) * | 2005-12-15 | 2007-06-21 | Bayer Healthcare Ag | Diaryl ureas for treating inflammatory skin, eye and/or ear diseases |
EP1959960A2 (en) * | 2005-12-15 | 2008-08-27 | Cytokinetics, Inc. | Certain chemical entities, compositions and methods |
EP1959960A4 (en) * | 2005-12-15 | 2010-08-04 | Cytokinetics Inc | Certain chemical entities, compositions and methods |
US7989455B2 (en) | 2005-12-19 | 2011-08-02 | Cytokinetics, Inc. | Compounds, compositions and methods |
EP2338488A1 (en) | 2006-05-26 | 2011-06-29 | Bayer HealthCare, LLC | Drug combinations with substituted diaryl ureas for the treatment of cancer |
US9957232B2 (en) | 2006-10-11 | 2018-05-01 | Bayer Healthcare Llc | 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrate |
WO2009054004A3 (en) * | 2007-10-22 | 2009-07-02 | Natco Pharma Ltd | Process for the preparation of sorafenib |
WO2009054004A2 (en) * | 2007-10-22 | 2009-04-30 | Natco Pharma Limited | Process for the preparation of sorafenib |
WO2009156070A1 (en) * | 2008-06-25 | 2009-12-30 | Bayer Schering Pharma Aktiengesellschaft | Diaryl urea for treating heart failure |
WO2010015672A1 (en) * | 2008-08-08 | 2010-02-11 | S.I.F.I. Societa' Industria Farmaceutica Italiana S.P.A. | Ophthalmic pharmaceutical compositions comprising sorafenib for the treatment of neoangiogenic pathologies of the eye |
EP2156834A1 (en) * | 2008-08-08 | 2010-02-24 | S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. | Ophthalmic pharmaceutical compositions comprising Sorafenib for the treatment of neoangiogenic pathologies of the eye |
CN102164600A (en) * | 2008-08-08 | 2011-08-24 | S.I.F.I.工业制药意大利有限公司 | Ophthalmic pharmaceutical compositions comprising sorafenib for the treatment of neoangiogenic pathologies of the eye |
US8293771B2 (en) | 2008-10-02 | 2012-10-23 | Respivert Ltd. | p38 MAP kinase inhibitors |
US8618140B2 (en) | 2008-10-02 | 2013-12-31 | Respivert Ltd | P38 MAP kinase inhibitors |
US8975285B2 (en) | 2008-10-02 | 2015-03-10 | Respivert Ltd. | P38 MAP kinase inhibitors |
US8293748B2 (en) | 2008-10-02 | 2012-10-23 | Respivert Ltd. | p38 MAP kinase inhibitors |
US8299074B2 (en) | 2008-12-11 | 2012-10-30 | Respivert Ltd. | P38 MAP kinase inhibitors |
US8299073B2 (en) | 2008-12-11 | 2012-10-30 | Respivert Ltd. | P38 MAP kinase inhibitors |
WO2010083649A1 (en) * | 2009-01-22 | 2010-07-29 | 沈阳药科大学 | Bisarylurea derivatives and their use |
US9242960B2 (en) | 2009-04-03 | 2016-01-26 | Respivert, Ltd. | P38MAP kinase inhibitors |
US8642773B2 (en) | 2009-04-03 | 2014-02-04 | Respivert Ltd. | P38MAP kinase inhibitor |
CN101550136B (en) * | 2009-05-06 | 2013-06-19 | 沈阳药科大学 | Diarylurea derivatives and application thereof used for preparing anti-neoplastic medicament |
US10813932B2 (en) | 2011-10-03 | 2020-10-27 | Respivert Limited | 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as P38 MAP knase inhibitors |
US9993478B2 (en) | 2011-10-03 | 2018-06-12 | Respivert, Ltd. | 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as P38 MAP knase inhibitors |
US10738032B2 (en) | 2011-10-03 | 2020-08-11 | Respivert Limited | 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-i-yl) ureas as P38 mapkinase inhibitors |
US9108950B2 (en) | 2011-10-03 | 2015-08-18 | Respivert, Ltd. | 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as p38 MAP kinase inhibitors |
US9475796B2 (en) | 2011-10-03 | 2016-10-25 | Respivert Limited | 1-pyrazolyl-3-((4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as p38 MAP kinase inhibitors |
US9724347B2 (en) | 2011-10-03 | 2017-08-08 | Respivert, Ltd. | 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as P38 MAP knase inhibitors |
US9850231B2 (en) | 2011-10-03 | 2017-12-26 | Respivert Limited | 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-I-yl) ureas as P38 mapkinase inhibitors |
US10266519B2 (en) | 2011-10-03 | 2019-04-23 | Respivert Limited | 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-I-yl) ureas as P38 mapkinase inhibitors |
US10238658B2 (en) | 2011-10-03 | 2019-03-26 | Respivert Limited | 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as p38 MAP kinase inhibitors |
CN102643252A (en) * | 2012-04-17 | 2012-08-22 | 沈阳药科大学 | Piperazinoacethydrazide-containing diarylurea derivatives and application thereof |
US9242977B2 (en) | 2012-04-26 | 2016-01-26 | Ono Pharmaceutical Co., Ltd. | Trk-inhibiting compound |
JPWO2013161919A1 (en) * | 2012-04-26 | 2015-12-24 | 小野薬品工業株式会社 | Trk inhibitory compound |
WO2013161919A1 (en) | 2012-04-26 | 2013-10-31 | 小野薬品工業株式会社 | Trk-INHIBITING COMPOUND |
WO2013175506A2 (en) | 2012-05-21 | 2013-11-28 | Hetero Research Foundation | Process for sorafenib tosylate polymorph iii |
US9156789B2 (en) | 2012-05-21 | 2015-10-13 | Hetero Research Foundation | Process for sorafenib tosylate polymorph III |
EP2922820A4 (en) * | 2012-05-23 | 2016-06-01 | Shilpa Medicare Ltd | Process for preparing crystalline sorafenib tosylate |
US9701670B2 (en) | 2012-08-17 | 2017-07-11 | Respivert Limited | Pyrazolyl-ureas as kinase inhibitors |
US9790209B2 (en) | 2012-08-29 | 2017-10-17 | Respivert Limited | Kinase inhibitors |
US9783556B2 (en) | 2012-08-29 | 2017-10-10 | Respivert Limited | Kinase inhibitors |
US9249125B2 (en) | 2012-08-29 | 2016-02-02 | Respivert Limited | Pyrazole derivatives as p38 MAP inhibitors |
US9796742B2 (en) | 2012-08-29 | 2017-10-24 | Respivert Limited | Kinase inhibitors |
US9732063B2 (en) | 2012-11-16 | 2017-08-15 | Respivert Limited | Kinase inhibitors |
WO2014076484A1 (en) | 2012-11-16 | 2014-05-22 | Respivert Limited | Kinase inhibitors |
WO2014129431A1 (en) | 2013-02-19 | 2014-08-28 | 小野薬品工業株式会社 | Trk-INHIBITING COMPOUND |
US9463192B2 (en) | 2013-02-19 | 2016-10-11 | Ono Pharmaceutical Co., Ltd. | Trk-inhibiting compound |
EP3800183A1 (en) | 2013-02-19 | 2021-04-07 | ONO Pharmaceutical Co., Ltd. | Urea derivatives as trk-inhibiting compounds |
US10765676B2 (en) | 2013-02-19 | 2020-09-08 | Ono Pharmaceutical Co., Ltd. | Trk-inhibiting compound |
US9498453B2 (en) | 2013-02-19 | 2016-11-22 | Ono Pharmaceutical Co., Ltd. | Trk-inhibiting compound |
US10300060B2 (en) | 2013-02-19 | 2019-05-28 | Ono Pharmaceutical Co., Ltd. | Trk-inhibiting compound |
EP3459935A1 (en) | 2013-02-19 | 2019-03-27 | ONO Pharmaceutical Co., Ltd. | Trk-inhibiting compound |
US9763943B2 (en) | 2013-02-19 | 2017-09-19 | Ono Pharmaceutical Co., Ltd. | Trk-inhibiting compound |
US9993479B2 (en) | 2013-02-19 | 2018-06-12 | Ono Pharmaceutical Co., Ltd. | Trk-inhibiting compound |
US9850233B2 (en) | 2013-03-14 | 2017-12-26 | Respivert Limited | Kinase inhibitors |
US10301288B2 (en) | 2013-03-14 | 2019-05-28 | Topivert Pharma Limited | Kinase inhibitors |
US10435361B2 (en) | 2013-04-02 | 2019-10-08 | Topivert Pharma Limited | Kinase inhibitors |
US9771353B2 (en) | 2013-04-02 | 2017-09-26 | Topivert Pharma Limited | Kinase inhibitors based upon N-alkyl pyrazoles |
US9481648B2 (en) | 2013-04-02 | 2016-11-01 | Respivert Limited | Kinase inhibitors |
US9790174B2 (en) | 2013-04-02 | 2017-10-17 | Respivert Limited | Kinase inhibitors |
US8927563B2 (en) | 2013-04-02 | 2015-01-06 | Respivert Limited | Kinase inhibitor |
US9890185B2 (en) | 2013-12-20 | 2018-02-13 | Respivert Limited | Urea derivatives useful as kinase inhibitors |
US9447076B2 (en) | 2014-02-14 | 2016-09-20 | Respivert Ltd. | Inhibitor of p38 map kinase |
US11142515B2 (en) | 2014-02-14 | 2021-10-12 | Respivert Limited | Pyrazolyl-ureas as kinase inhibitors |
US9624196B2 (en) | 2014-02-14 | 2017-04-18 | Respivert Ltd. | Inhibitor of p38 MAP kinase |
US10294216B2 (en) | 2014-02-14 | 2019-05-21 | Respivert Limited | Pyrazolyl ureas as kinase inhibitors |
US10815217B2 (en) | 2014-02-14 | 2020-10-27 | Respivert Ltd. | Inhibitor of p38 MAP kinase |
US11634406B2 (en) | 2014-02-14 | 2023-04-25 | Respivert Ltd. | Inhibitor of p38 MAP kinase |
US10045980B2 (en) | 2014-02-14 | 2018-08-14 | Respivert Ltd | Inhibitor of p38 map kinase |
US9884845B2 (en) | 2014-02-14 | 2018-02-06 | Respivert Limited | Pyrazolyl-ureas as kinase inhibitors |
US9815842B2 (en) | 2014-05-28 | 2017-11-14 | Novartis Ag | Pyrazolo pyrimidine derivatives and their use as MALT1 inhibitors |
US10442808B2 (en) | 2014-05-28 | 2019-10-15 | Novartis Ag | Pyrazolo pyrimidine derivatives and their use as MALT1 inhbitors |
CN104045598A (en) * | 2014-05-29 | 2014-09-17 | 烟台大学 | Thiourea compounds containing arylamine structure, and preparation method and application thereof |
US10399959B2 (en) | 2014-08-18 | 2019-09-03 | Ono Pharmaceutical Co., Ltd. | Acid-addition salt of Trk-inhibiting compound |
CN106573913B (en) * | 2014-08-18 | 2019-11-19 | 小野药品工业株式会社 | Inhibit the acid-addition salts of the compound of Trk |
CN110655502A (en) * | 2014-08-18 | 2020-01-07 | 小野药品工业株式会社 | Acid addition salts of Trk inhibiting compounds |
CN106573913A (en) * | 2014-08-18 | 2017-04-19 | 小野药品工业株式会社 | Acid-addition salt of trk-inhibiting compound |
US10941115B2 (en) | 2014-10-01 | 2021-03-09 | Oxular Acquisitions Limited | Kinase inhibitors |
US10392346B2 (en) | 2014-10-01 | 2019-08-27 | Topivert Pharma Limited | Kinase inhibitors |
US9822076B2 (en) | 2014-10-01 | 2017-11-21 | Respivert Limited | Kinase inhibitor |
US9499486B2 (en) | 2014-10-01 | 2016-11-22 | Respivert Limited | Kinase inhibitor |
US10125100B2 (en) | 2014-10-01 | 2018-11-13 | Respivert Limited | Kinase inhibitors |
US9751837B2 (en) | 2014-10-01 | 2017-09-05 | Respivert Limited | Kinase inhibitors |
US10745346B2 (en) | 2015-09-02 | 2020-08-18 | Kuen-Feng Chen | Agonists of protein tyrosine phosphatase SHP-1 |
WO2017036405A1 (en) * | 2015-09-02 | 2017-03-09 | 陈昆锋 | Compound having protein tyrosine phosphatase shp-1 agonist activity |
US10442828B2 (en) | 2016-04-06 | 2019-10-15 | Topivert Pharma Limited | Kinase inhibitors |
US10072034B2 (en) | 2016-04-06 | 2018-09-11 | Respivert Limited | Kinase inhibitors |
WO2017174758A1 (en) | 2016-04-07 | 2017-10-12 | Imba - Institut Für Molekulare Biotechnologie Gmbh | Combination of an apelin antagonist and an angiogenesis inhibitor for the treatment of cancer |
EP3228630A1 (en) | 2016-04-07 | 2017-10-11 | IMBA-Institut für Molekulare Biotechnologie GmbH | Combination of an apelin antagonist and an angiogenesis inhibitor for the treatment of cancer |
CN107814773A (en) * | 2017-11-13 | 2018-03-20 | 西安交通大学 | diaryl urea compound containing quinazolinone and its preparation method and application |
WO2020193621A1 (en) | 2019-03-26 | 2020-10-01 | Universidade De Santiago De Compostela | Prognostic markers, therapeutic target and treatment for acromegaly |
EP3715473A1 (en) | 2019-03-26 | 2020-09-30 | Universidade de Santiago de Compostela | Prognostic markers, therapeutic target and treatment for acromegaly |
Also Published As
Publication number | Publication date |
---|---|
US20120289552A1 (en) | 2012-11-15 |
AU2003209116A1 (en) | 2003-09-04 |
EP1478358B1 (en) | 2013-07-03 |
SI1478358T1 (en) | 2013-09-30 |
JP4636486B2 (en) | 2011-02-23 |
ES2425739T3 (en) | 2013-10-17 |
US8618141B2 (en) | 2013-12-31 |
CA2475703C (en) | 2016-12-20 |
JP2005522448A (en) | 2005-07-28 |
JP4685068B2 (en) | 2011-05-18 |
PT1478358E (en) | 2013-09-11 |
US7838541B2 (en) | 2010-11-23 |
JP2007302687A (en) | 2007-11-22 |
US20030207870A1 (en) | 2003-11-06 |
US20110015195A1 (en) | 2011-01-20 |
DK1478358T3 (en) | 2013-10-07 |
US20080227828A1 (en) | 2008-09-18 |
US8242147B2 (en) | 2012-08-14 |
EP1478358A1 (en) | 2004-11-24 |
MXPA04007832A (en) | 2005-09-08 |
CA2475703A1 (en) | 2003-08-21 |
EP2324825A1 (en) | 2011-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7838541B2 (en) | Aryl ureas with angiogenesis inhibiting activity | |
EP1043995B9 (en) | INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS | |
CA2526617C (en) | Diaryl ureas with kinase inhibiting activity | |
CN112689633A (en) | For inhibiting Nav1.8 pyridine carboxamide Compounds | |
TW202019900A (en) | Ptpn11 inhibitors | |
US10653684B2 (en) | Aryl ureas with angiogenisis inhibiting activity | |
WO2003068223A1 (en) | Aryl ureas with raf kinase and angiogenesis inhibiting activity | |
JP7352294B2 (en) | Antagonist of muscarinic acetylcholine receptor M4 | |
US20090306020A1 (en) | Combination therapy comprising diaryl ureas for treating diseases | |
JP2022534979A (en) | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith | |
WO2002038153A1 (en) | New use of 4, 5, 6, 7-tetrahydroimidazo-[4,5-c]pyridine derivatives | |
US20090068146A1 (en) | Diaryl ureas and combinations | |
CN111065393A (en) | Pyrrolopyridine-anilines for the treatment of skin diseases | |
JP2019532911A (en) | Amide derivatives as Nav1.7 and Nav1.8 blockers | |
BR112014026283B1 (en) | COMPOUNDS OF FORMULA (I), (II), (III), USE THEREOF, PHARMACEUTICAL COMPOSITION, AND PROCESS FOR PREPARING A PHARMACEUTICAL COMPOSITION | |
CN114650819A (en) | Avermectistat for treating graft rejection, bronchiolitis obliterans syndrome and graft-versus-host disease | |
JP7518900B2 (en) | Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (LP) - Patent Application 20070233334 | |
JP7406264B2 (en) | Cyanoaryl-aniline compounds for the treatment of skin disorders | |
JP2017513844A (en) | MGlu2 / 3 antagonists for the treatment of intellectual disabilities | |
JPWO2005034953A1 (en) | Angiogenesis inhibitor | |
JPWO2002048096A1 (en) | Hydrazone derivatives and their pharmaceutical uses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2475703 Country of ref document: CA Ref document number: 2003567410 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2004/007832 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003707846 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003707846 Country of ref document: EP |